Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome (Review)

Ruepert L, Quartero AO, de Wit NJ, van der Heijden GJ, Rubin G, Muris JWM

This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in *The Cochrane Library* 2013, Issue 3

http://www.thecochranelibrary.com

TABLE OF CONTENTS

[Intervention Review]

Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome

Lisa Ruepert[1], A Otto Quartero[2], Niek J de Wit[3], Geert J van der Heijden[4], Gregory Rubin[5], Jean WM Muris[6]

[1]University Medical Center Utrecht, 3508 AB Utrecht, Netherlands. [2]Huisartspraktijk Diepenveen, Diepenveen, Netherlands. [3]Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, Netherlands. [4]Department of Otorhinolaryngology & Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, Netherlands. [5]Durham University, Stockton on Tees, UK. [6]Department of General Practice, Maastricht University, Maastricht, Netherlands

Contact address: A Otto Quartero, Huisartspraktijk Diepenveen, Dorpsstraat 16, Diepenveen, 7431 CK, Netherlands. quartero@huisartsensalland.nl.

Editorial group: Cochrane Inflammatory Bowel Disease and Functional Bowel Disorders Group.
Publication status and date: Edited (no change to conclusions), published in Issue 3, 2013.
Review content assessed as up-to-date: 20 March 2009.

Citation: Ruepert L, Quartero AO, de Wit NJ, van der Heijden GJ, Rubin G, Muris JWM. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. *Cochrane Database of Systematic Reviews* 2011, Issue 8. Art. No.: CD003460. DOI: 10.1002/14651858.CD003460.pub3.

ABSTRACT

Background

Irritable bowel syndrome (IBS) is a common chronic gastrointestinal disorder. The role of pharmacotherapy for IBS is limited and focused mainly on symptom control.

Objectives

The objective of this systematic review was to evaluate the efficacy of bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome.

Search methods

Computer assisted structured searches of MEDLINE, EMBASE, The Cochrane library, CINAHL and PsychInfo were conducted for the years 1966-2009. An updated search in April 2011 identified 10 studies which will be considered for inclusion in a future update of this review.

Selection criteria

Randomized controlled trials comparing bulking agents, antispasmodics or antidepressants with a placebo treatment in patients with irritable bowel syndrome aged over 12 years were considered for inclusion. Only studies published as full papers were included. Studies were not excluded on the basis of language. The primary outcome had to include improvement of abdominal pain, global assessment or symptom score.

Data collection and analysis

Two authors independently extracted data from the selected studies. Risk Ratios (RR) and Standardized Mean Differences (SMD) with 95% confidence intervals (CI) were calculated. A proof of practice analysis was conducted including sub-group analyses for different types of bulking agents, spasmolytic agents or antidepressant medication. This was followed by a proof of principle analysis where only the studies with adequate allocation concealment were included.

Main results

A total of 56 studies (3725 patients) were included in this review. These included 12 studies of bulking agents (621 patients), 29 of antispasmodics (2333 patients), and 15 of antidepressants (922 patients). The risk of bias was low for most items. However, selection bias is unclear for many of the included studies because the methods used for randomization and allocation concealment were not described. No beneficial effect for bulking agents over placebo was found for improvement of abdominal pain (4 studies; 186 patients; SMD 0.03; 95% CI -0.34 to 0.40; P = 0.87), global assessment (11 studies; 565 patients; RR 1.10; 95% CI 0.91 to 1.33; P = 0.32) or symptom score (3 studies; 126 patients SMD -0.00; 95% CI -0.43 to 0.43; P = 1.00). Subgroup analyses for insoluble and soluble fibres also showed no statistically significant benefit. Separate analysis of the studies with adequate concealment of allocation did not change these results. There was a beneficial effect for antispasmodics over placebo for improvement of abdominal pain (58% of antispasmodic patients improved compared to 46% of placebo; 13 studies; 1392 patients; RR 1.32; 95% CI 1.12 to 1.55; P < 0.001; NNT = 7), global assessment (57% of antispasmodic patients improved compared to 39% of placebo; 22 studies; 1983 patients; RR 1.49; 95% CI 1.25 to 1.77; P < 0.0001; NNT = 5) and symptom score (37% of antispasmodic patients improved compared to 22% of placebo; 4 studies; 586 patients; RR 1.86; 95% CI 1.26 to 2.76; P < 0.01; NNT = 3). Subgroup analyses for different types of antispasmodics found statistically significant benefits for cimteropium/ dicyclomine, peppermint oil, pinaverium and trimebutine. Separate analysis of the studies with adequate allocation concealment found a significant benefit for improvement of abdominal pain. There was a beneficial effect for antidepressants over placebo for improvement of abdominal pain (54% of antidepressants patients improved compared to 37% of placebo; 8 studies; 517 patients; RR 1.49; 95% CI 1.05 to 2.12; P = 0.03; NNT = 5), global assessment (59% of antidepressants patients improved compared to 39% of placebo; 11 studies; 750 patients; RR 1.57; 95% CI 1.23 to 2.00; P < 0.001; NNT = 4) and symptom score (53% of antidepressants patients improved compared to 26% of placebo; 3 studies; 159 patients; RR 1.99; 95% CI 1.32 to 2.99; P = 0.001; NNT = 4). Subgroup analyses showed a statistically significant benefit for selective serotonin releasing inhibitors (SSRIs) for improvement of global assessment and for tricyclic antidepressants (TCAs) for improvement of abdominal pain and symptom score. Separate analysis of studies with adequate allocation concealment found a significant benefit for improvement of symptom score and global assessment. Adverse events were not assessed as an outcome in this review.

Authors' conclusions

There is no evidence that bulking agents are effective for treating IBS. There is evidence that antispasmodics are effective for the treatment of IBS. The individual subgroups which are effective include: cimetropium/dicyclomine, peppermint oil, pinaverium and trimebutine. There is good evidence that antidepressants are effective for the treatment of IBS. The subgroup analyses for SSRIs and TCAs are unequivocal and their effectiveness may depend on the individual patient. Future research should use rigorous methodology and valid outcome measures.

PLAIN LANGUAGE SUMMARY

Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome

This review evaluates the effectiveness of medical therapies for patients with irritable bowel syndrome (IBS). We considered studies involving bulking agents (a fibre supplement), antispasmodics (smooth muscle relaxants) or antidepressants (drugs used to treat depression that can also change pain perceptions) that used outcome measures including improvement of abdominal pain, global assessment (overall relief of IBS symptoms) or symptom score. We found that bulking agents are not effective for treating IBS. There is evidence that antispasmodics including cimetropium/dicyclomine peppermint oil, pinaverium and trimebutine are effective for the treatment of IBS. Antidepressants are effective for the treatment of IBS. The side effects of these medications were not evaluated in this review. Physicians should be aware of the limitations of drug therapies and discuss these limitations with their patients before prescribing medication for IBS.

BACKGROUND

Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by fluctuating complains of abdominal pain or discomfort and an altered bowel habit resulting in diarrhoea or constipation. The prevalence of IBS ranges from 5-18 % depending on the clinical setting and the diagnostic criteria that are used. IBS is slightly more common in females (Hungin 2003; Hillila 2004). IBS is associated with depressive and anxiety disorders as well with somatic co-morbidities including fibromyalgia, chronic fatigue syndrome and chronic pelvic pain (Riedl 2008).

Research shows that IBS can result in impaired health-related quality of life and that IBS symptoms have a large impact on work productivity (Pare 2006; Creed 2001). IBS is also associated with increased health care utilization and costs (Longstreth 2003).

In the absence of a gold-standard for diagnosing IBS, classification models have been developed including the Kruis scoring system, Manning criteria and Rome I, II, and III criteria (Manning 1978; Drossman 2006). Only the Rome I classification is validated (Ford 2010). These criteria are not widely used in clinical practice and the diagnosis of IBS is often made by a typical history, normal physical examination and the absence of alarm-symptoms such as gastrointestinal bleeding, weight loss, or an abdominal mass (Jones 2000a).

The pathophysiology of IBS is still unclear. There are several putative mechanisms including visceral hypersensitivity, altered colonic motility, abnormal brain activation, serotine dysregulation, inflammation, abnormal colonic flora, stress, psychological factors and genetic factors (Talley 2006).

In the absence of a clear pathophysiology, explanation and reassurance are essential elements in the management of IBS (Jones 2000b). Pharmacotherapeutic interventions are limited and focus mostly on symptom control. High fibres diets and bulking agents are traditionally advised for their effect on stools and transit time (Burkitt 1972). Antispasmodics are given for their supposed effect on gastrointestinal motility. The more recent therapeutic options include the use of antidepressants, which are also given for other diseases associated with chronic pain (Verdu 2008).

OBJECTIVES

The objective of this systematic review was to evaluate the efficacy of bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome.

METHODS

Criteria for considering studies for this review

Types of studies

Randomised controlled trials comparing bulking agents, antispasmodics or antidepressants with a placebo were considered for inclusion. Cross-over studies were eligible if data from the first phase were reported separately. Only studies published as a full paper were included. Studies were not excluded on the basis of language.

Types of participants

Patients aged over 12 years with irritable bowel syndrome, diagnosed either using predefined diagnostic criteria (e.g. Manning or Rome) or on clinical grounds were considered for inclusion. Studies including patients with functional bowel disorders without separate data for IBS patients were also included if the proportion of IBS patients was more than 75% of the total included patients.

Types of interventions

Interventions including bulking agents, antispasmodics or antidepressants compared with a placebo treatment were considered for inclusion.

Types of outcome measures

Outcome measures for clinical trials of interventions in IBS have been discussed in several studies (Irvine 2006; Schoenfeld 2006). Primary outcome measures included:

- Improvement of symptoms of abdominal pain;
- Improvement of patients overall global assessment; and
- Improvement of IBS-symptom score.

Subgroup analyses included:

- Soluble and insoluble bulking agents;
- Individual antispasmodics; and
- Selective serotonin releasing inhibitors (SSRIs) and tricyclic antidepressants (TCAs).

A sensitivity analysis excluded studies with poor methodological quality.

Search methods for identification of studies

Electronic searches

Computer assisted structured searches of MEDLINE, EMBASE, The Cochrane Library, CINAHL and PsychInfo were conducted, searching entries from 1966 to March 2009. The following search strategies were used:
Title/abstract search: spastic colon, irritable colon, irritable bowel, functional bowel, colonic disease, colonic diseases, IBS, gastrointestinal syndrome, gastrointestinal syndromes

Combined with title/abstract search: bulking agent, bulking agents, fiber, fibers, fibre, fibres, psyllium, plantago ovata, husk, bran, ispaghula, wheat, oat, sterculia, karaya gum
Or combined with title/abstract search: antispasmodic, antispasmodics, parasympatholytic, parasympatholytics. spasmolytic , spasmolytics, mebeverine, rociverine, pinaverium bromide, otilonium bromide, cimetropium bromide, trimebutine, pirenzipine, alverine, scopolamine, butylscopolamine, hyoscine , muscarinic antagonist, peppermint oil, mint oil
Or combined with title/abstract search: antidepressant, antidepressants, antidepressive agent, antidepressive agents, tricyclic, TCA, TCAs, selective serotonin reuptake inhibitor, selective serotonin reuptake inhibitors, SSRI, SSRIs
No limits or filters were used.
An updated search in April 2011 identified 10 studies which will be considered for inclusion in a future update of this review (See Characteristics of studies awaiting classification).

Searching other resources

The reference lists of the retrieved articles and reviews were hand searched to identify additional studies.

Data collection and analysis

Selection of studies

One author (LR) screened the title and abstract of all studies identified by the literature searches for eligibility . The full text articles were retrieved for all potentially eligible studies. The full text articles were screened according to predefined criteria by the same reviewer. All the doubtful articles were screened by a second reviewer (AOQ) and consensus on inclusions/ exclusion was achieved by discussion.
The predefined exclusion criteria included:

1. Not a randomised controlled trial
2. No placebo group
3. Inappropriate patient group
4. Patients younger than 12, diagnosis of functional bowel disorders not specified as IBS
5. Intervention not involving bulking agent, antispasmodic or antidepressant or mixed preparations
6. An outcome measurement other than abdominal pain, global assessment or IBS-symptom score.
7. No extractable results or cross-over trial with no report of first phase data
8. Duplicate trials

Data extraction and management

All studies were blinded for the reviewers in respect of authors, date of publication and journal or database of publication. Data were extracted independently by two authors for each study. A standardized data extraction form was used. Where necessary data were extracted from figures. If essential data were absent, the author of the article was contacted and requested to provide additional information.

Assessment of risk of bias in included studies

The methodological quality of included trials was independently assessed by two authors (AOQ and LR or NdW or GR).
Quality assessment criteria included: method of randomisation, concealment of allocation, blinding of patients and outcome measurers and description of lost to follow-up.
Differences of opinion were resolved by discussion between two reviewers, and in case of disagreement by all the reviewers. A methodology expert (GvdH) was consulted for specific queries
In consultation with the Dutch Cochrane centre, concealment of allocation was used for additional analyses, since concealment of allocation is the only quality item that has proven to be associated with study outcome (Pidal 2007, Wood 2008).

Measures of treatment effect

The analyses were conducted using RevMan 5.0 software. For the dichotomous outcomes the risk ratio (RR) with 95% confidence intervals were calculated. For the continuous data standardized mean difference (SMD) with 95% confidence intervals were calculated.
A fixed- or random-effects model was used, based on the heterogeneity between study data. Statistical heterogeneity was explored with the Chi square test with significance set at P <0.10. When statistically significant heterogeneity occurred, a random-effects model was used for the analyses.
There were differences in the direction of the scales for the continuous data. To correct for this the data from scales increasing with disease severity were multiplied by -1.
First, a proof of practice analysis was conducted, including all available data. This was followed by a proof of principle analysis where only the studies with adequate allocation concealment were included.

RESULTS

Description of studies

See: Characteristics of included studies; Characteristics of excluded studies; Characteristics of studies awaiting classification.
Bulking agents

The search identified 1118 studies, of which, after screening title and abstract 72 were potentially eligible. After applying the exclusion criteria to the full-text publications of these 72 potentially eligible studies, 12 articles remained for review and meta-analysis. Sixty articles were excluded (table of characteristics of excluded studies), of which twenty-six were not randomized controlled trials (exc1). Fourteen studies did not involve a placebo treatment (exc2). Four studies included patients with functional bowel disorders without providing extractable results for the patients with IBS (exc3 and exc4). Two studies involved an intervention with a mixed preparation (exc5). Two studies did not report the outcome of interest (exc6). Eleven studies were cross-over trials with no report of the first phase data or did not provide extractable results (exc7). One study was a duplicate publication (exc8).

Twelve papers remained for review and meta-analysis (Table of characteristics of included studies). Two studies had a cross-over design (Jalihal 1990; Lucey 1987). The studies were published between 1976 and 2005 (Soltoft 1976; Rees 2005). The research setting was a GI out patients' clinic in 11 studies, in the other three the setting was unclear (Arthurs 1983; Longstreth 1981; Soltoft 1976). Seven studies used a run-in period of 1 to 4 weeks before beginning the actual trial (Fowlie 1992; Longstreth 1981; Prior 1987; Rees 2005; Soltoft 1976). The studies included between 20 and 168 participants (Jalihal 1990; Nigam 1984). The mean age of the participants ranged from 28 years to 46 years (Arthurs 1983; Aller 2004). The percentage of female participants included ranged from 20% to 83% (Jalihal 1990; Longstreth 1981). Six studies used insoluble fibres as intervention (Aller 2004; Fowlie 1992; Kruis 1986; Lucey 1987; Rees 2005; Soltoft 1976) and six studies used soluble fibres as intervention (Arthurs 1983; Jalihal 1990; Longstreth 1981; Nigam 1984; Prior 1987; Ritchie 1979). The intervention period lasted from 4 weeks (Ritchie 1979) to 16 weeks (Kruis 1986).

Antispasmodics

The search identified 444 studies, of which, after screening title and abstract, 144 were potentially eligible. After applying the exclusion criteria to the full-text publications of these 144 potentially eligible studies, 29 articles remained for review and meta-analysis.

One hundred and fifteen articles were excluded (table of characteristics of excluded studies). Thirty-eight were not randomised controlled trials (exc1). Thirty four studies did not involve a placebo treatment (exc2). Six studies included patients with functional bowel disorders without providing extractable results for the patients with IBS (exc3 and exc4). Three studies involved an intervention with a mixed preparation (exc5). Twelve studies did not report the outcome of interest (exc6). Nineteen studies had no extractable results or were cross-over trials with no report of the first phase data (exc7). Three were duplicate publications (exc8) (Baldi 1992; Glende 2002; Koch 1998).

Twenty-nine papers remained review and meta-analysis (Table of characteristics of included studies; Awad 1995; Baldi 1991; Battaglia 1998; Capanni 2005; Cappello 2007; Centonze 1988; Chen 2004; Czalbert 1990; d'Arienzo 1980; Delmont 1981; Dobrilla 1990; Dubarry 1977; Fielding 1980; Ghidini 1986; Gilvarry 1989; Kruis 1986; Lech 1988; Levy 1977; Liu 1997; Mitchell 2002; Moshal 1979; Nigam 1984; Page 1981; Passaretti 1989a; Piai 1979; Pulpeiro 2000; Ritchie 1979; Schafer 1990; Virat 1987). Two studies had a cross-over design (Moshal 1979; Piai 1979). The studies were published between 1977 and 2007 (Levy 1977; Cappello 2007). The research setting was definitely defined as secondary care in 18 studies, none of the studies was definitely conducted in primary care. Fourteen studies used a run-in period of 1 to 4 weeks before beginning the actual trial. Five of these used a placebo during the run-in period and one used a high fibre diet (Gilvarry 1989). The studies included between 18 (Piai 1979) and 360 participants (Schafer 1990). The mean age of the participants ranged from 26 years (Fielding 1980) to 60.6 years (Baldi 1991). The percentage of female participants included ranged from 35% (Moshal 1979) to 100% (Awad 1995). The intervention period lasted from 1 week (Virat 1987) to 6 months (Centonze 1988). The antispasmodics are divided into ten pharmacological subgroups: Alverine (1 study), cimetropium/dicyclomine (4 studies), mebeverine (2 studies), Otilonium (6 studies), peppermint oil (5 studies), pinaverium (6 studies),pirenzepine (1 study), propinox (1 study), scopolamine derivates (4 studies), and trimebutine (3 studies).

Antidepressants

The search identified 419 studies, of which, after screening title and abstract 56 were potentially eligible. After applying the exclusion criteria on the full-text publications of these 56 potentially eligible studies, 15 articles remained for review and meta-analysis. Forty articles were excluded (table of characteristics of excluded studies). Twenty were not randomized controlled trials (exc1). Six studies did not involve a placebo treatment (exc2). One study involved an intervention with a mixed preparation (exc5). Four studies did not report the outcome of interest (exc6). Three studies had no extractable results or were cross-over trials with no report of the first phase data (exc7). Six studies were duplicate publications (exc8) (Kalpert 2005, Han 2009; Marks 2008; Block 1983; Tripathi 1983; Greenbaum 1987).

Fifteen studies remained for review and meta-analysis (table of characteristics of included studies). One study had a cross-over design (Tack 2006a). The studies were published between 1978 and 2009 (Heefner 1978; Masand 2009). Two studies were partly conducted in primary care (Myren 1982; Boerner 1988), the remainder in secondary care. Three studies used a run-in period of 1 to 2 weeks before beginning the actual trial (Rajagopalan 1998; Tack 2006a; Talley 2008a). One study had a placebo run-in period of unspecified duration (Masand 2009). One study randomised patients who had completed a 7 week open-label high-fibre trial (Tabas 2004). The studies included between 23 and 201 participants (Tack 2006a; Drossman 2003). The mean age of the

participants ranged from 32 years to 49 years (Masand 2009). The percentage of female participants included ranged from 13% (Heefner 1978) to 100% (Drossman 2003). Five studies used a SSRI as the intervention
(Kuiken 2003; Masand 2009; Tabas 2004; Tack 2006a; Vahedi 2005). Nine studies used a TCA the as intervention (Bahar 2008; Myren 1982; Boerner 1988; Drossman 2003; Heefner 1978; Rajagopalan 1998; Vahedi 2008; Vij 1991). One study compared an SSRI and a TCA with placebo treatment (Talley 2008a). The intervention period lasted from 4 weeks (Myren 1982) to 12 weeks (Vahedi 2005).

Risk of bias in included studies

The results of the risk of bias assessment are shown in Figure 1.The risk of bias was low for most items. However, selection bias is unclear for many of the included studies because the methods used for randomization and allocation concealment were not described.

Figure 1. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.



Allocation

Bulking agents

None of the twelve studies on bulking agents described the methods used for randomization and these studies were rated as unclear for this item. Five of the studies were rated as low risk for allocation concealment (Fowlie 1992; Jalihal 1990; Longstreth 1981; Ritchie 1979; Soltoft 1976). The other seven studies were rated as unclear for allocation concealment.

Antispasmodics

Three studies reported on the methods used for randomization (Capanni 2005; Cappello 2007; Piai 1979) and were rated as low risk for this item. The other twenty-six studies did not report on methods used for randomization and were rated as unclear. Four studies were rated as low risk for allocation concealment (Awad 1995; Chen 2004; Pulpeiro 2000; Ritchie 1979). The other studies were rated as unclear for this item.

Antidepressants

Seven studies were reported the methods used for randomization and were rated as low risk for this item (Drossman 2003; Kuiken 2003; Tabas 2004; Talley 2008a; Vahedi 2005; Vahedi 2008; Vij 1991). The other studies were rated as unclear. Six studies were rated as low risk for allocation concealment (Drossman 2003; Kuiken 2003; Tabas 2004; Talley 2008a; Vahedi 2005; Vahedi 2008). The other studies were rated as unclear for this item.

Blinding

Bulking agents

Six studies were rated as low risk for blinding (Fowlie 1992; Jalihal 1990; Longstreth 1981; Nigam 1984; Ritchie 1979; Soltoft 1976). Rees 2005 used a single blind design and was rated as a high risk of bias. The other studies did not describe methods used for blinding and were rated as unclear.

Antispasmodics

Eleven studies were rated as low risk for blinding (Awad 1995; Fielding 1980; Ghidini 1986; Liu 1997; Mitchell 2002; Moshal 1979; Nigam 1984; Page 1981; Passaretti 1989a; Pulpeiro 2000; Ritchie 1979). The other studies did not describe methods used for blinding and were rated as unclear.

Antidepressants

Nine studies were rated as low risk for blinding (Kuiken 2003; Myren 1982; Rajagopalan 1998; Tabas 2004; Tack 2006a; Talley 2008a; Vahedi 2005; Vahedi 2008; Vij 1991). Drossman 2003 used a single blind design and was rated as a high risk of bias. The other studies did not describe methods used for blinding and were rated as unclear.

Incomplete outcome data

Bulking agents

Eleven studies were rated as low risk for incomplete outcome date (Aller 2004; Arthurs 1983; Fowlie 1992; Jalihal 1990; Kruis 1986; Longstreth 1981; Nigam 1984; Prior 1987; Rees 2005; Ritchie 1979; Soltoft 1976). One study was rated as unclear for this item (Lucey 1987).

Antispasmodics

Twenty-four studies were rated as low risk for incomplete outcome data (Awad 1995; Baldi 1991; Battaglia 1998; Capanni 2005; Cappello 2007; Centonze 1988; Delmont 1981; Dobrilla 1990; Dubarry 1977; Fielding 1980; Ghidini 1986; Gilvarry 1989; Kruis 1986; Lech 1988; Levy 1977; Liu 1997; Mitchell 2002; Moshal 1979; Nigam 1984; Page 1981; Passaretti 1989a; Piai 1979; Pulpeiro 2000; Ritchie 1979). Five studies were rated as unclear for this item (Chen 2004; Czalbert 1990; d'Arienzo 1980; Schafer 1990; Virat 1987).

Antidepressants

Eleven studies were rated as low risk for incomplete outcome data (Bahar 2008; Drossman 2003; Heefner 1978; Kuiken 2003; Masand 2009; Myren 1982; Tabas 2004; Tack 2006a; Vahedi 2005; Vahedi 2008; Vij 1991). Four studies were rated as unclear for this item (Bergmann 1991; Boerner 1988; Rajagopalan 1998; Talley 2008a).

Selective reporting

Bulking agents

All twelve studies were rated as low risk for selective reporting (Aller 2004; Arthurs 1983; Fowlie 1992; Jalihal 1990; Kruis 1986; Longstreth 1981; Lucey 1987; Nigam 1984; Prior 1987; Rees 2005; Ritchie 1979; Soltoft 1976).

Antispasmodics

Twenty-six studies were rated as low risk for selective reporting (Awad 1995; Baldi 1991; Battaglia 1998; Capanni 2005; Cappello 2007; Centonze 1988; Delmont 1981; Dobrilla 1990; Dubarry 1977; Fielding 1980; Ghidini 1986; Gilvarry 1989; Kruis 1986; Lech 1988; Levy 1977; Liu 1997; Mitchell 2002; Moshal 1979; Nigam 1984; Page 1981; Passaretti 1989a; Piai 1979; Pulpeiro 2000; Ritchie 1979; Schafer 1990; Virat 1987). Three studies were rated as unclear for this item (Chen 2004; Czalbert 1990; d'Arienzo 1980).

Antidepressants

Fourteen studies were rated as low risk for selective reporting (Bahar 2008; Bergmann 1991; Drossman 2003; Heefner 1978; Kuiken 2003; Masand 2009; Myren 1982; Rajagopalan 1998; Tabas 2004; Tack 2006a; Talley 2008a; Vahedi 2005; Vahedi 2008; Vij 1991). One study was rated as unclear for this item (Boerner 1988).

Other potential sources of bias

Bulking agents

All twelve studies were rated as low risk for other potential sources of bias (Aller 2004; Arthurs 1983; Fowlie 1992; Jalihal 1990; Kruis 1986; Longstreth 1981; Lucey 1987; Nigam 1984; Prior 1987; Rees 2005; Ritchie 1979; Soltoft 1976).

Antispasmodics

Twenty-six studies were rated as low risk for other potential sources of bias Awad 1995; Baldi 1991; Battaglia 1998; Capanni 2005; Cappello 2007; Centonze 1988; Delmont 1981; Dobrilla 1990; Dubarry 1977; Fielding 1980; Ghidini 1986; Gilvarry 1989; Kruis 1986; Lech 1988; Levy 1977; Liu 1997; Mitchell 2002; Moshal 1979; Nigam 1984; Page 1981; Passaretti 1989a; Piai 1979; Pulpeiro 2000; Ritchie 1979; Schafer 1990; Virat 1987). Three studies were rated as unclear for this item (Chen 2004; Czalbert 1990; d'Arienzo 1980).

Antidepressants

Fourteen studies were rated as low risk for other potential sources of bias (Bahar 2008; Bergmann 1991; Drossman 2003; Heefner 1978; Kuiken 2003;Masand 2009; Myren 1982; Rajagopalan 1998; Tabas 2004; Tack 2006a; Talley 2008a; Vahedi 2005; Vahedi 2008; Vij 1991). One study was rated as unclear for this item (Boerner 1988).

Effects of interventions

Bulking agents

Improvement of abdominal pain (outcome 1)

One study with a total of 80 patients reported a dichotomous outcome for improvement of abdominal pain. The RR was 0.91 (95% CI 0.61 to 1.36) using a fixed-effect model. A planned subgroup analysis for insoluble compared to soluble bulking agents could not be performed because there was only one study with soluble (Prior 1987) bulking agents.

Four studies with a total of 186 patients reported a continuous outcome for improvement of abdominal pain. Two of these studies did not report sufficient data to calculate a SMD (Fowlie 1992; Rees 2005). One study of an insoluble bulking agent with a total of 56 patients remained (Aller 2004). There was one study of a soluble fibre (Longstreth 1981). The pooled SMD was 0.03 (95% CI -0.34 to 0.40) using a fixed-effect model.

Improvement of global assessment (outcome 2)

Eleven studies, with a total of 565 patients reported a dichotomous outcome for improvement of global assessment. The chi-square test for heterogeneity was not statistically significant (P = 0.12). The pooled relative risk was not statistically significant using a random-effects model (RR 1.10; 95% CI 0.91 to 1.33). A RR of 0.95 (95% CI 0.76 to 1.19) was calculated for the studies using an insoluble bulking agent (244 patients) (Fowlie 1992; Kruis 1986; Lucey 1987; Rees 2005; Soltoft 1976). In the six studies with a soluble bulking agent the RR was 1.28 (95% CI 0.91 to 1.78; 321 patients) (Arthurs 1983; Jalihal 1990; Longstreth 1981; Nigam 1984; Prior 1987; Ritchie 1979).

One study of an insoluble bulking agent, comprising 56 patients, reported a continuous outcome for improvement of global assessment (Aller 2004). The standardized mean difference was not statistically significant (SMD -0.22; 95% CI -0.74 to 0.31).

Improvement of IBS symptom score (outcome 3)

Three studies, with a total of 126 patients reported a continuous outcome for improvement of IBS symptom score. One study did not report sufficient data to calculate a SMD (Fowlie 1992). Two studies, both of insoluble fibre, with a total of 84 patients remained (Aller 2004; Fowlie 1992). The chi-square test for heterogeneity was not statistically significant (P = 0.16). The pooled SMD was not statistically significant (SMD 0.00; 95%CI -0.43 to 0.43).

The main results for the bulking agents studies are summarized in additional Table 1.

Antispasmodics

Improvement of abdominal pain (outcome 4)

Thirteen studies with a total of 1392 patients reported a dichotomous outcome for improvement of abdominal pain. The chi-square test for heterogeneity was statistically significant (P = 0.01). The pooled RR was 1.32 (95% CI 1.12 to 1.55) using a random-effects model. Subgroup analyses showed statistically significant benefit for pinaverium bromide (RR 1.57; 95% CI 1.08 to 2.26; 158 patients) (Delmont 1981; Dubarry 1977; Virat 1987) and trimebutine (RR 1.32; 95% CI 1.07 to 1.64; 140 patients) (Fielding 1980; Ghidini 1986; Moshal 1979). There was no statistically significant benefit for scopolamine derivatives (RR 1.00; 95% CI 0.84 to 1.19; 360 patients) (Page 1981; Schafer 1990). The other subgroups contained only one study each.

Eight studies comprising 455 patients reported a continuous outcome for improvement of abdominal pain. The chi-square test for heterogeneity was statistically significant (P < 0.00001) The pooled SMD was 1.14 (95% CI 0.47 to 1.81) using a random-effects model. Statistically significant benefit was present for the subgroup cimetropium/dicyclomine (SMD 1.08; 95% CI 0.73 to 1.43; 146 patients) (Centonze 1988; Dobrilla 1990; Passaretti 1989a). There was no statistically significant benefit for pinaverium (SMD 0.44; 95% CI -0.20 to 1.08; 114 patients) (Awad 1995; Virat 1987). The other subgroups contained none or only one study each.

Improvement of global assessment (outcome 5)

Twenty-two studies with a total of 1983 patients reported a dichotomous outcome for improvement of global assessment. The chi-square test for heterogeneity was statistically significant (P < 0.0001). The pooled relative risk was statistically significant (RR 1.49; 95% CI 1.25 to 1.77) using a random-effects model. Statistically significant benefit was present for the subgroups cimetropium/dicyclomine (RR 1.78; 95% CI 1.15 to 2.75; 255 patients) (Centonze 1988; Dobrilla 1990; Page 1981; Passaretti

1989a), otilonium (RR 1.79; 95% CI 1.31 to 2.44; 363 patients) (Battaglia 1998; d'Arienzo 1980; Piai 1979); peppermint-oil (RR 2.25; 95% CI 1.70 to 2.98; 225 patients) (Capanni 2005; Lech 1988) and pinaverium bromide (RR 1.66; 95% CI 1.25 to 2.19; 308 patients) (Chen 2004; Delmont 1981; Levy 1977; Virat 1987). There was no statistically significant benefit for alverine (RR 1.20; 95% CI 0.80 to 1.80; 107 patients) (Mitchell 2002); mebeverine (RR 0.42; 95% CI 0.16 to 1.07; 80 patients) (Kruis 1986), scolpamine derivates (RR 4.43; 95% CI 0.47 to 41.67; 426 patients) (Nigam 1984; Ritchie 1979; Schafer 1990) and trimebutine (RR 0.97; 95% CI 0.68 to 1.38; 120 patients) (Fielding 1980; Ghidini 1986).

Two studies comprising 331 patients reported a continuous outcome for improvement of global assessment. The pooled SMD could not be estimated because of lack of data provided by the studies (Battaglia 1998; Delmont 1981).

Improvement of IBS symptom score (outcome 6)

Four studies with a total of 586 patients reported a dichotomous outcome for improvement of IBS symptom score. The chi-square test for heterogeneity was statistically significant (P = 0.004). The pooled relative risk was statistically significant (RR 1.86; 95% CI 1.26 to 2.76) using a random-effects model. Statistically significant benefit was present for the subgroups peppermint-oil (RR 1.94; 95% CI 1.09 to 3.46; 269 patients) (Capanni 2005; Cappello 2007; Czalbert 1990) and otilonium (RR 1.64; 95% CI 1.15 to 2.34; 317 patients) (Battaglia 1998).

Four studies comprising 243 patients reported a continuous outcome for improvement of global assessment. The chi-square test for heterogeneity was statistically significant (P = 0.00001). The pooled SMD was statistically significant (SMD 2.39; 95% CI 0.50 to 4.29) using a random-effects model. A statistically significant benefit was found for the pinaverium subgroup (SMD 0.51; 95% CI 0.19 to 0.84; 158 patients) (Awad 1995; Chen 2004). The other subgroups contained none or only one study each.

The main results for antispasmodics are summarized in additional Table 2.

Individual spasmolytic agents:

Cimetropium/dicyclomine

No statistically significant effect for improvement of abdominal pain was found for *Cimetropium/dicyclomine* (SMD 1.08; 95% CI 0.73 to 1.43; 146 patients) (Centonze 1988; Dobrilla 1990; Passaretti 1989a). A statistically significant effect for improvement of global assessment was found for *Cimetropium/dicyclomine* (RR 1.88; 95% CI 1.04 to 3.42; 255 patients) (Centonze 1988; Dobrilla 1990; Page 1981; Passaretti 1989a).

Mebeverine

No statistically significant effect for improvement of global assessment was found for *Mebeverine* (RR 0.83; 95% CI 0.31 to 2.23; 149 patients) (Kruis 1986).

Peppermint oil

A statistically significant effect for improvement of global assessment was found for *peppermint oil* (RR 2.25; 95% CI 1.70 to 2.98; 225 patients) (Capanni 2005; Lech 1988). A statistically significant effect for improvement of IBS symptom score was found for *peppermint oil* (RR 1.94; 95% CI 1.09 to 3.46; 269 patients) (Capanni 2005; Cappello 2007; Czalbert 1990).

Pinaverium

Pinaverium provided a statistically significant benefit for improvement of abdominal pain, RR 1.57 (95% CI 1.08 to 2.26; 158 patients) (Delmont 1981; Dubarry 1977; Virat 1987) and SMD 0.44 (95% CI -0.20 to 1.08; 114 patients) (Awad 1995; Virat 1987). A statistically significant effect for improvement of global assessment, RR1.87 (95% CI1.41 to 2.48; 308 patients) (Chen 2004; Delmont 1981; Levy 1977; Virat 1987) and IBS-symptom score was also found, SMD 0.51 (95% CI 0.19 to 0.84; 158 patients) (Awad 1995; Chen 2004).

Scopolamine derivatives

No statistically significant effect for improvement of global assessment was found for *Scopolamine derivatives* (RR 1.42; 95% CI 0.94 to 2.14; 442 patients) (Nigam 1984; Ritchie 1979; Schafer 1990).

Trimebutine

A statistically significant effect for improvement of abdominal pain was found for *Trimebutine* (RR 1.32; 95% CI 1.07 to 1.64; 140 patients) (Fielding 1980; Ghidini 1986; Moshal 1979). No statistically significant effect for improvement of global assessment (RR 0.97; 95% CI 0.68 to 1.38; 120 patients) (Fielding 1980; Ghidini 1986).

Other subgroups

There was not enough data to calculate a pooled estimate effect.

Antidepressants

Improvement of abdominal pain (outcome 7)

Eight studies with a total of 517 patients reported a dichotomous outcome for improvement of abdominal pain. The chi-square test for heterogeneity was statistically significant (P = 0.01). The pooled relative risk was statistically significant (RR was 1.49; 95% CI 1.05 to 2.12) using a random-effects model. Subgroup analyses showed no benefit for SSRIs (RR 2.29; 95% CI 0.79 to 6.68; 197 patients) (Kuiken 2003; Tabas 2004; Tack 2006a; Vahedi 2005), and a statistically significant benefit for TCAs (RR 1.26; 95% CI 1.03 to 1.55; 320 patients) (Drossman 2003; Heefner 1978; Vahedi 2008; Vij 1991).

Three studies with a total of 124 patients reported a continuous outcome for improvement of abdominal pain. The chi-square test for heterogeneity was statistically significant (P < 0.00001). The

pooled RR was 1.80 (95% CI -0.57 to 4.16). Subgroup analyses showed no significant benefit for TCA's (SMD was 0.53; 95% CI -1.23 to 2.29; 101 patients) (Boerner 1988; Drossman 2003; Rajagopalan 1998).

Improvement of global assessment (outcome 8)
Twelve studies, with a total of 750 patients reported a dichotomous outcome for improvement of global assessment. The chi-square test for heterogeneity was statistically significant (P = 0.01). The pooled relative risk was statistically significant (RR 1.57; 95% CI 1.23 to 2.00) using a random-effects model. Subgroup analyses suggest a benefit for SSRIs (RR 1.79; 95% CI 1.01 to 3.20; P = 0.05; 227 patients) (Kuiken 2003; Masand 2009; Tabas 2004; Talley 2008a) and showed a statistically significant benefit for TCAs (RR 1.45; 95% CI 1.13 to 1.86; 523 patients) (Bergmann 1991; Boerner 1988; Drossman 2003; Myren 1982; Nigam 1984; Talley 2008a; Vahedi 2008; Vij 1991).
One study assessing an SSRI (Tack 2006a), with a total of 22 patients reported a continuous outcome for improvement of global assessment. The pooled SMD was 3.32 (95% CI 1.95 to 4.68).

Improvement of IBS symptom score (outcome 9)
Three studies with a total of 159 patients reported a dichotomous outcome for improvement of symptom score. The chi-square test for heterogeneity was not statistically significant (P = 0.12). The pooled RR was 1.99 (95% CI 1.32 to 2.99) using a fixed-effect model. Subgroup analyses showed a statistically significant benefit for TCAs (RR 3.16; 95% CI 1.59 to 6.29; 87 patients) (Bahar 2008; Vahedi 2008).
Two studies, with a total of 122 patients reported a continuous outcome for improvement of IBS symptom score. The chi-square test for heterogeneity was statistically significant (P = 0.07). The pooled SMD was 0.38 (95% CI -0.30 to 1.06) using a random-effects model.
The main results for antidepressants are summarized in Table 3.
Additional comparison: adequate concealment of allocation
Bulking agents abdominal pain (outcome 10.2)
Two studies of bulking agents with adequate concealment of allocation reported a continuous outcome for improvement of abdominal pain (Longstreth 1981; Fowlie 1992). The chi-square test for heterogeneity was not statistically significant (P = 0.88). The pooled SMD using a fixed-effect model was -0.04 (95%CI -0.40 to 0.32; 119 patients).

Bulking agents: global assessment (outcome 11.1)
Five studies of bulking agents with adequate concealment of allocation reported a dichotomous outcome for improvement of abdominal pain (Fowlie 1992; Jalihal 1990; Longstreth 1981; Ritchie 1979; Soltoft 1976). Using a random-effects model, the pooled RR was 0.91 (95% CI 0.68 to 1.23; 193 patients).

Antispasmodics: abdominal pain (outcome 12.1)
Two studies of spasmolytic agents with adequate concealment of allocation reported a continuous outcome for improvement of abdominal pain (Awad 1995; Pulpeiro 2000). The chi-square test for heterogeneity was not statistically significant (P = 0.88). Using a fixed-effect model, the pooled SMD was 0.43 (95% CI 0.06 to 0.80; 115 patients).

Antispasmodics: global assessment (outcome 13.1)
Three studies of spasmolytic agents with adequate concealment of allocation reported a dichotomous outcome for improvement of global assessment (Chen 2004; Pulpeiro 2000; Ritchie 1979). The chi-square test for heterogeneity was not statistically significant (P= 0.25). Using a fixed-effect model, the pooled RR was 1.35 (95% CI 0.85 to 2.12; 219 patients).

Antidepressants: abdominal pain (outcome 14.1)
Five studies of antidepressant agents with adequate concealment of allocation reported a dichotomous outcome for improvement of abdominal pain. The chi-square test for heterogeneity was statistically significant (P = 0.06). Using a random-effects model, the pooled RR was 1.35 (95% CI 0.98 to 1.86; 364 patients) . Subgroup analyses showed no statistically significant benefit for SSRIs (RR 1.20; 95% CI 0.87 to 1.67) (Kuiken 2003; Tabas 2004; Vahedi 2005) or TCAs (RR 2.19; 95% CI 0.59 to 8.11) (Drossman 2003; Vahedi 2008).

Antidepressants: global assessment (outcome 15.1)
Four studies of antidepressant agents with adequate concealment of allocation reported a dichotomous outcome for global assessment. The chi-square test for heterogeneity was not statistically significant (P = 0.23). Using a fixed-effect model, the pooled RR was 1.42 (95% CI 1.12 to 1.80; 329 patients) (Drossman 2003; Kuiken 2003; Tabas 2004; Talley 2008a).

Antidepressants: IBS symptom score (outcome 16.1)
One study of antidepressants with adequate concealment of allocation reported a continuous outcome for improvement of IBS symptom score (Vahedi 2008). Using a fixed-effect model, the SMD was 0.75 (95% CI 0.17 to 1.32; 50 patients).

DISCUSSION

Bulking agents

The pooled data suggest that bulking agents do not provide any benefit for the treatment of IBS. No statistically significant differences between bulking agents and placebo were found for abdominal pain, global assessment or symptom score. Only 7 of the included studies had more than 30 patients and all studies had quality limitations (i.e. method of randomisation, double-blinding, concealment of treatment allocation, description of with-

drawals). There were five studies with adequate allocation concealment (Fowlie 1992; Jalihal 1990; Longstreth 1981; Ritchie 1979; Soltoft 1976). A sensitivity analysis of those studies with adequate allocation concealment, did not change the results. Subgroup analyses for the different type of bulking agents, soluble versus insoluble fibre, also gave no statistically significant findings.

We are aware of five systematic reviews of bulking agents for IBS. Jailwala 2000, who used less strict exclusion criteria than the present review, also concluded from an analysis of 13 studies that the efficacy of bulking agents is not clearly established. When Jailwala 2000 separately analysed high and low quality trials, the conclusion remained the same (Jailwala 2000). Akehurst 2001 included 7 studies on bulking agents in a review of IBS therapies and concluded that there was little reason to believe that bulking agents were effective for IBS (Akehurst 2001). Lesbros-Pantoflickova 2004 included 13 studies in their meta-analyses, of which 5 studies reported a statistically significant benefit of fibre treatment for the relief of global symptoms (OR 1.9; 95% CI 1.5 to 2.4). However, after exclusion of the low-quality trials, this effect was not statistically significant. In conclusion, they found no evidence to recommend bulking agents for the treatment of IBS (Lesbros-Pantoflickova 2004). Ford 2008 included 12 studies comparing fibre with placebo, and used persistent symptoms after treatment as an outcome measure. Ford 2008 calculated a RR of 0.87 (95% CI 0.76 to 1.00). A subgroup analysis identified a statistically significant benefit for ispaghula a soluble fibre (RR 0.78; 95% CI 0.63 to 0.96). Ford 2008 had almost the same strict inclusion criteria as our review but included different outcome analyses. Ford 2008 did not use an ITT-analyses, only extracted dichotomous outcome and pooled all the outcomes (global assessment of symptoms and abdominal pain) as one. Bijkerk 2004 examined the separate effects of soluble and insoluble fibres, on global assessment and constipation. Bijkerk 2004 found a beneficial overall effect for fibre in general (RR 1.33; 95% CI 1.19 to 1.50) and soluble fibres for global assessment of IBS (RR 1.55; 95% CI 1.35 to 1.78). We could not reproduce these findings (outcomes 1.1 to 3.2). A possible explanation for this is that Bijkerk 2004 included cross-over trials (7 of the 17 included studies), which were excluded in this review. Bijkerk 2004 also included two studies with no placebo comparison.

Antispasmodics

Spasmolytic agents compared to placebo provided a statistically significant benefit for abdominal pain, global assessment and IBS-symptom score. Spasmolytic agents are pharmacologically diverse and arbitrary choices were made regarding the pooling of results. We decided to treat peppermint-oil as an anti-spasmodic because of its known effect on smooth muscles. Trimebutine appears to be effective for abdominal pain, pinaverium for abdominal pain and global assessment, cimetropium/dicyclominand for global assessment and peppermint-oil for global assessment and symptom score. Only four studies had adequate allocation concealment (Awad 1995; Chen 2004; Pulpeiro 2000; Ritchie 1979). It is important to note that none of the studies involving peppermint-oil had adequate allocation concealment. When analysing the studies with adequate allocation concealment separately, the results get weaker and only improvement of abdominal pain has still a statistically significant benefit. Spasmolytics are extensively studied for their use in the treatment of IBS, however due to the diversity of types of spasmolytic agents, the number of studies for each compound are limited. Therefore most subgroups could not be pooled, and a type II error could have occurred.

Eight systematic reviews of antispasmodics for IBS have been published (Akehurst 2001; Brandt 2002; Ford 2008; Jailwala 2000; Lesbros-Pantoflickova 2004; Poynard 1994; Poynard 2001; Tack 2006b). Jailwala 2000 included 13 studies and found that all of the 7 high-quality trials demonstrated a benefit, mainly for abdominal pain, less so for constipation. Akehurst 2001 identified 12 studies and came to similar conclusions. Ford 2008 found consistent evidence of efficacy for otilonium (RR 0.55; 95% CI 0.31 to 0.97) and scopolamine (RR 0.63; 95% CI 0.51 to 0.78). Ford 2008 identified peppermint-oil as an individual group, included 4 studies and calculated a RR of 0.43 (95% CI 0.33 to 0.59). These results are almost identical to our own. However, Ford 2008 used a different method to assess methodological quality (Jadad scale), and rated three studies as high quality, resulting in a greater effect than seen in this review. In an update of a 1994 meta-analysis, Poynard 2001 included 23 trials comprising 6 types of drugs. Using a fixed-effect model, there was a statistically significant benefit for global assessment (Peto OR 2.13; 95%CI 1.77 to 2.58) and pain (Peto OR 1.65; 95%CI 1.30 to 2.10) (Poynard 2001).This review provides similar evidence of the efficacy of spasmolytic agents for IBS. The reviews from Lesbros-Pantoflickova 2004 and Tack 2006b concluded that there is some evidence that antispasmodic may improve symptoms of abdominal pain but are careful in recommending antispasmodics for the treatment of IBS due to the low methodological quality of the included RCTs.

Antidepressants

Antidepressants provide a statistically significant benefit over placebo for abdominal pain, global assessment and IBS-symptom score. Subgroup analyses for SSRIs and TCAs, showed a statistically significant improvement in global assessment for SSRIs and a statistically significant improvement in abdominal pain and symptom score for TCAs. A sensitivity analysis of the six studies with adequate allocation concealment showed a statistically significant benefit for improvement of symptom score and global assessment (Drossman 2003; Kuiken 2003; Tabas 2004; Talley 2008a; Vahedi 2005; Vahedi 2008).

Given the significantly positive effects of antidepressant medica-

tion, the clinical indication of antidepressant medication in IBS needs to be discussed. Careful examination of the domain descriptions in the individual studies, shows no differences in patient population between studies investigating antidepressants, antispasmodics or bulking agents. Two studies performed a direct comparison of antidepressants with bulking agents or antispasmodics (Nigam 1984; Ritchie 1979), but found no proof of the superiority of either compound.

We are aware of eight systematic reviews of antidepressants for IBS (Akehurst 2001; Brandt 2002; Ford 2009; Jailwala 2000; Jackson 2000; Lesbros-Pantoflickova 2004; Tack 2006b; Rahimi 2009). Most of these reviews are consistent with our results. Akehurst 2001 concluded from two studies that antidepressants were effective. Ford 2009 included 13 RCTs and found a RR of 0.66 (95% CI 0.57 to 0.78) for persistent symptoms after treatment, and no difference between SSRIs and TCAs. The Jailwala 2000 meta-analysis included 7 studies, all reporting beneficial effect, and concluded that it was not clear whether this was due to resolving abdominal symptoms, or to improved psychological health. The Jackson 2000 review included 11 studies on functional gastrointestinal disorders, 8 of which were enrolled IBS patients exclusively. Jackson 2000 identified a statistically significant effect for overall assessment (7 studies; OR 4.2; 95% CI 2.3 to 7.9) and abdominal pain (9 studies; SMD 0.9; 95% CI 0.6 to 1.2). The Lesbros-Pantoflickova 2004 review included 12 studies and found an OR: 2.6 (95% CI 1.9 to 3.5). They recommend antidepressant medication for the treatment of patients with severe IBS symptoms, i.e. patients with daily or persistent pain. Rahimi 2009 only investigated TCAs and found clinically and statistically significant control of IBS symptoms. They advised that treatment with TCAs should be limited to patients with moderate to severe IBS.

Brandt 2002 and Tack 2006b (a extended version of Brandt 2002) reported no beneficial effect for antidepressant medication. This difference may be due to less strict inclusion criteria: both included cross-over studies with no report of the first phase data. They also failed to conduct a meta-analysis of the data.

AUTHORS' CONCLUSIONS

Implications for practice

The limitations of drug therapy should be discussed with the patient before deciding to prescribe medication for IBS. Agreement should be reached on treatment objectives, usually this will be relief of the most troublesome symptom. Our findings support the use of antispasmodics, although, it is not entirely clear whether one antispasmodic is more effective than another. Physicians will be limited to those antispasmodics which are locally available.

Antidepressants may also have a role for the treatment of IBS. Antidepressants could be used in patients who seek drug therapy and who have not responded to antispasmodics. The effectiveness of antidepressants may vary with individual patient features.

Implications for research

It is likely that two different disease entities exist: constipation predominant IBS, and diarrhea predominant IBS. There may even be a third entity, patients with an alternating stool pattern. The pharmacological properties of bulking agents, spasmolytic agents and antidepressive medication suggest that different responses might be expected in these patient groups and this issue should be studied in future trials of "classic" drugs.

The variation in methods of outcome assessment in IBS studies is a validity problem. It is uncertain how precisely current outcome measures reflect the actual health status of the IBS patient. The need for more meaningful measures of response to treatment has led to the development of health-related quality of life measures including stool frequency and consistency, social, daily, physical and sexual functioning, sleep, pain, emotion, and change of health. Future research should use validated outcome measures for IBS, such as the IBS Quality of Life Questionnaire (IBSQOL), the IBS Quality of Life Measure (IBS-QOL), the Digestive Health Status Instrument (DHSI), the Functional Digestive Disorder Quality of Life questionnaire (FDDQOL), or the IBS-Q.

The concept of the brain-gut axis invites trials aimed at central and peripheral neural levels; apart from drug trials these may include cognitive behavioural therapy or other psychological interventions (e.g. hypnotherapy).

ACKNOWLEDGEMENTS

Funding for the IBD/FBD Review Group (September 1, 2010 - August 31, 2015) has been provided by the Canadian Institutes of Health Research (CIHR) Knowledge Translation Branch (CON - 105529) and the CIHR Institutes of Nutrition, Metabolism and Diabetes (INMD); and Infection and Immunity (III).

Miss Ila Stewart has provided support for the IBD/FBD Review Group through the Olive Stewart Fund.

REFERENCES

References to studies included in this review

Aller 2004 *{published data only}*
Aller R, de Luis DA, Izaola O, La Calle F, del Olmo L, Fernandez L, et al.Dietary intake of a group of patients with irritable bowel syndrome; relation between dietary fiber and symptoms. *Nutrition* 2004;**20**:735–7.

Arthurs 1983 *{published data only}*
Arthurs Y, Fielding JF. Double blind trial of ispaghula/poloxamer in the irritable bowel syndrome. *Ir Med J* 1983;**76**(5):253.

Awad 1995 *{published data only}*
Awad R, Dibildox M, Ortiz F. Irritable bowel syndrome treatment using pinaverium bromide as a calcium channel blocker. A randomized double-blind placebo-controlled trial. *Acta Gastroenterol Latinoam* 1995;**25**(3):137–44.

Bahar 2008 *{published data only}*
Bahar RJ, Collins BS, Steinmetz B, Ament ME. Double-blind placebo-controlled trial of amitriptyline for the treatment of irritable bowel syndrome in adolescents. *J Pediatr* 2008 Dec;**153**(6):872.

Baldi 1991 *{published data only}*
Baldi F, Longanesi A, Blasi A, Monello S, Cestari R, Missale G, et al.Clinical and functional evaluation of the efficacy of otilonium bromide: a multicenter study in Italy. *Ital J Gastroenterol* 1991;**23**(8 Suppl 1):60–3.

Battaglia 1998 *{published data only}*
Battaglia G, Morselli-Labate AM, Camarri E, Francavilla A, De Marco F, Mastropaolo G, et al.Otilonium bromide in irritable bowel syndrome: a double-blind, placebo-controlled, 15-week study. *Aliment Pharmacol Ther* 1998;**12**(10):1003–10.

Bergmann 1991 *{published data only}*
Bergmann M, Heddergott A, Schlosser T. Therapy of irritable colon with trimipramine (Herphonal) - A controlled clinical study [Die therapie des colon irritabile mittrimipramin (Herphonal) – Eine kontrollierte studie]. *Z Klin Med* 1991;**46**(23):1621–8.

Boerner 1988 *{published data only}*
Boerner D, Eberhardt R, Metz K, Schick E. Wirksamkeit ind vertraeglichkeit eines antidepressivums beim colon irritablie. *Therapiewoche* 1988;**38**:201–8.

Capanni 2005 *{published data only}*
Capanni M, Surrenti E, Biagini M R, Milani S, Surrenh C, Galli A. Efficacy of peppermint oil in the treatment of irritable bowel syndrome: A randomized, controlled trial. *Gazz Med Ital Arch Sci Med* 2005;**164**(2):119–26.

Cappello 2007 *{published data only}*
Cappello G, Spezzaferro M, Grossi L, Manzoli L, Marzio L. Peppermint oil (Mintoil) in the treatment of irritable bowel syndrome: a prospective double blind placebo-controlled randomized trial. *Dig Liver Dis* 2007;**39**(6):530–6.

Centonze 1988 *{published data only}*
Centonze V, Imbimbo BP, Campanozzi F, Attolini E, Daniotti S, Albano O. Oral cimetropium bromide, a new antimuscarinic drug, for long-term treatment of irritable bowel syndrome. *Am J Gastroenterol* 1988;**83**(11):1262–6.

Chen 2004 *{published data only}*
Chen SJ, Li GX, Wang LJ, Sun LM, Si JM. SF-36 quality of life in effectiveness assessment for irritable bowel syndrome. *World Chin J Dig* 2004;**12**(4):920–3.

Czalbert 1990 *{published data only}*
Czalbert HJ, Neder M, Feher K. Experiences with colpermintherapy (Tillots-England) at patients of irritable colon syndrome. *Gyogyszereszet* 1990;**34**(5):251–3.

d'Arienzo 1980 *{published data only}*
d'Arienzo A, d'Agotino L. L'ottilonio bromuro nel trattamento della sindrome del colon irritabile. *Rass Int Clin Ter* 1980;**60**(10):649–56.

Delmont 1981 *{published data only}*
Delmont J. The value of adding an antispasmodic musculotropic agent in the treatment of painful constipation in functional colopathies with bran. Double-blind study [Interet de l'adjonction d'un antispasmodique musculotrope au traitement des constipations douloureuses des colopathies fonctionnelles par le son. Essai en double insu]. *Med Chir Dig* 1981;**10**(4):365–70.

Dobrilla 1990 *{published data only}*
Dobrilla G, Imbimbo BP, Piazzi L, Bensi G. Longterm treatment of irritable bowel syndrome with cimetropium bromide: a double blind placebo controlled clinical trial. *Gut* 1990;**31**(3):355–8.

Drossman 2003 *{published data only}*
Drossman DA, Toner BB, Whitehead WE, Diamant NE, Dalton CB, Duncan S, et al.Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. *Gastroenterology* 2003;**125**:19–31.

Dubarry 1977 *{published data only}*
Dubarry JJ, Quinton A. Effet a court terme du bromure de pinaverium dans les oesophagites, gastro-duodenites et colopathies fonctionnelles. *Bordeaux Medical* 1977;**10**(21):1457–9.

Fielding 1980 *{published data only}*
Fielding JF. Double blind trial of trimebutine in the irritable bowel syndrome. *Ir Med J* 1980;**73**(10):377–9.

Fowlie 1992 *{published data only}*
Fowlie S, Eastwood MA, Prescott R. Irritable bowel syndrome: assessment of psychological disturbance and its influence on the response to fibre supplementation. *J Psychosom Res* 1992;**36**(2):175–80.

Ghidini 1986 *{published data only}*
Ghidini O, Saponati G, Intrieri L. Single drug treatment for irritable colon: Rociverine versus trimebutine maleate. *Curr Ther Res Clin Exp* 1986;**39**(4):541–8.

Gilvarry 1989 *{published data only}*
Gilvarry J, Kenny A, Fielding J F. The non-effect of pirenzepine in dietary resistant irritable bowel syndrome. *Ir J Med Sci* 1989;**158**(10):262.

Heefner 1978 *{published data only}*
Heefner JD, Wilder RM, Wilson ID. Irritable colon and depression. *Psychosomatics* 1978;**19**(9):540–7.

Jalihal 1990 *{published data only}*
Jalihal A, Kurian G. Ispaghula therapy in irritable bowel syndrome: improvement in overall well-being is related to reduction in bowel dissatisfaction. *J Gastroenterol Hepatol* 1990;**5**(5):507–13.

Kruis 1986 *{published data only}*
Kruis W, Weinzierl M, Schussler P, Holl J. Comparison of the therapeutic effect of wheat bran, mebeverine and placebo in patients with the irritable bowel syndrome. *Digestion* 1986;**34**(3):196–201.

Kuiken 2003 *{published data only}*
Kuiken S D, Tytgat G N, Boeckxstaens G E. The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: a double blind, randomized, placebo-controlled study. *Clin Gastroenterol Hepatol* 2003;**1**(3): 219–28.

Lech 1988 *{published data only}*
Lech Y, Olesen KM, Hey H, Rask-Pedersen E, Vilien M, Ostergaard O. Treatment of irritable bowel syndrome with peppermint oil. A double-blind study with a placebo [Behandling af colon irritabile med pebermynteolie. En dobbeltblind undersogelse med placebo]. *Ugeskr Laeger* 1988;**150**(40):2388–9.

Levy 1977 *{published data only}*
Levy C, Charbonnier A, Cachin M. Pinaverium bromide and functional colonic disease (double-blind study) [Bromure de pinaverium et colopathie fonctionnelle (etude a double insu)]. *Sem Hop Ther* 1977;**53**(7-8):372–4.

Liu 1997 *{published data only}*
Liu JH, Chen GH, Yeh HZ, Huang CK, Poon SK. Enteric-coated peppermint-oil capsules in the treatment of irritable bowel syndrome: a prospective, randomized trial. *J Gastroenterol* 1997;**32**(6):765–8.

Longstreth 1981 *{published data only}*
Longstreth GF, Fox DD, Youkeles L, Forsythe AB, Wolochow DA. Psyllium therapy in the irritable bowel syndrome. A double-blind trial. *Ann Intern Med* 1981;**95** (1):53–6.

Lucey 1987 *{published data only}*
Lucey MR, Clark ML, Lowndes J, Dawson AM. Is bran efficacious in irritable bowel syndrome? A double blind placebo controlled crossover study. *Gut* 1987;**28**(2):221–5.

Masand 2009 *{published data only}*
Masand PS, Pae CU, Krulewicz S, Peindl K, Mannelli P, Varia I M, et al.A double-blind, randomized, placebo-controlled trial of paroxetine controlled-release in irritable bowel syndrome. *Psychosomatics* 2009;**50**(1):78–86.

Mitchell 2002 *{published data only}*
Mitchell SA, Mee AS, Smith GD, Palmer KR, Chapman RW. Alverine citrate fails to relieve the symptoms of irritable bowel syndrome: results of a double-blind, randomized, placebo-controlled trial. *Aliment Pharmacol Ther* 2002;**16** (6):1187–95.

Moshal 1979 *{published data only}*
Moshal MG, Herron M. A clinical trial of trimebutine (Mebutin) in spastic colon. *J Int Med Res* 1979;**7**(3):231–4.

Myren 1982 *{published data only}*
Myren J, Groth H, Larssen SE, Larsen S. The effect of trimipramine in patients with the irritable bowel syndrome. A double-blind study. *Scand J Gastroenterol* 1982;**17**(7): 871–5.

Nigam 1984 *{published data only}*
Nigam P, Kapoor KK, Rastog CK, Kumar A, Gupta AK. Different therapeutic regimens in irritable bowel syndrome. *J Assoc Physicians India* 1984;**32**(12):1041–4.

Page 1981 *{published data only}*
Page JG, Dirnberger GM. Treatment of the irritable bowel syndrome with Bentyl (dicyclomine hydrochloride). *J Clin Gastroenterol* 1981;**3**(2):153–6.

Passaretti 1989a *{published data only}*
Passaretti S, Guslandi M, Imbimbo BP, Daniotti S, Tittobello A. Effects of cimetropium bromide on gastrointestinal transit time in patients with irritable bowel syndrome. *Aliment Pharmacol Ther* 1989;**3**(3):267–76.

Piai 1979 *{published data only}*
Piai G, Mazzacca G. Prifinium bromide in the treatment of the irritable colon syndrome. *Gastroenterology* 1979;**77**(3): 500–2.

Prior 1987 *{published data only}*
Prior A, Whorwell PJ. Double blind study of ispaghula in irritable bowel syndrome. *Gut* 1987;**28**(11):1510–3.

Pulpeiro 2000 *{published data only}*
Pulpeiro A, Marti ML, De Los Santos AR, Di Girolamo G. Propinox in the treatment of irritable bowel syndrome [Propinox en sindrome de intestino irritable]. *Prensa Medica Argentina* 2000;**87**(3):299–307.

Rajagopalan 1998 *{published data only}*
Rajagopalan M, Kurian G, John J. Symptom relief with amitriptyline in the irritable bowel syndrome. *J Gastroenterol Hepatol* 1998;**13**(7):738–41.

Rees 2005 *{published data only}*
Rees G, Davies J, Thompson R, Parker M, Liepins P. Randomised-controlled trial of a fibre supplement on the symptoms of irritable bowel syndrome. *J R Soc Health* 2005;**125**(1):30–4.

Ritchie 1979 *{published data only}*
Ritchie JA, Truelove SC. Treatment of irritable bowel syndrome with lorazepam, hyoscine butylbromide, and ispaghula husk. *Br Med J* 1979;**1**(6160):376–8.

Schafer 1990 *{published data only}*
Schafer E, Ewe K. The treatment of irritable colon. Efficacy and tolerance of buscopan plus, buscopan, paracetamol

and placebo in ambulatory patients with irritable colon [Behandlung des Colon irritabile. Wirksamkeit und Vertraglichkeit von Buscopan plus, Buscopan, Paracetamol und Plazebo bei ambulanten Patienten mit Colon irritabile]. *Fortschr Med* 1990;**108**(25):488–92.

Soltoft 1976 *{published data only}*
Soltoft J, Krag B, Gudmand-Hoyer E, Kristensen E, Wulff HR. A double-blind trial of the effect of wheat bran on symptoms of irritable bowel syndrome. *Lancet* 1976;**1** (7954):270–2.

Tabas 2004 *{published data only}*
Tabas G, Beaves M, Wang J, Friday P, Mardini H, Arnold G. Paroxetine to treat irritable bowel syndrome not responding to high-fiber diet: A double-blind, placebo-controlled trial. *Am J Gastroenterol* 2004;**99**(5):914–20.

Tack 2006a *{published data only}*
Tack J, Broekaert D, Fischler B, Van Oudenhove L, Gevers A M, Janssens J. A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. *Gut* 2006;**55**(8):1095–103.

Talley 2008a *{published data only}*
Talley NJ, Kellow JE, Boyce P, Tennant C, Huskic S, Jones M. Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial. *Dig Dis Sci* 2008;**53**(1):108–15.

Vahedi 2005 *{published data only}*
Vahedi H, Merat S, Rashidioon A, Ghoddoosi A, Malekzadeh R. The effect of fluoxetine in patients with pain and constipation-predominant irritable bowel syndrome: a double-blind randomized-controlled study. *Aliment Pharmacol Ther* 2005;**22**(5):381–5.

Vahedi 2008 *{published data only}*
Vahedi H, Merat S, Momtahen S, Kazzazi A S, Ghaffari N, Olfati G, et al.Clinical trial: the effect of amitriptyline in patients with diarrhoea-predominant irritable bowel syndrome. *Aliment Pharmacol Ther* 2008;**27**(8):678–84.

Vij 1991 *{published data only}*
Vij JG, Jiloha RC, Kumar N. Effect of antidepressant drug (doxepin) on irritable bowel syndrome patients. *Indian J Psychiatry* 1991;**33**:243–6.

Virat 1987 *{published data only}*
Virat J, Hueber D. Colopathy pain and dicetel. *Prat Med* 1987;**43**:32–4.

References to studies excluded from this review

Achord 1979 *{published data only}*
Achord JL. Irritable bowel syndrome and dietary fiber. *J Am Diet Assoc* 1979;**75**(4):452–3.

Alevizos 1989 *{published data only}*
Alevizos B, Christodoulou GN, Ioannidis C, Voulgari A, Mantidis A, Spiliadis C. The efficacy of amineptine in the treatment of depressive patients with irritable bowel syndrome. *Clin Neuropharmacol* 1989;**12 Suppl 2**:S66–76.

Andre 1979 *{published data only}*
Andre PP, De Windt J, Dony A. Basic treatment of spastic colon (multicenter trial with oxazepam plus scopolamine butyl nitrate). *ARS MED INT TIJDSCHR PRAKT THER* 1979;**8**(19):1673–7.

Anonymous 1966 *{published data only}*
Anonymous. Evaluation of an antispasmodic agent. Methixene hydrochloride (Trest). *JAMA* 1966;**195**(10): 851.

Anonymous 1976 *{published data only}*
Anonymous. Irritable colon syndrome treated with an antispasmodic drug. *Practitioner* 1976;**217**(1298):276–80.

Anonymous 1982 *{published data only}*
Anonymous. Is pinaverium bromide suitable for treatment of spastic colon?. *Ned Tijdschr Geneeskd* 1982;**126**(38): 1746.

Anonymous 1986 *{published data only}*
Anonymous. Some antispasmodic drugs for the irritable bowel syndrome. *Drug Ther Bull* 1986;**24**(24):93–5.

Anonymous 1995 *{published data only}*
Anonymous. Effective and well-tolerated spasmolytic agent in the treatment of irritable colon syndrome. *Therapiewoche* 1995;**45**(9):560, 562-4.

Anonymous 1998 *{published data only}*
Anonymous. Mebeverine suspension in childhood irritable bowel syndrome. *Arztliche Prax Padiatr* 1998;**12**:26–7.

Anonymous 2002a *{published data only}*
Anonymous. SSRIs to treat irritable bowel?. *Pharm J* 2002; **268**:755.

Anonymous 2002b *{published data only}*
Anonymous. Trimebutine: Another therapeutic choice for irritable bowel syndrome. *Chin J Gastroenterol* 2002;**7**(4): 206–8.

Anonymous 2008 *{published data only}*
Anonymous. Peppermint oil can relieve symptoms of irritable bowel syndrome. *Dtsch Apoth* 2008;**148**(50):41.

Arffmann 1985 *{published data only}*
Arffmann S, Andersen JR, Hegnhoj J, Schaffalitzky de Muckadell OB, Mogensen NB, Krag E. The effect of coarse wheat bran in the irritable bowel syndrome. A double-blind cross-over study. *Scand J Gastroenterol* 1985;**20**(3):295–8.

Awad 1997 *{published data only}*
Awad RA, Cordova VH, Dibildox M, Santiago R, Camacho S. Reduction of post-prandial motility by pinaverium bromide a calcium channel blocker acting selectively on the gastrointestinal tract in patients with irritable bowel syndrome. *Acta Gastroenterol Latinoam* 1997;**27**(4):247–51.

Baldi 1992 *{published data only}*
Baldi F, Longanesi A, Blasi A, Monello S, Cestari R, Missale G, et al.Octylonium bromide in the treatment of the irritable bowel syndrome: a clinical-functional study. *Hepatogastroenterology* 1992;**39**(5):392–5.

Barbier 1981 *{published data only}*
Barbier P. Double blind controlled trial of a new colonic antispasmodic agent, actylonium bromide [Etude controlee

en double aveugle d'un nouvel antspasmodique colique]. *Ars Medici* 1981;**36**(21):1879–80.

Bassotti 1988 ***{published data only}***
Bassotti G. Dietary fibers in gastroenterology. *MED RIV ENCICL MED ITAL* 1988;**8**(2):141–5.

Baume 1972 ***{published data only}***
Baume P. Mebeverine, an effective agent in the irritable colon syndrome. *Aust NZ J Med* 1972;**2**(1):34–6.

Bazzocchi 1992 ***{published data only}***
Bazzocchi G, Difalco A, Bensi G, Lanfranchi GA. The effect of muscarinic blockade on anorectal function in patients with constipation-predominant irritable bowel syndrome. *Curr Ther Res Clin Exp* 1992;**52**(1):135–43.

Berthelot 1981 ***{published data only}***
Berthelot J, Centonze V. Etude controlee en double aveugle Duspatalin (Mebeverine) contre placebo, dans le traitement du colon irritable. *Gaz Med Fr* 1981;**88**(16):2341–3.

Birt 1989 ***{published data only}***
Birt M, Dumitrascu D. Treatment with antidepressants in biliary dyskinesia and irritable colon. *Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna* 1989; **41**(3):277–82.

Bixquert-Jimenez 2005 ***{published data only}***
Bixquert-Jimenez M, Bixquert-Pla L. Antidepressant therapy in functional gastrointestinal disorders. *Gastroenterol Hepatol* 2005;**28**(8):485–92.

Block 1983 ***{published data only}***
Block J, Myren J, Larssen SE, Larsen S. Trimipramin (Surmontil) and placebo in irritable colon syndrome. A double-blind study [Trimipramin (Surmontil) og placebo ved irritable colon syndrom. En dobbeltblind studie]. *Tidsskr Nor Laegeforen* 1983;**103**(11):903–5.

Bosaeus 2004 ***{published data only}***
Bosaeus I. Fiber effects on intestinal functions (diarrhoea, constipation and irritable bowel syndrome). *Clin Nutr Suppl* 2004;**1**(2):33–8.

Bouchoucha 2000 ***{published data only}***
Bouchoucha M, Faye A, Devroede G, Arsac M. Effects of oral pinaverium bromide on colonic response to food in irritable bowel syndrome patients. *Biomed Pharmacother* 2000;**54**(7):381–7.

Budavari 2002 ***{published data only}***
Budavari AI, Olden KW. The use of antidepressants in irritable bowel syndrome. *Pract Gastroenterol* 2002;**26**(3): 13–27.

Burden 2001 ***{published data only}***
Burden S. Dietary treatment of irritable bowel syndrome: current evidence and guidelines for future practice. *J Hum Nutr Diet* 2001;**14**(3):231–41.

Camarri 1981 ***{published data only}***
Camarri E, Guidoni G, Marini G, Schiaroli G. La terapia del colon irritabile. Risultati del trattamento con un nuovo antispastico: l'ottilonio bromuro. *Policlinico [Prat]* 1981; **88**:174–84.

Camarri 1986 ***{published data only}***
Camarri E. Fenoverine: Smooth muscle synchronizer for the management of gastro-intestinal conditions. II. A trimebutine-controlled, double-blind, crossover clinical evaluation. *Curr Med Res Opin* 1986;**10**(1):52–7.

Camatte 1966 ***{published data only}***
Camatte R, Sarles H. Functional colonic diseases and Mebeverine. *Sem Ther* 1966;**42**(9):509–10.

Cann 1984 ***{published data only}***
Cann PA, Read NW, Holdsworth CD. What is the benefit of coarse wheat bran in patients with irritable bowel syndrome?. *Gut* 1984;**25**(2):168–73.

Capron 1981 ***{published data only}***
Capron JP, Zeitoun P, Julien D. A multicenter controlled trial of a combination of kaolin, sterculia gum, meprobamate, and magnesium salts, in the irritable bowel syndrome (author's transl) [Effets d'un medicament associant kaolin, gomme sterculia, magnesium et meprobamate le traitement du colon irritable. Resultats d'une etude controlee multicentrique]. *Gastroenterol Clin Biol* 1981;**5**(1):67–72.

Capurso 1984 ***{published data only}***
Capurso L, Koch M, Tarquini M, Dezi A, Papi C, Fracasso P. The irritable bowel syndrome. A cross-over study of octilonium bromide, mebeverine and placebo. *Clin Trials J* 1984;**21**(5):285–91.

Capurso 1992 ***{published data only}***
Capurso L, Del Sette F, Ferrario F, Tarquini M. The octylonium bromide-benzodiazepine combination for management of the irritable bowel syndrome. *Clin Ter* 1992;**141**(8):121–7.

Carling 1989 ***{published data only}***
Carling L, Svedberg LE, Hulten S. Short term treatment of the irritable bowel syndrome: A placebo-controlled trial of peppermint oil against hyoscyamine. *Opuscula Medica* 1989;**34**(3):55–7.

Cerrato 2001 ***{published data only}***
Cerrato PL. Altmed watch. Peppermint oil holds its own as a treatment for IBS. *Contemp Ob Gyn* 2001;**46**(5):128.

Chapman 1990 ***{published data only}***
Chapman ND, Grillage MG, Mazumder R, Atkinson SN. A comparison of mebeverine with high-fibre dietary advice and mebeverine plus ispaghula in the treatment of irritable bowel syndrome: an open, prospectively randomised, parallel group study. *Br J Clin Pract* 1990;**44**(11):461.

Chassany 2007 ***{published data only}***
Chassany O, Bonaz B, Bruley Des Varannes S, Bueno L, Cargill G, Coffin B, et al.Acute exacerbation of pain in irritable bowel syndrome: efficacy of phloroglucinol/ trimethylphloroglucinol. A randomized, double-blind, placebo-controlled study. *Aliment Pharmacol Ther* 2007;**25** (9):1115–23.

Chen 1999 ***{published data only}***
Chen ZY, Yao JH. Alverine/dimeticone versus nifedipine in treating irritable bowel syndrome. *Chinese Journal of New Drugs and Clinical Remedies* 1999;**18**(2):94–6.

Chen 2004a *{published data only}*
Chen Y, Wang X, Shang J. Paroxetine and Polyethylene Glycol (PEG) 4000 Therapy in Irritable Bowel Syndrome. *Chinese Mental Health Journal* 2004;**18**(11):806–9.

Chevrel 1978 *{published data only}*
Chevrel B. Treatment of functional intestinal disorders with carbomucil [Traitement des troubles fonctionnels intestinaux par le carbomucil]. *Med Chir Dig* 1978;**7**(5): 443–5.

Chicharro 2007 *{published data only}*
Chicharro Serrano L. Fiber in the treatment of intestinal diseases. *Farm Hosp* 2007;**187**:7–13.

Christen 1990 *{published data only}*
Christen MO. Action of pinaverium bromide, a calcium-antagonist, on gastrointestinal motility disorders. *Gen Pharmacol* 1990;**21**(6):821–5.

Clouse 1994 *{published data only}*
Clouse RE, Lustman PJ, Geisman RA, Alpers DH. Antidepressant therapy in 138 patients with irritable bowel syndrome: a five-year clinical experience. *Aliment Pharmacol Ther* 1994;**8**(4):409–16.

Clouse 2003 *{published data only}*
Clouse RE. Antidepressants for irritable bowel syndrome. *Gut* 2003;**52**(4):598–9.

Cook 1990 *{published data only}*
Cook IJ, Irvine EJ, Campbell D, Shannon S, Reddy SN, Collins SM. Effect of dietary fiber on symptoms and rectosigmoid motility in patients with irritable bowel syndrome. A controlled, crossover study. *Gastroenterology* 1990;**98**(1):66–72.

Copé 1981 *{published data only}*
Copé R. Comparative clinical study of the combination of clidinium(br)-chlordiazepoxide and trimebutine in the treatment of functional colopathies. *Med Chir Dig* 1981;**10** (8):713–7.

Corazza 1983 *{published data only}*
Corazza GR, Vaira D, Milletti S. Controlled clinical evaluation of pinaverium bromide and trimebutine in functional disorders of the colon. *Acta Ther* 1983;**9**(4): 383–9.

Corazziari 1999 *{published data only}*
Corazziari E. Role of opioid ligands in the irritable bowel syndrome. *Can J Gastroenterol* 1999;**13 Suppl A**:71A–5A.

Creed 2003 *{published data only}*
Creed F, Fernandes L, Guthrie E, Palmer S, Ratcliffe J, Read N, et al.The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. *Gastroenterology* 2003;**124**:303–17.

Creed 2006 *{published data only}*
Creed F. How do SSRIs help patients with irritable bowel syndrome?. *Gut* 2006;**55**(8):1065–7.

Crowell 2004 *{published data only}*
Crowell MD, Jones MP, Harris LA, Dineen TN, Schettler VA, Olden KW. Antidepressants in the treatment of irritable bowel syndrome and visceral pain syndromes. *Curr Opin Investig Drugs* 2004;**5**(7):736–42.

Curtiss 2008 *{published data only}*
Curtiss FR. Irritable bowel syndrome and antidepressants. *J Manag Care Pharm* 2008;**14**(9):882–5.

Czimmer 2001 *{published data only}*
Czimmer J, Suto G, Kiraly A, Mozsik G. Otilonium bromide enhances sensory thresholds of volume and pressure in patients with irritable bowel syndrome. *J Physiol Paris* 2001;**95**(1-6):153–6.

Darnis 1980 *{published data only}*
Darnis F. Clinical study of a new medication in the treatment of functional colopathies [Etude clinique d'une medication nouvelle dans le traitement des colopathies fonctionnelles]. *Med Chir Dig* 1981;**10**(5):461–2.

Defrance 1991 *{published data only}*
Defrance P, Casini A. A comparison of the action of otilonium bromide and pinaverium bromide: study conducted under clinical control. *Ital J Gastroenterol* 1991; **23**(8 Suppl 1):64–6.

De Groote 1968 *{published data only}*
De Groote J, Standaert L. The effect of a new musculotropic subtance 9 (Mebeverine) on irritable colon. *Tijdschr Gastroenterol* 1968;**11**(5):524–8.

de la Garoullaye 1991 *{published data only}*
de la Garoullaye G, Bordet P. The combination fenoverine/ PVPP + karaya gum in the treatment of irritable bowel. *Comptes Rendus de Therapeutique et de Pharmacologie Clinique* 1991;**9**(93):3–10.

Delvaux 1997 *{published data only}*
Delvaux M, Wingate D. Trimebutine: mechanism of action, effects on gastrointestinal function and clinical results. *J Int Med Res* 1997;**25**(5):225–46.

Dettmar 1998 *{published data only}*
Dettmar PW, Sykes J. A comparison between a fixed combination of ispaghula husk and mebeverine hydrochloride or mebeverine hydrochloride plus high-fibre dietary advice in the treatment of irritable bowel syndrome. *J Clin Res* 1998;**1**:453–9.

Dettmar 1999 *{published data only}*
Dettmar PW, Sykes J. A multicentre, general practice study of the effectiveness and acceptability of an ispaghula husk-mebeverine hydrochloride combination product in irritable bowel syndrome. *J Clin Res* 1998;**1**:429–38.

Dew 1984 *{published data only}*
Dew MJ, Evans BK, Rhodes J. Peppermint oil for the irritable bowel syndrome: a multicentre trial. *Br J Clin Pract* 1984;**38**(11-12):394, 398.

Diaz-Rubio 1985 *{published data only}*
Diaz-Rubio M, De Onis Sanz, Enriquez Gonzalez L, Esteban Bernaldez JM. Effects of wheat bran in the irritable bowel syndrome. *Ann Med Interna* 1985;**2**(9):420–2.

Dioguardi 1991 *{published data only}*
Dioguardi N, De FR, Agape D, Antoniozzi F, Ballarin E, Ferrara A, et al.Octilonium bromide-diazepam versus

propantheline bromide-bromazepam in the treatment of irritable bowel-syndrome: A multicenter, randomized, controlled, double-blind trial. *Ter Mod* 1991;**5**(4):97–104.

Dubinin 1987 ***{published data only}***
Dubinin AV, Kabanov AV, Kirkin BV, Kolkunova GK, Igorianova NA. Bran in the treatment of irritable bowel syndrome. *Vopr Pitan* 1987;**1**:13–6.

Ehsanullah 1985 ***{published data only}***
Ehsanullah M, Lee DA, Williams T, Pollard P, Gazzard B. The effect of secoverine hydrochloride on stimulated sigmoid motility: a double-blind, placebo controlled cross-over study in irritable bowel syndrome. *Br J Clin Pharmacol* 1985;**19**(3):301–5.

Eisenburg 1978 ***{published data only}***
Eisenburg J, Kruis W, Schussler P, Weinzierl M. The irritable colon syndrome. New therapeutic possibilities in the treatment of a frequent syndrome [Das irritable kolon–syndrom. Neue therapeuische wege bei der behandlung eines haufigen krakheitsbildes]. *Fortschr Med* 1978;**96**(41):2064–70.

Evangelista 2004 ***{published data only}***
Evangelista S. Quaternary ammonium derivatives as spasmolytics for irritable bowel syndrome. *Curr Pharm Des* 2004;**10**(28):3561–8.

Evans 1996 ***{published data only}***
Evans JM, Fleming KC, Talley NJ, Schleck CD, Zinsmeister AR, Melton LJ. Relation of colonic transit to functional bowel disease in older people: a population-based study. *J Am Geriatr Soc* 1998;**46**(1):83–7.

Ferrari 1986 ***{published data only}***
Ferrari A, Cavallero M, Spandre M. Double-blind study of a new antimuscarinic, cimetropium bromide, in patients with irritable bowel syndrome. *Clin Ther* 1986;**8**(3):320–8.

Fielding 1979 ***{published data only}***
Fielding JF, Melvin K. Dietary fibre and the irritable bowel syndrome. *J Hum Nutr* 1979;**33**(4):243–7.

Fielding 1984 ***{published data only}***
Fielding JF, Kehoe M. Different dietary fibre formulations and the irritable bowel syndrome. *Ir J Med Sci* 1984;**153** (5):178–80.

Fioramonti 1988 ***{published data only}***
Fioramonti J, Frexinos J, Staumont G, Bueno L. Inhibition of the colonic motor response to eating by pinaverium bromide in irritable bowel syndrome patients. *Fundam Clin Pharmacol* 1988;**2**(1):19–27.

Floch 1988 ***{published data only}***
Floch MH. The irritable bowel syndrome: the possible link between dietary fiber deficiency and disturbed intestinal motility. *Am J Gastroenterol* 1988;**83**(9):963–4.

Francis 1994 ***{published data only}***
Francis CY, Whorwell PJ. Bran and irritable bowel syndrome: time for reappraisal. *Lancet* 1994;**344**(8914): 39–40.

Frexinos 1985 ***{published data only}***
Frexinos J, Fioramonti J, Bueno L. Effect of trimebutine on colonic myoelectrical activity in IBS patients. *Eur J Clin Pharmacol* 1985;**28**(2):181–5.

Fritz 1967 ***{published data only}***
Fritz A, Sardet M, Tendil H. Contribution to the treatment of colonic diseases. (Apropos of the uses of a new synthetic spasmolytic drug, mebeverine hydrochloride). *Rev Corps Sante.Armees Terre Mer Air* 1967;**8**(3):349–58.

Galeone 1986a ***{published data only}***
Galeone M, Benazzi E, Bossi M. Clinical and instrumental evaluation by multiple colonic manometry of tiropramide, trimebutine and octilonium bromide in irritable colon: II. Multiple dose oral administration. *Pharmatherapeutica* 1986;**4**(8):496–509.

Galeone 1986b ***{published data only}***
Galeone M, Stock F, Moise G. Pinaverium bromide versus otilonium bromide in patients with irritable bowel syndrome. *Curr Ther Res Clin Exp* 1986;**39**(4):613–24.

Geismar 1971 ***{published data only}***
Geismar P. Investigation of the effect of a new spasmolytic preparation (Spasmeks) on spastic colon [Undersogelse over virkningen of et nyt spasmolytikum (Spasmeks) pa colon irritabile]. *Ugeskr Laeger* 1971;**133**(33):1610–2.

Geoffroy 1977 ***{published data only}***
Geoffroy H. The treatment of the irritable colon syndrome by a musculotropic antispasmodic: Duspatalin. *Gaz Med Fr* 1977;**84**(12):1331–3.

Giaccari 2001 ***{published data only}***
Giaccari S, Grasso G, Tronci S, Allegretta L, Sponziello G, Montefusco A, et al.Partially hyrdrolyzed guar gum: A fiber as coadiuvant in irritable bowel syndrome. *Clinica Terapeutica* 2001;**152**(1):21–5.

Giannini 2006 ***{published data only}***
Giannini E G, Mansi C, Dulbecco P, Savarino V. Role of partially hydrolyzed guar gum in the treatment of irritable bowel syndrome. *Nutrition* 2006;**22**(3):334–42.

Gibbons 1979 ***{published data only}***
Gibbons D. Oral hyoscine butylbromide for irritable bowel syndrome?. *Br Med J* 1979;**1**(6165):752.

Gilbody 2000 ***{published data only}***
Gilbody JS, Fletcher CP, Hughes IW, Kidman SP. Comparison of two different formulations of mebeverine hydrochloride in irritable bowel syndrome. *Int J Clin Pract* 2000;**54**(7):461–4.

Glende 2002 ***{published data only}***
Glende M, Morselli-Labate AM, Battaglia G, Evangelista S. Extended analysis of a double-blind, placebo-controlled, 15-week study with otilonium bromide in irritable bowel syndrome. *Eur J Gastroenterol Hepatol* 2002;**14**(12): 1331–8.

Gnauck 1977 ***{published data only}***
Gnauck R. Value of high fiber diet in treatment of diverticulosis, constipation and irritable colon. *Therapiewoche* 1977;**27**(37):6411–2.

Golechha 1982 *{published data only}*
Golechha AC, Chadda VS, Chadda S, Sharma SK, Mishra SN. Role of ispaghula husk in the management of irritable bowel syndrome (a randomized double-blind crossover study). *J Assoc Physicians India* 1982;**30**(6):353–5.

Gorard 1994 *{published data only}*
Gorard DA, Libby GW, Farthing MJ. Influence of antidepressants on whole gut and orocaecal transit times in health and irritable bowel syndrome. *Aliment Pharmacol Ther* 1994;**8**(2):159–66.

Gorard 1995 *{published data only}*
Gorard DA, Libby GW, Farthing MJ. Effect of a tricyclic antidepressant on small intestinal motility in health and diarrhea-predominant irritable bowel syndrome. *Dig Dis Sci* 1995;**40**(1):86–95.

Greenbaum 1981 *{published data only}*
Greenbaum DS, Stein GE. Psyllium and the irritable bowel syndrome. *Ann Intern Med* 1981;**95**(5):660.

Greenbaum 1984 *{published data only}*
Greenbaum DS. Preliminary report on antidepressant treatment of irritable bowel syndrome: comments on comparison with anxiolytic therapy. *Psychopharmacol Bull* 1984;**20**(4):622–8.

Greenbaum 1987 *{published data only}*
Greenbaum DS, Mayle JE, Vanegeren LE, Jerome JA, Mayor JW, Greenbaum RB, et al.Effects of desipramine on irritable bowel syndrome compared with atropine and placebo. *Dig Dis Sci* 1987;**32**(3):257–66.

Grigoleit 2005 *{published data only}*
Grigoleit H, Grigoleit P. Peppermint oil in irritable bowel syndrome. *Phytomedicine* 2005;**12**(8):601–6.

Guerre 1979 *{published data only}*
Guerre J, Neuman M. Treatment of chronic colonic diseases with a new topical digestive agent, mucilage (karaya gum) combined with polyvinylpolypyrrolidone (P.V.P.P.). *Med Chir Dig* 1979;**8**(7):679–82.

Halpert 2005 *{published data only}*
Halpert A, Dalton CB, Diamant NE, Toner BB, Hu Y, Morris CB, et al.Clinical response to tricyclic antidepressants in functional bowel disorders is not related to dosage. *Am J Gastroenterol* 2005;**100**:664–71.

Han 2009 *{published data only}*
Han C, Masand PS, Krulewicz S, Peindl K, Mannelli P, Varia IM, et al.Childhood abuse and treatment response in patients with irritable bowel syndrome: a post-hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release. *J Clin Pharm Ther* 2009;**34**(1):79–88.

Hebden 2002 *{published data only}*
Hebden JM, Blackshaw E, D'Amato M, Perkins AC, Spiller RC. Abnormalities of GI transit in bloated irritable bowel syndrome: effect of bran on transit and symptoms. *Am J Gastroenterol* 2002;**97**:2315–20.

Herxheimer 1979 *{published data only}*
Herxheimer A, Misiewicz JJ. Oral hyoscine butylbromide for irritable bowel syndrome?. *Br Med J* 1979;**1**(6165):752.

Hotz 1994 *{published data only}*
Hotz J, Plein K. Effect of psyllium seeds compared to wheat bran on stool frequency and complaints in patients with irritable bowel syndrome and constipation. *Medizinische Klinik* 1994;**89**(12):645–51.

Houghton 1997 *{published data only}*
Houghton LA, Rogers J, Whorwell PJ, Campbell FC, Williams NS, Goka J. Zamifenacin (UK-76, 654) a potent gut M3 selective muscarinic antagonist, reduces colonic motor activity in patients with irritable bowel syndrome. *Aliment Pharmacol Ther* 1997;**11**(3):561–8.

Inauen 1994 *{published data only}*
Inauen W, Halter F. Clinical efficacy, safety and tolerance of mebeverine slow release (200 mg) vs mebeverine tablets in patients with irritable bowel syndrome. *Drug Invest* 1994;**8**(4):234–40.

Iwanaga 2002 *{published data only}*
Iwanaga Y. Physicochemical and pharmacological characteristic and clinical efficacy of an anti-irritable bowel syndrome agent, polycarbophil calcium (Polyful). *Nippon Yakurigaku Zasshi* 2002;**119**(3):185–90.

Jackson 1998 *{published data only}*
Jackson II A, Ofman J. Peppermint oil for irritable bowel syndrome: Remedy or herbal folklore. *Integr Med* 1998;**1**(4):163–5.

Jafri 2006 *{published data only}*
Jafri W, Yakoob J, Hussain S, Jafri N, Islam M. Phloroglucinol in irritable bowel syndrome. *J Pak Med Assoc* 2006;**56**(1):5–8.

Jayanthi 1998 *{published data only}*
Jayanthi V, Malathi S, Ramathilakam B, Dinakaran N, Balasubramanian V, Mathew S. Role of pinaverium bromide in south Indian patients with irritable bowel syndrome. *J Assoc Physicians India* 1998;**46**(4):369–71.

Ji 2007 *{published data only}*
Ji HZ, Wu XW, Xu XB, Sun Q, Liu Y, Zhang L, et al.Evaluating the clinical effect and quality of life in the elderly with functional bowel disorder after treatment with pinaverium bromide. *J Clin Rehab Tissue Eng Res* 2007;**11**(12):2275–8.

Jing 2004 *{published data only}*
Jing D, Xu M, Chen Z, Zhang J, Wang P, Jiang H, et al.Emotional disorders and treatment in patients with refractory irritable bowel syndrome. *Chin J Gastroenterol* 2004;**9**(2):90–3.

Kaushik 2002 *{published data only}*
Kaushik A, Pursnani ML, Kar P. Multicenter phase III clinical trial of otilonium bromide in irritable bowel syndrome. *Indian Journal of Gastroenterology* 2002;**21**:85–6.

Kirsch 2000 *{published data only}*
Kirsch MA, Louie AK. Paroxetine and irritable bowel syndrome. *Am J Psychiatry* 2000;**157**(9):1523–4.

Koch 1998 *{published data only}*
Koch TR. Peppermint oil and irritable bowel syndrome. *Am J Gastroenterol* 1998;**93**(11):2304–5.

Koruda 1993 *{published data only}*
Koruda M J. Dietary fiber and gastrointestinal disease. *Surg Gynecol Obstet* 1993;**177**(2):209–14.

Kountouras 2002 *{published data only}*
Kountouras J, Chatzopoulos D, Zavos C, Boura P, Venizelos J, Kalis A. Efficacy of trimebutine therapy in patients with gastroesophageal reflux disease and irritable bowel syndrome. *Hepato-Gastroenterology* 2002;**49**:193–7.

Kumar 1987 *{published data only}*
Kumar A, Kumar N, Vij JC, Sarin SK, Anand BS. Optimum dosage of ispaghula husk in patients with irritable bowel syndrome: correlation of symptom relief with whole gut transit time and stool weight. *Gut* 1987;**28**(2):150–5.

Kunze 1990 *{published data only}*
Kunze M, Seidel HJ, Stube G. Comparative studies of the effectiveness of brief psychotherapy, acupuncture and papaverin therapy in patients with irritable bowel syndrome. *Z Gesamte Inn Med* 1990;**45**(20):625–7.

Lafon 1982 *{published data only}*
Lafon J, Cougard A, Pin G, Julien D. Is the combination of kaolin, sterculia gum and magnesium superior to sound in the treatment of irritable colon? Controlled clinical trial [L'association kaolin, gomme sterculia,magnesium est–elle suerieure au son dans le traitement symptomatique du colon irritable? Etude clinique controlee]. *Rev Proct* 1982; **1**:67–76.

Lambert 1989 *{published data only}*
Lambert JP, Dickerson JW. A survey of high-fibre diet-sheets used in the treatment of irritable bowel syndrome in Great Britain. *J Hum Nutr Diet* 1989;**2**(6):429–35.

Lambert 1991a *{published data only}*
Lambert JP, Brunt PW, Mowat NA, Khin CC, Lai CK, Morrison V, et al.The value of prescribed 'high-fibre' diets for the treatment of the irritable bowel syndrome. *Eur J Clin Nutr* 1991;**45**(12):601–9.

Lambert 1991b *{published data only}*
Lambert JP, Morrison V, Brunt PW, Mowat NA, Eastwood MA, Dickerson JW. Dietary fibre intake of irritable bowel patients prescribed a high fibre diet. *J Hum Nutr Diet* 1991; **4**(3):155–64.

Lawson 1988 *{published data only}*
Lawson MJ, Knight RE, Tran K, Walker G, Roberts-Thomson IC. Failure of enteric-coated peppermint oil in the irritable bowel syndrome: A randomized, double-blind crossover study. *J Gastroenterol Hepatol* 1988;**3**(3):235–8.

Levitan 1981 *{published data only}*
Levitan MK, Dubinin AV, Beiul EA, Iurkov M, Shechovskaia AK. Treatment of colonic diverticulosis and irritable colon with wheat bran. *Sov Med* 1981;**8**(8):109–12.

Lin 2003 *{published data only}*
Lin JK, Hu PJ, Wang WA, Chen Q, Chen MH. Effects of otilonium bromide on anorectal visceral sensorimotor functions of patients with diarrhea-predominant irritable bowel syndrome. *World Chin J Dig* 2003;**11**(12):1926–8.

Liu 2006 *{published data only}*
Liu DL, Huo JR, Wu XP. Effect of subclincal dosage of antidepressants on refractory irritable bowel syndrome. *Chinese Journal of Clinical Psychology* 2006;**14**(4):424–5.

Locke 2004 *{published data only}*
Locke GR III. Review: soluble fibre improves overall symptoms and constipation but not abdominal pain in irritable bowel syndrome. *Evid Based Med* 2004;**9**(6):172.

Lu 2000 *{published data only}*
Lu CL, Chen CY, Chang FY, Chang SS, Kang LJ, Lu RH, et al.Effect of a calcium channel blocker and antispasmodic in diarrhoea-predominant irritable bowel syndrome. *J Gastroenterol Hepatol* 2000;**15**(8):925–30.

Luttecke 1978 *{published data only}*
Luttecke K. A trial of trimebutine in spastic colon. *J Int Med Res* 1978;**6**(2):86–8.

Luttecke 1980 *{published data only}*
Luttecke K. A three-part controlled study of trimebutine in the treatment of irritable colon syndrome. *Curr Med Res Opin* 1980;**6**(6):437–43.

Lydiard 2007 *{published data only}*
Lydiard RB. Psychopharmacology in the treatment of irritable bowel syndrome. *Prim Psychiatry* 2007;**14**(4): 40–50.

MacRae 1979 *{published data only}*
MacRae KD. Oral hyoscine butylbromide for irritable bowel syndrome?. *Br Med J* 1979;**1**(6165):752.

Manning 1976 *{published data only}*
Manning AP, Heaton KW, Harvey RF, Uglow P. Cereal fibre and the irritable bowel: a controlled trial. *Gut* 1976;**17**(10): 822–3.

Manning 1977 *{published data only}*
Manning AP, Heaton KW, Harvey RF. Wheat fibre and irritable bowel syndrome. A controlled trial. *Lancet* 1977;**2** (8035):417–8.

Marks 2008 *{published data only}*
Marks DM, Han C, Krulewicz S, Pae CU, Peindl K, Patkar AA, et al.History of depressive and anxiety disorders and paroxetine response in patients with irritable bowel syndrome: post hoc analysis from a placebo-controlled study. *Prim Care Companion J Clin Psychiatry* 2008;**10**(5): 368–75.

Masamune 1998 *{published data only}*
Masamune O, Miwa T, Fukutomi H, Matsuo Y, Sasaki D, Chiba M, et al.Clinical phase III comparative study of calcium polycarbophil tablet on irritable bowel syndrome - A double-blind study in comparison with torimebutine maleate. *Jpn Pharmacol Ther* 1998;**26**:63–92.

Masand 2002 *{published data only}*
Masand PS, Gupta S, Schwartz TL, Virk S, Lockwood K, Hameed A, et al.Paroxetine in patients with irritable bowel syndrome: A pilot open-label study. *Prim Care Companion J Clin Psychiatry* 2002;**4**(1):12–6.

Masand 2005 *{published data only}*
Masand PS, Gupta S, Schwartz TL, Virk S, Hameed A, Kaplan DS. Open-label treatment with citalopram in patients with irritable bowel syndrome: a pilot study. *Prim Care Companion J Clin Psychiatry* 2005;**7**(4):162–6.

Matts 1967 *{published data only}*
Matts SG. An assessment of dicyclomine hydrochloride ('Merbentyl') in the irritable colon syndrome. *Br J Clin Pract* 1967;**21**(11):549–51.

Meier 1996 *{published data only}*
Meier R, Beglinger Ch, Brignoli R, the IBS-CIS study group. Symptoms and colonic transit time in the irritable bowel syndrome treated with psyllium and cisapride or placebo (abstract). *Gut* 1996;**39 Suppl 3**:A33.

Miller 2006 *{published data only}*
Miller V, Lea R, Agrawal A, Whorwell PJ. Bran and irritable bowel syndrome: the primary-care perspective. *Dig Liver Dis* 2006;**38**(10):737–40.

Misra 1989 *{published data only}*
Misra SP, Thorat VK, Sachdev GK, Anand BS. Long-term treatment of irritable bowel syndrome: results of a randomized controlled trial. *Q J Med* 1989;**73**(270):931–9.

Modena 1993 *{published data only}*
Modena L. Single drug treatment for irritable colon syndrome: Rociverine 20 mg t.i.d. *Minerva Med* 1993;**84**(5):263–8.

Mollica 1992 *{published data only}*
Mollica G, Manno G. Otilonium bromide-diazepam in the treatment of the irritable colon. A controlled study versus otilonium bromide. *Clin Ter* 1992;**141**(8):129–34.

Morgan 2005 *{published data only}*
Morgan V, Pickens D, Gautam S, Kessler R, Mertz H. Amitriptyline reduces rectal pain related activation of the anterior cingulate cortex in patients with irritable bowel syndrome. *Gut* 2005;**54**(5):601–7.

Morrison 1987 *{published data only}*
Morrison V, Lai C KW, Khin CC. High fibre diets and irritable bowel syndrome - The role of the dietitian. *Scott Med J* 1987;**32**(4):124.

Mortensen 1987 *{published data only}*
Mortensen PB, Andersen JR, Arffmann S, Krag E. Short-chain fatty acids and the irritable bowel syndrome: the effect of wheat bran. *Scand J Gastroenterol* 1987;**22**(2):185–92.

Nash 1986 *{published data only}*
Nash P, Gould SR, Bernardo DE. Peppermint oil does not relieve the pain of irritable bowel syndrome. *Br J Clin Pract* 1986;**40**(7):292–3.

Nedogoda 2000 *{published data only}*
Nedogoda SV, Parshev VV. Treatment of irritable bowel syndrome with dicetelium and spasmomen. *Klin Med* 2000;**78**(10):42–6.

Noel 1989 *{published data only}*
Noel B. A multicentric study of pinaverium bromide on irritable bowel syndrome, performed in Mexico. *Investigacion Medica Internacional* 1989;**15**(4):190–6.

Olden 2005 *{published data only}*
Olden KW. The use of antidepressants in functional gastrointestinal disorders: new uses for old drugs. *CNS Spectr* 2005;**10**(11):891–6.

Pardell 1982 *{published data only}*
Pardell H, Marcillas J, Celdran E. Double-blind parallel study of clebopride and hyoscine N-butylbromide in patients with irritable colon syndrome. *Curr Ther Res Clin Exp* 1982;**31**(1):S74–9.

Parisi 2002 *{published data only}*
Parisi GC, Zilli M, Miani MP, Carrara M, Bottona E, Verdianelli G, et al.High-fiber diet supplementation in patients with irritable bowel syndrome (IBS): a multicenter, randomized, open trial comparison between wheat bran diet and partially hydrolyzed guar gum (PHGG). *Dig Dis Sci* 2002;**47**(8):1697–1704.

Parisi 2005 *{published data only}*
Parisi G, Bottona E, Carrara M, Cardin F, Faedo A, Goldin D, et al.Treatment effects of partially hydrolyzed guar gum on symptoms and quality of life of patients with irritable bowel syndrome. A multicenter randomized open trial. *Dig Dis Sci* 2005;**50**(6):1107–12.

Passaretti 1985 *{published data only}*
Passaretti S, Fesce E, Fanti L. Effect of tiropramide hydrochloride on the intestinal transit time in patients with irritable bowel syndrome. *Minerva Med* 1985;**76**(19-20):923–6.

Passaretti 1989b *{published data only}*
Passaretti S, Sorghi M, Colombo E, Mazzotti G, Tittobello A, Guslandi M. Motor effects of locally administered pinaverium bromide in the sigmoid tract of patients with irritable bowel syndrome. *Int J Clin Pharmacol Ther Toxicol* 1989;**27**(1):47–50.

Pearson 2000 *{published data only}*
Pearson RL. How effective are antidepressant medications in the treatment of irritable bowel syndrome and nonulcer dyspepsia?. *J Fam Pract* 2000;**49**(5):396.

Piai 1987a *{published data only}*
Piai G, Visconti M, d'Angelo V, Sauro A, Sparano R, Mazzacca G. Glucomannan in treatment of irritable colon. Results of a controlled clinical trial [Il glucomannano nel trattamento del colon irritabile; risultati di uno studio clinico controllato]. *Quaderni di Medicina e Chirurgia* 1987;**3**(1):83–6.

Piai 1987b *{published data only}*
Piai G, Visconti M, Imbimbo BP, Minieri M, Sollazzo R, Mazzacca G. Long-term treatment of irritable bowel syndrome with cimetropium bromide, a new antimuscarinic compound. *Curr Ther Res Clin Exp* 1987;**41**(6):967–77.

Pittler 1998 *{published data only}*
Pittler MH, Ernst E. Peppermint oil for irritable bowel syndrome: a critical review and metaanalysis. *Am J Gastroenterol* 1998;**93**(7):1131–5.

Prior 1986a *{published data only}*
Prior A, Whorwell PJ. Management of irritable bowel syndrome. *Biomed Pharmacother* 1986;**40**(1):4–5.

Prior 1986b *{published data only}*
Prior A, Akbar FA, Shroff NE, Whorwell PJ. A double blind study of ispaghula in irritable bowel syndrome (abstract). *Gut* 1986;**27**(Suppl 5):A625.

Prout 1983 *{published data only}*
Prout B J. The treatment of irritable bowel syndrome. Two doses of mebeverine compared. *Practitioner* 1983;**227** (1384):1607–8.

Quilici 1998 *{published data only}*
Quilici FA, Dos Reis Neto, Cordeiro F, Ciquini S, Dos Reis J. Treatment of irritable bowel syndrome with pinaverium bromide. *GED Gastrentologia Endosc Dig* 1998;**17**(3): 79–86.

Quilici 2003 *{published data only}*
Quilici FA, Cordeiro F, Ciquini SA, Cunha HA, Bertocello LC, Sugahara R, et al.Treatment of irritable bowel syndrome: Single drug therapy with mebeverine. *GED Gastrentologia Endosc Dig* 2003;**22**(6):219–26.

Rasmussen 1982 *{published data only}*
Rasmussen SN, Bondesen S, Edmund C, Frandsen I, Andersen I, Kempel K, et al.Treatment of irritable bowel with dietary fiber. A controlled clinical study [Behandling af colon irritabile med kostfiberrig diaet. En kontrolleret klinisk undersogelse]. *Ugeskr Laeger* 1982;**144**(33):2415–7.

Rees 1979 *{published data only}*
Rees WD, Evans BK, Rhodes J. Treating irritable bowel syndrome with peppermint oil. *Br Med J* 1979;**2**(6194): 835–6.

Rhodes 1978 *{published data only}*
Rhodes JB, Abrams JH, Manning RT. Controlled clinical trial of sedative-anticholinergic drugs in patients with the irritable bowel syndrome. *J Clin Pharmacol* 1978;**18**(7): 340–5.

Rhodes 1980 *{published data only}*
Rhodes J, Evans BK, Rees WD. Peppermint oil in enteric coated capsules for the treatment of irritable bowel syndrome: A double blind controlled trial. *Hepatogastroenterology* 1980;**27**(Suppl):E31–6.

Ritchie 1980 *{published data only}*
Ritchie JA, Truelove SC. Comparison of various treatments for irritable bowel syndrome. *Br Med J* 1980;**281**(6251): 1317–9.

Sagduyu 2002 *{published data only}*
Sagduyu K. Peppermint oil for irritable bowel syndrome. *Psychosomatics* 2002;**43**(6):508–9.

Sato 2006 *{published data only}*
Sato M, Murakami M. Treatment for irritable bowel syndrome--psychotropic drugs, antidepressants and so on. *Nippon Rinsho* 2006;**64**(8):1495–500.

Schaffstein 1990 *{published data only}*
Schaffstein W, Panijel M, Luttecke K. Comparative safety and efficacy of trimebutine versus mebeverine in the treatment of irritable bowel syndrome. A multicenter double-blind study. *Curr Ther Res Clin Exp* 1990;**47**(1): 136–45.

Schutz 1992 *{published data only}*
Schutz E, Peters-Hartel W, Mauersberger H, Munster U. The treatment of irritable colon with mebeverine. Pain relief most important. *Therapiewoche Schweiz* 1992;**8**(10): 759-760, 762.

Secco 1983 *{published data only}*
Secco G B, Di Somma C, Arnulfo G, Ricci C. Controlled clinical study of the action of mebeverine hydrochloride in the treatment of irritable colon. *Minerva Med.* 1983;**74** (13):699–702.

Sharma 1987 *{published data only}*
Sharma S, Saini RK, Goswami SK, Sharma A, Singh S. Role of dietary fibre in irritable bowel syndrome: a clinical study. *Indian J Med Sci* 1987;**41**(2):29–33.

Shaughnessy 2000 *{published data only}*
Shaughnessy A. Are antidepressants effective in the treatment of the functional gastrointestinal (GI) disorders of irritable bowel syndrome and nonulcer dyspepsia?. *Evid Based Pract* 2000;**3**(5):4, insert 2p.

Shrivastava 1984 *{published data only}*
Shrivastava R K, Siegel H. The role of tricyclics and benzodiazepine compounds in the treatment of irritable gut syndrome and peptic ulcer disease. *Psychopharmacol Bull* 1984;**20**(4):616–21.

Singh 2007 *{published data only}*
Singh B. Psyllium as therapeutic and drug delivery agent. *Int J Pharm* 2007;**334**(1-2):1–14.

Slawson 2002 *{published data only}*
Slawson D. How do high-fiber supplements compare with guar gum for irritable bowel syndrome?. *Evid Based Pract* 2002;**5**(11):3–4.

Snook 1994 *{published data only}*
Snook J, Shepherd HA. Bran supplementation in the treatment of irritable bowel syndrome. *Aliment Pharmacol Ther* 1994;**8**(5):511–4.

Soifer 1987 *{published data only}*
Soifer LO, De Paula JA, Caruso P. Effects of medicinal fiber on colonic transit in patients with irritable colon syndrome. *Acta Gastroenterol Latinoam* 1987;**17**(4):317–23.

Soifer 1992 *{published data only}*
Soifer L, Varela E, Olmos J. Manometric effects of pinaverium bromide in irritable bowel syndrome [Efectos manometricos del bromuro de pinaverio en el sindrome de intestino irritable]. *Acta Gastroenterol Latinoam* 1992;**22**(1): 37–43.

Soriano 1992 *{published data only}*
Soriano C, Espejo H, Garcia L. Treatment of irritable bowel syndrome with a calcium antagonist (pinaverium bromide): experience with 40 cases. *Rev Gastroenterol Peru* 1992;**12** (1):36–8.

Stiefelhagen 2008 *{published data only}*
Stiefelhagen P. Peppermint oil is helpful in irritable bowel syndrome. *MMW-Fortschr Med* 2008;**150**(47):25.

Swiatczak 1998 *{published data only}*
Swiatczak C, Jawien A, Swiatkowski M, Slominski JM, Kowianski Z, Zasieczny W. Duodenogastric reflux in patients with irritable bowel syndrome treated with wheat bran. *Pol Merkuriusz Lek* 1998;**4**(22):196–8.

Talley 2003 *{published data only}*
Talley NJ. SSRIs in IBS: sensing a dash of disappointment. *Clin Gastroenterol Hepatol* 2003;**1**(3):155–9.

Talley 2004 *{published data only}*
Talley NJ. Antidepressants in IBS: are we deluding ourselves?. *Am J Gastroenterol* 2004;**99**(5):921–3.

Talley 2008b *{published data only}*
Talley NJ. Newer antidepressants in irritable bowel syndrome: What is the evidence?. *Arch Med Sci* 2008;**4**(1): 77–8.

Tan 2007 *{published data only}*
Tan KY, Seow-Choen F. Fiber and colorectal diseases: Separating fact from fiction. *World J Gastroenterol* 2007;**13** (31):4161–7.

Tanum 1996 *{published data only}*
Tanum L, Malt UF. A new pharmacologic treatment of functional gastrointestinal disorder. A double-blind placebo-controlled study with mianserin. *Scand J Gastroenterol* 1996;**31**(4):318–25.

Tanum 2000 *{published data only}*
Tanum L, Malt UF. Personality traits predict treatment outcome with an antidepressant in patients with functional gastrointestinal disorder. *Scand J Gastroenterol* 2000;**35**(9): 935–41.

Tarpila 2004 *{published data only}*
Tarpila S, Tarpila A, Grohn P, Silvennoinen T, Lindberg L. Efficacy of ground flaxseed on constipation in patients with irritable bowel syndrome. *Current Topics in Nutraceuticals Research* 2002;**2**(2):119–25.

Tarquini 1984 *{published data only}*
Tarquini M, Sannino L, Bazuro G. The irritable bowel syndrome: therapeutic effect of octilonium bromide alone and combined with a benzodiazepine. A double-blind study. *Clinica Terapeutica* 1984;**109**(6):525–31.

Tasman-Jones 1973 *{published data only}*
Tasman-Jones C. Mebeverine in patients with the irritable colon syndrome: double blind study. *N Z Med J* 1973;**77** (491):232–5.

Tinozzi 1984 *{published data only}*
Tinozzi S, Valesi MG. Controlled clinical trial of the effectiveness of tiropramide hydrochloride versus octylonium bromide in the treatment of irritable colon syndrome. *Minerva Med* 1984;**75**(1-2):23–31.

Tomas-Ridocci 1992 *{published data only}*
Tomas-Ridocci M, Anon R, Minguez M, Zaragoza A, Ballester J, Benages A. The efficacy of Plantago ovata as a regulator of intestinal transit. A double-blind study compared to placebo. *Rev Esp Enferm Dig* 1992;**82**(1): 17–22.

Toussaint 1981 *{published data only}*
Toussaint J, Cremer M, Pintens H. Single blind study of trimebutine and mebeverine in irritable colon and dyspepsia. *Acta Ther* 1981;**7**(3):261–8.

Tripathi 1983 *{published data only}*
Tripathi BM, Misra NP, Gupta AK. Evaluation of tricyclic compound (trimipramine) vis-a-vis placebo in irritable bowel syndrome. (Double blind randomised study). *J Assoc Physicians India* 1983;**31**(4):201–3.

Tsuneoka 1987 *{published data only}*
Tsuneoka K, Miyoshi A, Kawakami K, Sekiguchi T, Nakazawa S. Clinical evaluation of TM 906 (trimebutine maleate) in the treatment of irritable bowel syndrome. Multi center double blind study in comparison with mepenzolate bromide. *Rinsho Hyoka (Clinical Evaluation)* 1987;**15**:307–34.

Tudor 1986 *{published data only}*
Tudor GJ. A general practice study to compare alverine citrate with mebeverine hydrochloride in the treatment of irritable bowel syndrome. *Br J Clin Pract* 1986;**40**(7): 276–8.

van Kerkhoven 2007 *{published data only}*
van Kerkhoven LA, Laheij RJ, Jansen JB. The role of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. *Gut* 2007;**56**(5):733; author reply 733.

Van Outryve 1995 *{published data only}*
Van Outryve M, Mayeur S, Meeus MA, Rosillon D, Hendrickx B, Ceuppens M. A double-blind crossover comparison study of the safety and efficacy of mebeverine with mebeverine sustained release in the treatment of irritable bowel syndrome. *J Clin Pharm Ther* 1995;**20**(5): 277–82.

Van Steensel 1990 *{published data only}*
Van Steensel CJ. Effect of dietary fiber on symptoms and rectosigmoid motility in patients with irritable bowel syndrome. *Gastroenterology* 1990;**99**(5):1538.

Villagrasa 1991 *{published data only}*
Villagrasa M, Boix J, Humbert P, Quer JC. Aleatory clinical study comparing otilonium bromide with a fiber-rich diet in the treatment of irritable bowel syndrome. *Ital J Gastroenterol* 1991;**8 Suppl 1**:67–70.

Wald 1990 *{published data only}*
Wald A. Fiber supplements for irritable bowel syndrome: do they really make a difference?. *Am J Gastroenterol* 1990; **85**(12):1652–3.

Wald 2002 *{published data only}*
Wald A. Psychotropic agents in irritable bowel syndrome. *J Clin Gastroenterol* 2002;**35**(1 Suppl):S53–7.

Wang 2003 *{published data only}*
Wang WA, Qian JM, Pan GZ. Treatment of refractory irritable bowel syndrome with subclinical dosage of antidepressants. *Chung-Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao* 2003;**25**(1):74–8.

Wittmann 1999 *{published data only}*
Wittmann T, Feher A, Rosztoczy A, Janosi J. Effectiveness of pinaverium bromide therapy on colonic motility disorders in irritable bowel syndrome. *Orv Hetil* 1999;**140**(9): 469–73.

Woolner 2000 *{published data only}*
Woolner JT, Kirby GA. Clinical audit of the effects of low-fibre diet on irritable bowel syndrome. *J Hum Nutr Diet* 2000;**13**(4):249–53.

Yuan 2003 *{published data only}*
Yuan Y, Xu B, Ke M, Liu Y, Fu L, Li Z, et al.Efficacy and safety of otilonium bromide for irritable bowel syndrome. *Chin J Gastroenterol* 2003;**8**(5):279–82.

Yuan 2005 *{published data only}*
Yuan Y, Xu B, Mo J, Wang J, Li Z. Efficacy and safety use of trimebutine maleate in treatment of irritable bowel syndrome. *Chin.J.Gastroenterol.* 2005;**10**(3):143–7.

Zhang 2002 *{published data only}*
Zhang HB, Han GH, Zhou XM, Guo XG, Wang BL, Wu KC, et al.Effects of treatments with otilonium bromide, collodal bismuth tartrate and compound diphenoxylate in the irritable bowel syndrome: a double-blind random controlled study. *The Chinese Journal of Clinical Pharmacology* 2002;**18**(5):328–32.

Zhou 2002 *{published data only}*
Zhou HQ, Li DG, Sogn GH. Effect of paroxetine hydrochloride and pinaverium bromide therapy in patients with irritable bowel syndrome. *Chin J Clin Rehab* 2002;**6** (23):3576–7.

Zuckerman 2006 *{published data only}*
Zuckerman MJ. The role of fiber in the treatment of irritable bowel syndrome: therapeutic recommendations. *J Clin Gastroenterol* 2006;**40**(2):104–8.

References to studies awaiting assessment

Abdul-Baki 2009 *{published data only}*
Abdul-Baki H, El Hajj II, Elzahabi L, Azar C, Aoun E, Skoury A, et al.A randomized controlled trial of imipramine in patients with irritable bowel syndrome. *World J Gastroenterol* 2009;**15**(29):3636–42.

Bijkerk 2009 *{published data only}*
Bijkerk CJ, de Wit NJ, Muris JW, Whorwell PJ, Knottnerus JA, Hoes AW. Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial. *BMJ* 2009;**339**:b3154.

Everitt 2010 *{published data only}*
Everitt HA, Moss-Morris RE, Sibelli A, Tapp L, Coleman NS, Yardley L, et al.Management of irritable bowel syndrome in primary care: feasibility randomised controlled trial of mebeverine, methylcellulose, placebo and a patient self-management cognitive behavioural therapy website. (MIBS trial). *BMC Gastroenterol* 2010;**10**:136.

Khalif 2009 *{published data only}*
Khalif IL, Quigley EM, Makarchuk PA, Golovenko OV, Podmarenkova LF, Dzhanayev YA. Interactions between symptoms and motor and visceral sensory responses of irritable bowel syndrome patients to spasmolytics (antispasmodics). *J Gastrointestin Liver Dis* 2009;**18**(1): 17–22.

Ladabaum 2010 *{published data only}*
Ladabaum U, Sharabidze A, Levin TR, Zhao WK, Chung E, Bacchetti P, et al.Citalopram provides little or no benefit in nondepressed patients with irritable bowel syndrome. *Clin Gastroenterol Hepatol* 2010;**8**(1):42–8.

Merat 2010 *{published data only}*
Merat S, Khalili S, Mostajabi P, Ghorbani A, Ansari R, Malekzadeh R. The effect of enteric-coated, delayed-release peppermint oil on irritable bowel syndrome. *Dig Dis Sci* 2010;**55**(5):1385–90.

Pace 2010 *{published data only}*
Pace F, Maurano A, Ciacci C, Savarino V, Attili A, Iaquinto G, et al.Octatropine methyl bromide and diazepam combination (Valpinax) in patients with irritable bowel syndrome: a multicentre, randomized, placebo-controlled trial. *Eur Rev Med Pharmacol Sci* 2010;**14**(3):155–62.

Reme 2010 *{published data only}*
Reme SE, Kennedy T, Jones R, Darnley S, Chalder T. Predictors of treatment outcome after cognitive behavior therapy and antispasmodic treatment for patients with irritable bowel syndrome in primary care. *J Psychosom Res* 2010;**68**(4):385–8.

Saps 2009 *{published data only}*
Saps M, Youssef N, Miranda A, Nurko S, Hyman P, Cocjin J, et al.Multicenter, randomized, placebo-controlled trial of amitriptyline in children with functional gastrointestinal disorders. *Gastroenterology* 2009;**137**(4):1261–9.

Wittmann 2010 *{published data only}*
Wittmann T, Paradowski L, Ducrotté P, Bueno L, Andro Delestrain MC. Clinical trial: the efficacy of alverine citrate/simeticone combination on abdominal pain/discomfort in irritable bowel syndrome--a randomized, double-blind, placebo-controlled study. *Aliment Pharmacol Ther* 2010;**31** (6):615–24.

Additional references

Akehurst 2001
Akehurst R, Kaltenthaler E. Treatment of irritable bowel syndrome: A review of randomised controlled trials. *Gut* 2001;**48**(2):272–82.

Bijkerk 2004
Bijkerk CJ, Muris JW, Knottnerus JA, Hoes AW, de Wit NJ. Systematic review: the role of different types of fibre in the treatment of irritable bowel syndrome. *Aliment Pharmacol Ther* 2004;**19**(3):245–51.

Brandt 2002
Brandt LJ, Bjorkman D, Fennerty MB, Locke GR, Olden K, Peterson W, et al.Systematic review on the management of irritable bowel syndrome in North America. *Am J Gastroenterol* 2002;**97**(11 Suppl):S7–26.

Burkitt 1972
Burkitt DP, Walker AR, Painter NS. Effect of dietary fibre on stools and the transit-times, and its role in the causation of disease. *Lancet* 1972;**2**(7792):1408–12.

Creed 2001
Creed F, Ratcliffe J, Fernandez L, Tomenson B, Palmer S, Rigby C, et al.Health-related quality of life and health care costs in severe, refractory irritable bowel syndrome. *Ann Intern Med* 2001;**134**(9 Pt 2):860–8.

Drossman 2006
Drossman DA. The functional gastrointestinal disorders and the Rome III process. *Gastroenterology* 2006;**130**(5): 1377–90.

Ford 2008
Ford AC, Talley NJ, Spiegel BM, Foxx-Orenstein AE, Schiller L, Quigley EM, et al.Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. *BMJ (Clinical research ed)* 2008;**337**:a2313.

Ford 2009
Ford A C, Talley N J, Schoenfeld P S, Quigley E M, Moayyedi P. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. *Gut* 2009;**58**(3):367–78.

Ford 2010
Ford AC, Guyatt GH, Talley NJ, Moayyedi P. Errors in the conduct of systematic reviews of pharmacological interventions for irritable bowel syndrome. *The American Journal of Gastroenterology* 2010;**105**(2):280–8.

Hillila 2004
Hillila MT, Farkkila MA. Prevalence of irritable bowel syndrome according to different diagnostic criteria in a non-selected adult population. *Aliment Pharmacol Ther* 2004;**20** (3):339–45.

Hungin 2003
Hungin AP, Whorwell PJ, Tack J, Mearin F. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. *Aliment Pharmacol Ther* 2003;**17**(5):643–50.

Irvine 2006
Irvine EJ, Whitehead WE, Chey WD, Matsueda K, Shaw M, et al.Design of treatment trials for functional gastrointestinal disorders. *Gastroenterology* 2006;**130**(5): 1538–51.

Jackson 2000
Jackson JL, O'Malley PG, Tomkins G, Balden E, Santoro J, Kroenke K. Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. *Am J Med* 2000;**108**(1):65–72.

Jailwala 2000
Jailwala J, Imperiale TF, Kroenke K. Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials. *Ann Intern Med* 2000;**133**(2):136–47.

Jones 2000a
Jones J, Boorman J, Cann P, Forbes A, Gomborone J, Heaton K, et al.British Society of Gastroenterology guidelines for the management of the irritable bowel syndrome. *Gut* 2000;**47 Suppl 2**:ii1–19.

Jones 2000b
Jones R. IBS: prime problem in primary care. *Gut* 2000;**46** (1):7–8.

Lesbros-Pantoflickova 2004
Lesbros-Pantoflickova D, Michetti P, Fried M, Beglinger C, Blum A L. Meta-analysis: The treatment of irritable bowel syndrome. *Aliment Pharmacol Ther* 2004;**20**(11-12): 1253–69.

Longstreth 2003
Longstreth GF, Wilson A, Knight K, Wong J, Chiou CF, Barghout V, et al.Irritable bowel syndrome, health care use, and costs: a U.S. managed care perspective. *Am J Gastroenterol* 2003;**98**(3):600–7.

Manning 1978
Manning AP, Thompson WG, Heaton KW, Morris AF. Towards positive diagnosis of the irritable bowel. *Br Med J* 1978;**2**(6138):653–4.

Pare 2006
Pare P, Gray J, Lam S, Balshaw R, Khorasheh S, Barbeau M, et al.Health-related quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome: baseline results from LOGIC (Longitudinal Outcomes Study of Gastrointestinal Symptoms in Canada), a naturalistic study. *Clin Ther* 2006; **28**(10):1726-35; discussion 1710-1.

Poynard 1994
Poynard T, Naveau S, Mory B, Chaput JC. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. *Aliment Pharmacol Ther* 1994;**8**(5):499–510.

Poynard 2001
Poynard T, Regimbeau C, Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. *Aliment Pharmacol Ther* 2001;**15**(3):355–61.

Rahimi 2009
Rahimi R, Nikfar S, Rezaie A, Abdollahi M. Efficacy of tricyclic antidepressants in irritable bowel syndrome: a meta-analysis. *World J Gastroenterol* 2009;**15**(13):1548–53.

Riedl 2008
Riedl A, Schmidtmann M, Stengel A, Goebel M, Wisser AS, Klapp BF, et al.Somatic comorbidities of irritable bowel syndrome: a systematic analysis. *J Psychosom Res* 2008;**64** (6):573–82.

Schoenfeld 2006
Schoenfeld P, Talley NJ. Measuring successful treatment of irritable bowel syndrome: is "satisfactory relief " enough?. *Am J Gastroenterol* 2006;**101**(5):1066–8.

Tack 2006b
Tack J, Fried M, Houghton LA, Spicak J, Fisher G. Systematic review: the efficacy of treatments for irritable

bowel syndrome--a European perspective. *Aliment Pharmacol Ther* 2006;**24**(2):183–205.

Talley 2006

Talley NJ. A unifying hypothesis for the functional gastrointestinal disorders: really multiple diseases or one irritable gut?. *Rev Gastroenterol Disord* 2006;**6**(2):72–8.

Verdu 2008

Verdu B, Decosterd I, Buclin T, Stiefel F, Berney A. Antidepressants for the treatment of chronic pain. *Drugs* 2008;**68**(18):2611–32.

* *Indicates the major publication for the study*

CHARACTERISTICS OF STUDIES

Characteristics of included studies *[ordered by study ID]*

Aller 2004

Methods	RCT
Participants	56 patients Rome II criteria 53% diarrhea-predominant Setting unclear Mean age 46 years 67% female
Interventions	Bulking agent 30 g fibre of which 25 g insoluble, over the day for 13 weeks
Outcomes	Abdominal pain, continuous Symptom score, continuous
Notes	Half a week run-in

Risk of bias

Bias	**Authors' judgement**	**Support for judgement**
Random sequence generation (selection bias)	Unclear risk	Not described
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Single-blind - not described in detail
Incomplete outcome data (attrition bias) All outcomes	Low risk	No patients dropped out of the study
Selective reporting (reporting bias)	Low risk	All expected outcomes were reported
Other bias	Low risk	The study appears to be free of other sources of bias

Arthurs 1983

Methods	RCT
Participants	80 patients Setting unclear Diagnostic criteria not defined Mean age 27.7 years 78% female
Interventions	Bulking agent 4 weeks ispaghula husk 2 sachets/day
Outcomes	Global assessment, dichotomous
Notes	Unclear setting No run-in

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not described
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Double-blind but procedures not described
Incomplete outcome data (attrition bias) All outcomes	Low risk	Two dropouts
Selective reporting (reporting bias)	Low risk	All expected outcomes were reported
Other bias	Low risk	The study appears to be free of other sources of bias

Awad 1995

Methods	RCT
Participants	40 patients Tertiary care Rome criteria Mean age 31.3 years 100% female
Interventions	Spasmolytic pinaverium 50 mg od for 3 weeks

Awad 1995 (*Continued*)

Outcomes	Abdominal pain, continuous symptom score, continuous
Notes	No run-in

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not described
Allocation concealment (selection bias)	Low risk	Adequate
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind, identical placebo, neither doctors nor patients knew which treatment was given
Incomplete outcome data (attrition bias) All outcomes	Low risk	Two dropouts one from each treatment group
Selective reporting (reporting bias)	Low risk	All expected outcomes were reported
Other bias	Low risk	The study appears to be free of other sources of bias

Bahar 2008

Methods	RCT
Participants	33 adolescent patients secondary care Rome criteria mean age 15 years 65% female
Interventions	Antidepressant amitriptyline 10 to 30 mg dd for 8 weeks
Outcomes	Abdominal pain, change score (not included global assessment, change score (not included) and dichotomous
Notes	2 weeks run in period adolescents

Risk of bias

Bias	Authors' judgement	Support for judgement

Bahar 2008 (*Continued*)

Random sequence generation (selection bias)	Unclear risk	Not described
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Not described
Incomplete outcome data (attrition bias) All outcomes	Low risk	2 drop-outs
Selective reporting (reporting bias)	Low risk	All expected outcomes were reported
Other bias	Low risk	The study appears to be free of other sources of bias

Baldi 1991

Methods	RCT	
Participants	71 patients with IBS 8 GI centres Mean age 40 years 60.6% female	
Interventions	Spasmolytic 4 weeks otilonium 40 mg tds	
Outcomes	abdominal pain	
Notes	2 wk run-in with placebo	
Risk of bias		
Bias	**Authors' judgement**	**Support for judgement**
Random sequence generation (selection bias)	Unclear risk	Not described
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Double-blind, methods not described
Incomplete outcome data (attrition bias) All outcomes	Low risk	One drop-out

Baldi 1991 (*Continued*)

Selective reporting (reporting bias)	Low risk	All expected outcomes were reported
Other bias	Low risk	The study appears to be free of other sources of bias

Battaglia 1998

Methods	RCT	
Participants	325 patients multicentre GI outpatients Rome criteria Mean age 47.7 years 69% female	
Interventions	Spasmolytic 15 weeks otilonium 40 mg tds	
Outcomes	abdominal pain, dichotomous global assessment, continuous	
Notes	2 weeks run-in, with placebo	

Risk of bias

Bias	**Authors' judgement**	**Support for judgement**
Random sequence generation (selection bias)	Unclear risk	Not described
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Double-blind, methods not described
Incomplete outcome data (attrition bias) All outcomes	Low risk	Missing outcome data balanced in numbers across intervention groups with similar reasons for missing data across groups
Selective reporting (reporting bias)	Low risk	All expected outcomes were reported
Other bias	Low risk	The study appears to be free of other sources of bias

Bergmann 1991

Methods	RCT
Participants	35 patients Secondary care Clinical diagnosis and investigations
Interventions	Antidepressant 3 months Trimipramine 50 mg OD
Outcomes	Global assessment, dichotomous
Notes	

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not described
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Double-blind, methods not described
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Not described
Selective reporting (reporting bias)	Low risk	Expected outcomes reported
Other bias	Low risk	The study appears to be free of other sources of bias

Boerner 1988

Methods	RCT
Participants	79 IBS patients partly from primary care
Interventions	Antidepressive doxepine od 50 mg for 8 weeks
Outcomes	Abdominal pain, continuous Global assessment, dichotomous
Notes	No run-in

Risk of bias

Boerner 1988 (*Continued*)

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not described
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Not described
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Not described
Selective reporting (reporting bias)	Unclear risk	Not described
Other bias	Unclear risk	Not described

Capanni 2005

Methods	RCT
Participants	178 patients secondary care Rome II criteria Mean age 42 years 75% female
Interventions	Spasmolytics peppermint oil for 3 months, dose not stated
Outcomes	Global assessment, dichotomous IBS-symptoms, dichotomous
Notes	4 weeks run-in Dosage of intervention not clear

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer generated
Allocation concealment (selection bias)	Unclear risk	Not described

Capanni 2005 (*Continued*)

Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Described as double-blind
Incomplete outcome data (attrition bias) All outcomes	Low risk	3 drop-outs from peppermint oil group and 2 drop-outs from placebo
Selective reporting (reporting bias)	Low risk	All expected outcomes were reported
Other bias	Low risk	The study appears to be free of other sources of bias

Cappello 2007

Methods	RCT
Participants	57 patients Setting unclear Rome II criteria mean age 41 years 76% female
Interventions	Spasmodic peppermint oil capsules 500 mg for 4 weeks
Outcomes	Abdominal pain, continuous IBS-symptom score, continuous and dichotomous
Notes	No run in

Risk of bias

Bias	**Authors' judgement**	**Support for judgement**
Random sequence generation (selection bias)	Low risk	Computer generated
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Double blind, methods not described
Incomplete outcome data (attrition bias) All outcomes	Low risk	Missing outcome data balanced in numbers across intervention groups with similar reasons for missing data across groups
Selective reporting (reporting bias)	Low risk	All expected outcomes were reported

Cappello 2007 (*Continued*)

Other bias	Low risk	The study appears to be free of other sources of bias

Centonze 1988

Methods	RCT
Participants	48 patients Outclinic 50% female Mean duration of symptoms 4 years
Interventions	Spasmolytic cimetropium tds 50 mg for 6 months
Outcomes	Abdominal pain, continuous Global assessment, dichotomous
Notes	3 weeks run-in without placebo

Risk of bias

Bias	**Authors' judgement**	**Support for judgement**
Random sequence generation (selection bias)	Unclear risk	Not described
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Double-blind, procedures not described
Incomplete outcome data (attrition bias) All outcomes	Low risk	Four patients (one in the drug group, three in the placebo group) did not complete the study, three because of noncompliance and one because he moved away.
Selective reporting (reporting bias)	Low risk	All expected outcomes were reported
Other bias	Low risk	The study appears to be free of other sources of bias

Chen 2004

Methods	RCT
Participants	120 IBS patients Setting unclear Rome II criteria Mean age 43 years 48% female
Interventions	Spasmolytic pinaverium bromide 100 mg tds for 8 weeks
Outcomes	Global assessment, dichotomous Symptom score, continuous
Notes	No run-in

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not described
Allocation concealment (selection bias)	Low risk	Adequate
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Not described
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Not described
Selective reporting (reporting bias)	Unclear risk	Not described
Other bias	Unclear risk	Not described

Czalbert 1990

Methods	RCT
Participants	34 IBS Hospital out clinic Mean age 49.3 years
Interventions	Spasmolytic peppermint oil 0.2 ml tds for 10 days
Outcomes	Symptom score, dichotomous

Czalbert 1990 (*Continued*)

Notes	No run-in	
Risk of bias		
Bias	**Authors' judgement**	**Support for judgement**
Random sequence generation (selection bias)	Unclear risk	Not described
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Not described
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Not described
Selective reporting (reporting bias)	Unclear risk	Not described
Other bias	Unclear risk	Not described

d'Arienzo 1980

Methods	RCT	
Participants	28 IBS patients Unclear setting Diagnostic criteria not defined 39% female	
Interventions	Spasmolytic otilonium tds 20 mg 4 weeks	
Outcomes	Symptom score, continuous	
Notes	No run-in	
Risk of bias		
Bias	**Authors' judgement**	**Support for judgement**
Random sequence generation (selection bias)	Unclear risk	Not described
Allocation concealment (selection bias)	Unclear risk	Not described

d'Arienzo 1980 (*Continued*)

Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Double blind, procedures not described
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Not described
Selective reporting (reporting bias)	Unclear risk	Not described
Other bias	Unclear risk	Not described

Delmont 1981

Methods	RCT
Participants	60 IBS patients Setting unclear Mean age 57 years 67% female
Interventions	Spasmolytic pinaverium tds for 30 days
Outcomes	abdominal pain, dichotomous global assessment, dichotomous
Notes	unclear setting No run-in

Risk of bias

Bias	**Authors' judgement**	**Support for judgement**
Random sequence generation (selection bias)	Unclear risk	Not described
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Double blind - procedures not described
Incomplete outcome data (attrition bias) All outcomes	Low risk	3 drop-outs
Selective reporting (reporting bias)	Low risk	Expected outcomes were reported
Other bias	Low risk	The study appears to be free of other sources of bias

Dobrilla 1990

Methods	RCT
Participants	70 IBS patients Hospital out clinic Mean age 45 years 67% female Mean duration of symptoms 3 years
Interventions	Spasmolytic 13 weeks cimetropium tds 50mg
Outcomes	Abdominal pain, continuous Global assessment, dichotomous
Notes	2 weeks run-in without placebo

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not described
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Double-blind - procedures not described
Incomplete outcome data (attrition bias) All outcomes	Low risk	1 drop-out
Selective reporting (reporting bias)	Low risk	All expected outcomes were reported
Other bias	Low risk	The study appears to be free of other sources of bias

Drossman 2003

Methods	RCT
Participants	216 patients with functional bowel disorders, 80% with IBS Secondary care Rome criteria Mean age 39.9 years 100% female
Interventions	Antidepressant desipramine 50-100-150mg od for 12 weeks

Drossman 2003 (*Continued*)

Outcomes	Abdominal pain, continuous and dichotomous Global assessment, continuous and dichotomous Symptom score, continuous and dichotomous	
Notes	No run-in; minimum duration of symptoms of 6 months	
Risk of bias		
Bias	**Authors' judgement**	**Support for judgement**
Random sequence generation (selection bias)	Low risk	Computer generated
Allocation concealment (selection bias)	Low risk	Adequate
Blinding of participants and personnel (performance bias) All outcomes	High risk	Investigator-blinded
Incomplete outcome data (attrition bias) All outcomes	Low risk	Missing outcome data balanced in numbers across intervention groups with similar reasons for missing data across groups
Selective reporting (reporting bias)	Low risk	All expected outcomes were reported
Other bias	Low risk	The study appears to be free of other sources of bias

Dubarry 1977

Methods	RCT	
Participants	20 IBS patients Outpatient setting Diagnostic criteria not defined	
Interventions	Spasmolytic 6 days pinaverium 50 mg tds	
Outcomes	Abdominal pain, dichotomous	
Notes	No run-in	
Risk of bias		
Bias	**Authors' judgement**	**Support for judgement**
Random sequence generation (selection bias)	Unclear risk	Not described

Dubarry 1977 (*Continued*)

Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Double-blind, methods not described
Incomplete outcome data (attrition bias) All outcomes	Low risk	No drop-outs
Selective reporting (reporting bias)	Low risk	Expected outcomes were reported
Other bias	Low risk	The study appears to be free of other sources of bias

Fielding 1980

Methods	RCT
Participants	60 IBS patients Unclear setting Diagnostic criteria not defined Mean age 26 years 75% female mean duration of symptoms 2 years
Interventions	Spasmolytic trimebutine tds 200 mg for 6 months
Outcomes	Abdominal pain, dichotomous Global assessment, dichotomous
Notes	No run-in

Risk of bias

Bias	**Authors' judgement**	**Support for judgement**
Random sequence generation (selection bias)	Unclear risk	Not described
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind, identical placebo
Incomplete outcome data (attrition bias) All outcomes	Low risk	7 drop-outs

Fielding 1980 (*Continued*)

Selective reporting (reporting bias)	Low risk	All expected outcomes were reported
Other bias	Low risk	The study appears to be free of other sources of bias

Fowlie 1992

Methods	RCT
Participants	49 patients Gastro intestinal outpatient clinic Mean age 40 years 65% female Mean duration of symptoms 3.8 years
Interventions	Bulking agent 3 months mixed cereal and fruit fibre 4.1 g/day
Outcomes	Abdominal pain Global assessment Symptom score
Notes	GI Outpatients 1 week run-in

Risk of bias

Bias	**Authors' judgement**	**Support for judgement**
Random sequence generation (selection bias)	Unclear risk	Not described
Allocation concealment (selection bias)	Low risk	Adequate
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind, identical placebo
Incomplete outcome data (attrition bias) All outcomes	Low risk	Missing outcome data balanced in numbers across intervention groups with similar reasons for missing data across groups
Selective reporting (reporting bias)	Low risk	All expected outcomes were reported
Other bias	Low risk	The study appears to be free of other sources of bias

Ghidini 1986

Methods	RCT
Participants	60 IBS patients Hospital setting Mean age 42 years 60% female
Interventions	Spasmolytic rociverine tds 20 mg for 60 days trimebutine 3 dd 100 mg
Outcomes	Abdominal pain, dichotomous Global assessment, dichotomous
Notes	No run-in

Risk of bias

Bias	**Authors' judgement**	**Support for judgement**
Random sequence generation (selection bias)	Unclear risk	Not described
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind design with preparations that were outwardly indistinguishable
Incomplete outcome data (attrition bias) All outcomes	Low risk	No drop-outs
Selective reporting (reporting bias)	Low risk	Expected outcomes are reported
Other bias	Low risk	The study appears to be free of other sources of bias

Gilvarry 1989

Methods	RCT
Participants	24 IBS patients Unclear setting Diagnostic criteria not defined Mean age 32 years 79% female
Interventions	Antispasmodic pirenzepine 100 mg for 4 weeks

Gilvarry 1989 (*Continued*)

Outcomes	Abdominal pain, dichotomous Global assessment, dichotomous
Notes	4 to 8 weeks run-in with high fibre diet (> 30 g/day) continued high fibre diet during study period

Risk of bias

Bias	**Authors' judgement**	**Support for judgement**
Random sequence generation (selection bias)	Unclear risk	Not described
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Double blind, methods not described
Incomplete outcome data (attrition bias) All outcomes	Low risk	2 drop outs
Selective reporting (reporting bias)	Low risk	Expected outcomes were reported
Other bias	Low risk	The study appears to be free of other sources of bias

Heefner 1978

Methods	RCT
Participants	31 patients Outpatients clinic Diagnostic criteria not defined Mean age 48 years 13% female
Interventions	Antidepressive desipramine od 150 mg, 2months
Outcomes	Abdominal pain, dichotomous
Notes	No run-in

Risk of bias

Bias	**Authors' judgement**	**Support for judgement**

Heefner 1978 (*Continued*)

Random sequence generation (selection bias)	Unclear risk	Not described
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Double blind, methods not described
Incomplete outcome data (attrition bias) All outcomes	Low risk	Missing outcome data balanced in numbers across intervention groups with similar reasons for missing data across groups
Selective reporting (reporting bias)	Low risk	Expected outcomes were reported
Other bias	Low risk	The study appears to be free of other sources of bias

Jalihal 1990

Methods	RCT with Cross-over design
Participants	20 patients Gastro intestinal outpatients clinic Diagnoses on clinical grounds Mean age 38 years 20% female
Interventions	Bulking agent 4 weeks ispaghula husk 30 g/day
Outcomes	Abdominal pain, dichotomous Global assessment, dichotomous
Notes	GI Outpatients No run-in

Risk of bias

Bias	**Authors' judgement**	**Support for judgement**
Random sequence generation (selection bias)	Unclear risk	Not described
Allocation concealment (selection bias)	Low risk	Adequate
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind, treatment was indistinguishable from the placebo

Jalihal 1990 (*Continued*)

Incomplete outcome data (attrition bias) All outcomes	Low risk	No drop-outs. Two patients were eligible but dropped out before the study
Selective reporting (reporting bias)	Low risk	Expected outcomes were reported
Other bias	Low risk	The study appears to be free of other sources of bias

Kruis 1986

Methods	RCT
Participants	80 patients Outpatients clinic Mean age 41 years 61% female
Interventions	Bulking agent 16 weeks wheat bran fibre 8 g/day Spasmolitic agent 16 weeks mebeverine 100 mg 4 dd
Outcomes	Global assessment, dichotomous Abdomianl pain, dichotomous
Notes	GI patients No run-in

Risk of bias

Bias	**Authors' judgement**	**Support for judgement**
Random sequence generation (selection bias)	Unclear risk	Not described
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Mebeverine and placebo arms were double-blind. Methods not described
Incomplete outcome data (attrition bias) All outcomes	Low risk	Missing outcome data balanced in numbers across intervention groups with similar reasons for missing data across groups
Selective reporting (reporting bias)	Low risk	Expected outcomes were reported
Other bias	Low risk	The study appears to be free of other sources of bias

Kuiken 2003

Methods	RCT
Participants	40 patients, GI out clinic Rome I criteria Mean age 40 years 55% female Mean duration of symptoms 5.9 years
Interventions	Antidepressive fluoxetine (SSRI) 20 mg od for 6 weeks
Outcomes	Abdominal pain, dichotomous Global assessment, dichotomous
Notes	No run-in

Risk of bias

Bias	**Authors' judgement**	**Support for judgement**
Random sequence generation (selection bias)	Low risk	Computer generated
Allocation concealment (selection bias)	Low risk	Centralized randomization by pharmacy
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind, identical placebo
Incomplete outcome data (attrition bias) All outcomes	Low risk	6 patients dropped out (2 from treatment group and 4 from placebo)
Selective reporting (reporting bias)	Low risk	All expected outcomes were reported
Other bias	Low risk	The study appears to be free of other sources of bias

Lech 1988

Methods	RCT
Participants	47 IBS patients Hospitals outpatients clinic Mean age 42 years 76% female
Interventions	Spasmolytic 4 weeks peppermint oil 3 dd 200 mg

Lech 1988 (*Continued*)

Outcomes	Global assessment, dichotomous	
Notes	No run-in	
Risk of bias		
Bias	**Authors' judgement**	**Support for judgement**
Random sequence generation (selection bias)	Unclear risk	Not described
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Double-blind, methods not described
Incomplete outcome data (attrition bias) All outcomes	Low risk	No drop-outs
Selective reporting (reporting bias)	Low risk	Expected outcomes reported
Other bias	Low risk	The study appears to be free of other sources of bias

Levy 1977

Methods	RCT	
Participants	50 IBS patients Unclear setting Diagnostic criteria not defined Mean age 48 years 46% female	
Interventions	Spasmolytic Pinaverium tds 50 mg 15 days	
Outcomes	Global assessment, dichotomous	
Notes	No run-in	
Risk of bias		
Bias	**Authors' judgement**	**Support for judgement**
Random sequence generation (selection bias)	Unclear risk	Not described

Levy 1977 (*Continued*)

Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Double-blind, methods not described
Incomplete outcome data (attrition bias) All outcomes	Low risk	No drop outs
Selective reporting (reporting bias)	Low risk	Expected outcomes reported
Other bias	Low risk	The study appears to be free of other sources of bias

Liu 1997

Methods	RCT
Participants	101 IBS patients Unclear setting 40% females
Interventions	Spasmolytic 4 weeks peppermint oil tds-qid 187 mg
Outcomes	Abdominal pain, dichotomous
Notes	No run-in

Risk of bias

Bias	**Authors' judgement**	**Support for judgement**
Random sequence generation (selection bias)	Unclear risk	Not described
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind, identical placebo
Incomplete outcome data (attrition bias) All outcomes	Low risk	9 drop-outs: 3 patients on Colpermin and 6 on placebo did not return for follow-up
Selective reporting (reporting bias)	Low risk	Expected outcomes were reported
Other bias	Low risk	The study appears to be free of other sources of bias

Longstreth 1981

Methods	RCT
Participants	77 patients Setting unclear Mean age 38.4 years 83% female Mean duration of symptoms 7.9 years
Interventions	Bulking agent 8 weeks psyllium 19 g/day
Outcomes	Abdominal pain, continuous Global assessment, dichotomous
Notes	Unclear setting 2 weeks run-in

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not described
Allocation concealment (selection bias)	Low risk	Adequate
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind, identical sachets
Incomplete outcome data (attrition bias) All outcomes	Low risk	Missing outcome data balanced in numbers across intervention groups with similar reasons for missing data across groups
Selective reporting (reporting bias)	Low risk	Expected outcomes were reported
Other bias	Low risk	The study appears to be free of other sources of bias

Lucey 1987

Methods	RCT with Cross-over design
Participants	44 Patients Gastrointestinal outpatient clinic Manning criteria Mean age 32 years 68% female Mean duration of symptoms 60 months

Lucey 1987 (*Continued*)

Interventions	Bulking agent 3 months wheat bran fibre 13g/day	
Outcomes	IBS symptom score, continuous	
Notes	GI Outpatients No run-in	
Risk of bias		
Bias	**Authors' judgement**	**Support for judgement**
Random sequence generation (selection bias)	Unclear risk	Not described
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Double-blind, methods not described
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	16 patients dropped out. Reasons for withdrawal not reported
Selective reporting (reporting bias)	Low risk	Expected outcomes reported
Other bias	Low risk	The study appears to be free of other sources of bias

Masand 2009

Methods	RCT
Participants	72 patient Secondary care Rome II criteria Mean age 49 years 88% female
Interventions	Antidepressant paroxetine 12.5-50 mg for 12 weeks
Outcomes	Global assessment, dichotomous IBS-symptoms, continuous, dichotomous
Notes	run in with placebo, time period not described
Risk of bias	

Masand 2009 (*Continued*)

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not described
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Double-blind, methods not described
Incomplete outcome data (attrition bias) All outcomes	Low risk	Missing outcome data balanced in numbers across intervention groups with similar reasons for missing data across groups
Selective reporting (reporting bias)	Low risk	All expected outcomes were reported
Other bias	Low risk	The study appears to be free of other sources of bias

Mitchell 2002

Methods	RCT
Participants	107 IBS patients Secondary care 3 different hospitals Rome criteria Mean age 53 years 80% female
Interventions	Antispasmodic Alverine citrate 360 mg for 12 weeks
Outcomes	Global assessment Abdominal pain
Notes	2 weeks run-in without placebo

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not described
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind, identical placebo

Mitchell 2002 (*Continued*)

Incomplete outcome data (attrition bias) All outcomes	Low risk	Missing outcome data balanced in numbers across intervention groups with similar reasons for missing data across groups
Selective reporting (reporting bias)	Low risk	Expected outcomes were reported
Other bias	Low risk	The study appears to be free of other sources of bias

Moshal 1979

Methods	RCT with cross-over design
Participants	20 IBS patients Unclear setting Diagnostic criteria not defined Mean age 27 years 35% females Mean duration of symptoms 1 year
Interventions	Spasmolytic trimebutine tds 200 mg for 4 weeks
Outcomes	Abdominal pain, dichotomous
Notes	No run-in

Risk of bias

Bias	**Authors' judgement**	**Support for judgement**
Random sequence generation (selection bias)	Unclear risk	Not described
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind, identical placebo
Incomplete outcome data (attrition bias) All outcomes	Low risk	No drop-outs
Selective reporting (reporting bias)	Low risk	Expected outcomes reported
Other bias	Low risk	The study appears to be free of other sources of bias

Myren 1982

Methods	RCT
Participants	61 patients Primary care setting Mean age 38.9 years 54% female
Interventions	Antidepressive trimipramine 1 dd 50 mg 4 weeks
Outcomes	Global assessment, dichotomous
Notes	No run-in

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not described
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind, identical placebo
Incomplete outcome data (attrition bias) All outcomes	Low risk	No drop-outs
Selective reporting (reporting bias)	Low risk	Expected outcomes reported
Other bias	Low risk	The study appears to be free of other sources of bias

Nigam 1984

Methods	RCT
Participants	168 patients Secondary care Mean age 34.5 years 45% female
Interventions	Bulking agents Ispaghula husk, unclear dose, 12 weeks Spasmolitic agent Hyoscinebutylbromide, unclear dose, 12 weeks
Outcomes	Global assessment, dichotomous

Nigam 1984 (*Continued*)

Notes	Inclear dose of intervention No run in

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not described
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind, double-dummy
Incomplete outcome data (attrition bias) All outcomes	Low risk	No drop-outs
Selective reporting (reporting bias)	Low risk	Expected outcomes reported
Other bias	Low risk	The study appears to be free of other sources of bias

Page 1981

Methods	RCT
Participants	97 patients Unclear setting Mean age 36.7 years 83% females Mean duration of symptoms 2 years
Interventions	Spasmolytic dicyclomine qid 40 mg for 2 weeks
Outcomes	Abdominal pain, dichotomous Global assessment, dichotomous
Notes	2 weeks placebo run-in

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not described

Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind, methods not described
Incomplete outcome data (attrition bias) All outcomes	Low risk	Missing outcome data balanced in numbers across intervention groups with similar reasons for missing data across groups
Selective reporting (reporting bias)	Low risk	Expected outcomes reported
Other bias	Low risk	The study appears to be free of other sources of bias

Passaretti 1989a

Methods	RCT
Participants	40 patients Out patient clinic Mean age 39 years 60% females
Interventions	Spasmolytic 4 weeks cimetropium tds 50 mg
Outcomes	Abdominal pain, continuous Global assessment, dichotomous
Notes	2 weeks run-in without placebo

Risk of bias

Bias	**Authors' judgement**	**Support for judgement**
Random sequence generation (selection bias)	Unclear risk	Not described
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind, methods not described
Incomplete outcome data (attrition bias) All outcomes	Low risk	Missing outcome data balanced in numbers across intervention groups with similar reasons for missing data across groups
Selective reporting (reporting bias)	Low risk	Expected outcomes reported

Passaretti 1989a (*Continued*)

Other bias	Low risk	The study appears to be free of other sources of bias

Piai 1979

Methods	RCT with cross-over design
Participants	18 patients Unclear setting Diagnostic criteria not defined 56% females
Interventions	Spasmolytic prifinium 30 mg tds for 3 weeks
Outcomes	Global assessment, dichotomous
Notes	No run-in

Risk of bias

Bias	**Authors' judgement**	**Support for judgement**
Random sequence generation (selection bias)	Low risk	Random number table
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Double-blind, methods not described
Incomplete outcome data (attrition bias) All outcomes	Low risk	No drop-outs
Selective reporting (reporting bias)	Low risk	All expected outcomes are reported
Other bias	Low risk	The study appears to be free of other sources of bias

Prior 1987

Methods	RCT
Participants	80 patients Outpatients 90% female

Prior 1987 (*Continued*)

Interventions	Bulking agents 12 weeks ispaghula husk 19 g/day
Outcomes	Abdominal pain, dichotomous Global assessment, dichotomous
Notes	Outpatients 2 weeks run-in

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not described
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Double-blind, methods not described
Incomplete outcome data (attrition bias) All outcomes	Low risk	Missing outcome data balanced in numbers across intervention groups with similar reasons for missing data across groups
Selective reporting (reporting bias)	Low risk	Expected outcomes were reported
Other bias	Low risk	The study appears to be free of other sources of bias

Pulpeiro 2000

Methods	RCT
Participants	85 IBS patients Hospital GI department Mean age 45.2 years 69% female
Interventions	Spasmolytic Propinox 4 dd for 4 weeks
Outcomes	Abdominal pain, continuous Global assessment, dichotomous
Notes	No run-in Dose unclear

Risk of bias

Pulpeiro 2000 (*Continued*)

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not described
Allocation concealment (selection bias)	Low risk	Adequate
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind, identical placebo
Incomplete outcome data (attrition bias) All outcomes	Low risk	No drop-outs
Selective reporting (reporting bias)	Low risk	Expected outcomes reported
Other bias	Low risk	The study appears to be free of other sources of bias

Rajagopalan 1998

Methods	RCT
Participants	22 patients Outpatients clinic Rome criteria Mean age 35 years 50% female
Interventions	Antidepressive amitriptyline to 75 mg od for 12 weeks
Outcomes	Abdominal pain, continuous
Notes	1 week run-in

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not described
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind, identical placebo, all investigators and patients were blind to the treatment

Rajagopalan 1998 (*Continued*)

Incomplete outcome data (attrition bias) All outcomes	Unclear risk	The same number of patients dropped out from each group. Reasons for drop-out were not reported
Selective reporting (reporting bias)	Low risk	Expected outcomes were reported
Other bias	Low risk	The study appears to be free of other sources of bias

Rees 2005

Methods	RCT
Participants	28 patients GI out clinic Rome criteria Mean age 36.1 years 86% female
Interventions	Bulking agent 10-20 g coarse wheat bran once daily for 8 to 12 weeks
Outcomes	Abdominal pain, continuous Global assessment, dichotomous
Notes	No run in period

Risk of bias

Bias	**Authors' judgement**	**Support for judgement**
Random sequence generation (selection bias)	Unclear risk	Not described
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	High risk	Single-blind (patients)
Incomplete outcome data (attrition bias) All outcomes	Low risk	2 patients dropped out from treatment group and 4 dropped out from placebo
Selective reporting (reporting bias)	Low risk	Expected outcomes were reported
Other bias	Low risk	The study appears to be free of other sources of bias

Ritchie 1979

Methods	RCT
Participants	24 patients Secondary setting Diagnostic criteria not defined Mean age 38 years 77% female
Interventions	Bulking agent 4 weeks ispaghula husk, 1 sachet 2 dd Spasmolytics hyoscine 4 dd 10 mg 4 weeks
Outcomes	Global assessment, dichotomous
Notes	Hospital setting No run-in

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not described
Allocation concealment (selection bias)	Low risk	Centralized randomization by hospital pharmacist
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind, double-dummy. Dummy preparations were identical to active
Incomplete outcome data (attrition bias) All outcomes	Low risk	4 drop-outs
Selective reporting (reporting bias)	Low risk	Expected outcomes were reported
Other bias	Low risk	The study appears to be free of other sources of bias

Schafer 1990

Methods	RCT
Participants	360 IBS pat from various origin (prim care, GI clinic, int med)
Interventions	Spasmolytic 4 weeks butylscopamine 30 mg/day
Outcomes	Abdominal pain Global assessment

Schafer 1990 (*Continued*)

Notes	0.5 wk run-in	
Risk of bias		
Bias	**Authors' judgement**	**Support for judgement**
Random sequence generation (selection bias)	Unclear risk	Not described
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Double-blind, methods not described
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Drop outs not described
Selective reporting (reporting bias)	Low risk	Expected outcomes reported
Other bias	Low risk	The study appears to be free of other sources of bias

Soltoft 1976

Methods	RCT
Participants	59 patients Setting unclear Mean age 40 years 64% female
Interventions	Bulking agent 6 weeks wheat bran 30 g/day
Outcomes	Global assessment, dichotomous
Notes	Unclear setting >1 week run-in

Risk of bias		
Bias	**Authors' judgement**	**Support for judgement**
Random sequence generation (selection bias)	Unclear risk	Not described
Allocation concealment (selection bias)	Low risk	Adequate

Soltoft 1976 (*Continued*)

Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind, placebo of similar appearance
Incomplete outcome data (attrition bias) All outcomes	Low risk	Missing outcome data balanced in numbers across intervention groups with similar reasons for missing data across groups
Selective reporting (reporting bias)	Low risk	All expected outcomes were reported
Other bias	Low risk	The study appears to be free of other sources of bias

Tabas 2004

Methods	RCT
Participants	90 patients Voluntary participants through advertisement Rome I criteria Mean age 46 years 74% female
Interventions	Antidepressant paroxetine (SSRI) 10 or 20 mg od for 12 weeks
Outcomes	Abdominal pain, dichotomous Global assessment, dichotomous
Notes	69 of 81 took part in high-fibre open label trial 7 weeks before

Risk of bias

Bias	**Authors' judgement**	**Support for judgement**
Random sequence generation (selection bias)	Low risk	Computer generated
Allocation concealment (selection bias)	Low risk	Centralized randomization by hospital pharmacist
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind, researchers and patients were unaware of assignment until the conclusion of the last visit
Incomplete outcome data (attrition bias) All outcomes	Low risk	Missing outcome data balanced in numbers across intervention groups with similar reasons for missing data across groups
Selective reporting (reporting bias)	Low risk	Expected outcomes were reported

Tabas 2004 (*Continued*)

Other bias	Low risk	The study appears to be free of other sources of bias

Tack 2006a

Methods	Crossoveer with first phase data reported
Participants	23 IBS patients Tertiary setting Rome II criteria Mean age 40 years 78% female
Interventions	Antidepressant citalopram (SSRI) 20-40mg for 6 weeks
Outcomes	Abdominal pain, continuous Global assessment, continuous
Notes	2 weeks run-in

Risk of bias

Bias	**Authors' judgement**	**Support for judgement**
Random sequence generation (selection bias)	Unclear risk	Not described
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind, matching placebo
Incomplete outcome data (attrition bias) All outcomes	Low risk	Missing outcome data balanced in numbers across intervention groups with similar reasons for missing data across groups
Selective reporting (reporting bias)	Low risk	Expected outcomes were reported
Other bias	Low risk	The study appears to be free of other sources of bias

Talley 2008a

Methods	RCT
Participants	51 patients Setting secondary care Rome criteria 60% female 70% diarrhea predominant
Interventions	Antidepressive Imipramine (TCA) 50 mg dd for 12 weeks Citalopram (SSRI) 40 mg dd for 12 weeks
Outcomes	Abdominal pain, changes score (not included) global assessment, dichotomous and change score (not included)
Notes	2 weeks run-in period

Risk of bias

Bias	**Authors' judgement**	**Support for judgement**
Random sequence generation (selection bias)	Low risk	Computer generated
Allocation concealment (selection bias)	Low risk	Centralized randomization by hospital pharmacy
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind, double-dummy, identical capsules
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Reasons for drop-out not provided
Selective reporting (reporting bias)	Low risk	Expected outcomes reported
Other bias	Low risk	The study appears to be free of other sources of bias

Vahedi 2005

Methods	RCT
Participants	44 IBS patients GI clinic Rome II criteria Mean age 35 years 61% female
Interventions	Antidepressant fluoxetine(SSRI) 20mg od for 12 weeks

Vahedi 2005 (*Continued*)

Outcomes	Abdominal pain	
Notes	Only 44 of 64 eligible patients included. No run-in No run in period	
Risk of bias		
Bias	**Authors' judgement**	**Support for judgement**
Random sequence generation (selection bias)	Low risk	Computer generated
Allocation concealment (selection bias)	Low risk	Adequate
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind, identical placebo. Both patients and researchers were unaware of the true identity of the prescribed medicine
Incomplete outcome data (attrition bias) All outcomes	Low risk	No drop-outs
Selective reporting (reporting bias)	Low risk	Expected outcomes were reported
Other bias	Low risk	The study appears to be free of other sources of bias

Vahedi 2008

Methods	RCT
Participants	50 diarrhoea-predominant IBS patients Tertiary GI clinic Rome II criteria Mean age 36 years 42% female Mean duration of symptoms 39 months
Interventions	Antidepressant amitriptyline 10 mg for 2 months
Outcomes	Abdominal pain, dichotomous IBS-symptom score, continuous and dichotomous
Notes	No run-in Only diarrhoea-predominant IBS
Risk of bias	

Vahedi 2008 (*Continued*)

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer-generated
Allocation concealment (selection bias)	Low risk	Adequate
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind, identical placebo. Both patients and researchers were unaware of the true identity of the prescribed medicine
Incomplete outcome data (attrition bias) All outcomes	Low risk	Missing outcome data balanced in numbers across intervention groups with similar reasons for missing data across groups
Selective reporting (reporting bias)	Low risk	Expected outcomes were reported
Other bias	Low risk	The study appears to be free of other sources of bias

Vij 1991

Methods	RCT
Participants	50 IBS patient Unclear setting Mean age 32 Years 28% female
Interventions	Antidepressive doxepin od 75mg for 6 weeks
Outcomes	Abdominal pain, dichotomous Global assessment, dichotomous
Notes	No run-un

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Table of random numbers
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind, identical placebo

Vij 1991 (*Continued*)

Incomplete outcome data (attrition bias) All outcomes	Low risk	Missing outcome data balanced in numbers across intervention groups with similar reasons for missing data across groups
Selective reporting (reporting bias)	Low risk	Expected outcomes reported
Other bias	Low risk	The study appears to be free of other sources of bias

Virat 1987

Methods	RCT
Participants	78 IBS patients GI Outpatients Diagnostic criteria not defined Mean age 44 years 67% female
Interventions	Spasmolytic pinaverium 50 mg tds 1 week
Outcomes	Abdominal pain, dichotomous Global assessment, dichotomous
Notes	No run-in

Risk of bias

Bias	**Authors' judgement**	**Support for judgement**
Random sequence generation (selection bias)	Unclear risk	Not described
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Not described
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Not described
Selective reporting (reporting bias)	Low risk	Expected outcome reported
Other bias	Low risk	The study appears to be free of other sources of bias

Characteristics of excluded studies *[ordered by study ID]*

Study	Reason for exclusion
Achord 1979	Not an RCT
Alevizos 1989	Not appropriate patients: depressive patients with IBS
Andre 1979	Mixed intervention: composite of oxazepam and scopolamine butyl nitrate
Anonymous 1966	Not an RCT
Anonymous 1976	No extractable results
Anonymous 1982	Not an RCT
Anonymous 1986	Not an RCT; a review
Anonymous 1995	Not an RCT
Anonymous 1998	Not an RCT
Anonymous 2002a	Not an RCT
Anonymous 2002b	Not an RCT
Anonymous 2008	Not an RCT; a report from Ford 2008
Arffmann 1985	Cross-over study; no first phase data available
Awad 1997	Not outcome of interest; post-prandial motility
Baldi 1992	Duplicate publication with Baldi 1991
Barbier 1981	Cross-over study; no first phase data available
Bassotti 1988	Not an RCT
Baume 1972	Cross-over study; no first phase data available
Bazzocchi 1992	Not outcome of interest; anorectal function
Berthelot 1981	Only 28% of patients had true IBS. Separate results were not available for these patients
Birt 1989	Not available
Bixquert-Jimenez 2005	Not an RCT

(*Continued*)

Block 1983	Duplicate publication with Myren 1982
Bosaeus 2004	Not an RCT; a review
Bouchoucha 2000	Not outcome of interest; colonic response to food
Budavari 2002	Not an RCT
Burden 2001	Not an RCT; a review
Camarri 1981	Cross-over study; no first phase data available
Camarri 1986	No placebo group; comparing fenoverine and trimebutine
Camatte 1966	Not an RCT
Cann 1984	Cross-over study; no first phase data available
Capron 1981	Mixed intervention; composite of bulk, sedative and laxative
Capurso 1984	Cross over design with no parallel placebo administration in the first phase
Capurso 1992	Mixed intervention; composite of octylonium bromide and diazepam
Carling 1989	Cross-over study with no reporting of outcomes before first cross-over
Cerrato 2001	Inappropriate patients; children
Chapman 1990	No placebo; comparing mebeverine with high-fibre dietary advice and mebeverine with ispaghula
Chassany 2007	Inapproptiate patients; acute exacerbation
Chen 1999	No placebo; comparing Alverine/dimeticone and nifedipine
Chen 2004a	No placebo
Chevrel 1978	No placebo
Chicharro 2007	Not an RCT
Christen 1990	Not an RCT; a review
Clouse 1994	Not an RCT; a chart review
Clouse 2003	Not an RCT; a review
Cook 1990	Cross-over study; no first phase data available

(*Continued*)

Copé 1981	No placebo; comparing clidiniumbromide-chlordiazepoxide and trimebutine
Corazza 1983	No placebo; comparing pinaverium bromide and trimebutine
Corazziari 1999	Not an RCT; a review
Creed 2003	No placebo; comparing SSRI and psychotherapy with usual care
Creed 2006	Not an RCT; a review
Crowell 2004	Not an RCT; a review
Curtiss 2008	Not an RCT
Czimmer 2001	Not outcome of interest; sensory thresholds and recto-sigmoideal distention
Darnis 1980	No placebo; comparing bran and kaologenis
De Groote 1968	Not an RCT
de la Garoullaye 1991	No placebo; comparing fenoverine with PVOO and karaya gum
Defrance 1991	No placebo; comparing otilonium and pinaverium bromide
Delvaux 1997	Not an RCT; a review
Dettmar 1998	Not an RCT
Dettmar 1999	No placebo; comparing ispaghula husk with mebeverine and mebeverine with high fibre diet
Dew 1984	Cross-over study; no first phase data available
Diaz-Rubio 1985	Not available
Dioguardi 1991	No placebo; comparing octilonium bromide-diazepam and propantheline bromide-bromazepam
Dubinin 1987	No placebo; comparing bran and bran with other drugs
Ehsanullah 1985	Not outcome of interest; motility index
Eisenburg 1978	Not an RCT
Evangelista 2004	Not an RCT; a review
Evans 1996	Not outcome of interest; motility index
Ferrari 1986	No placebo; comparing octylonium bromide and cimetropium bromide

(*Continued*)

Fielding 1979	Not an RCT
Fielding 1984	No placebo; comparing different dietary fibres
Fioramonti 1988	Not outcome of interest; colonic motility
Floch 1988	Not an RCT
Francis 1994	Not an RCT
Frexinos 1985	Not outcome of interest; colonic motility
Fritz 1967	Not an RCT
Galeone 1986a	No placebo; comparing tiropramide, trimebutine and octilonium bromide
Galeone 1986b	No placebo; comparing pinaverium bromide and otilonium bromide
Geismar 1971	No extractable results; no clinically relevant data, only preferences
Geoffroy 1977	No placebo
Giaccari 2001	Not an RCT; patients divided in two groups bases on BMI
Giannini 2006	Not an RCT
Gibbons 1979	Not an RCT; a letter
Gilbody 2000	No placebo; comparing two different formulations of mebeverine hydrochloride
Glende 2002	Double-publication with Battaglia 1998
Gnauck 1977	Not an RCT
Golechha 1982	Cross-over study; no first phase data available
Gorard 1994	Not outcome of interest; whole gut and orocaecal transit times
Gorard 1995	Not outcome of interest; small intestinal motility
Greenbaum 1981	Not an RCT; a letter
Greenbaum 1984	Duplicate publication with Greenbaum 1987
Greenbaum 1987	Cross-over study; no first phase data available
Grigoleit 2005	Not an RCT; a review

(*Continued*)

Guerre 1979	No placebo; comparing karay gum and polyvinylpolypyrrolidone
Halpert 2005	Duplicate publication; paper based on same patients as Drossman 2003
Han 2009	Duplicate publication; same patients as Masand 2009
Hebden 2002	Cross-over study; no first phase data available
Herxheimer 1979	Not an RCT; a letter
Hotz 1994	No placebo
Houghton 1997	Not outcome of interest; colonic motility
Inauen 1994	No placebo; comparing mebeverine slow release and mebeverine tablets
Iwanaga 2002	Not an RCT; a review
Jackson 1998	Not an RCT
Jafri 2006	Not an RCT
Jayanthi 1998	Not an RCT
Ji 2007	Inappropriate patients; patients with functional bowel disorder not specified as IBS
Jing 2004	No placebo
Kaushik 2002	Not an RCT
Kirsch 2000	Not an RCT; a case report
Koch 1998	Double publication with Liu 1997
Koruda 1993	Not an RCT
Kountouras 2002	Inappropriate patients; patients with GERD, who also have IBS
Kumar 1987	No placebo; comparing different doses of ispaghula husk
Kunze 1990	No Placebo; comparing brief psychotherapy, acupuncture and papaverin
Lafon 1982	No data extractable
Lambert 1989	Not an RCT; a survey
Lambert 1991a	Not an RCT

(*Continued*)

Lambert 1991b	Inappropriate intervention; dietary advice
Lawson 1988	Cross-over study; no first phase data available
Levitan 1981	Inappropriate patients; mixed IBS and diverticulosis
Lin 2003	Not outcome of interest; anorectal visceral sensorimotor functions
Liu 2006	Not an RCT
Locke 2004	Not an RCT; a review article
Lu 2000	No placebo; comparing pinaverlum bromide and mebeverine
Luttecke 1978	Not outcome of interest; only preference
Luttecke 1980	Cross-over study; no first phase data available
Lydiard 2007	Not an RCT
MacRae 1979	Not an RCT; a letter
Manning 1976	No placebo
Manning 1977	No placebo; Comparing high and low-fibre diet
Marks 2008	Duplicate publication; same patients as Masand 2009
Masamune 1998	No placebo; comparing calcium polycarbophil and torimebutine maleate
Masand 2002	Not an RCT
Masand 2005	Not an RCT
Matts 1967	No extractable data
Meier 1996	Mixed intervention; psyllium and Cisapride versus placebo
Miller 2006	Not an RCT
Misra 1989	Not the appropriate patients; patients who had recovered completely after treatment
Modena 1993	No placebo
Mollica 1992	No placebo; comparing Otilonium bromide-diazepam and otilonium bromide
Morgan 2005	Cross-over study; no first phase data available

(*Continued*)

Morrison 1987	Not outcome of interest; the role of the dietitian
Mortensen 1987	Not outcome of interest; short-chain fatty acids (SCFA) in faeces
Nash 1986	Cross-over study; no first phase data available
Nedogoda 2000	No placebo; comparing pinaverium bromide and otilonium bromide
Noel 1989	Not an RCT
Olden 2005	Not an RCT; a review
Pardell 1982	No placebo; comparing clebopride and hyoscine N-butylbromide
Parisi 2002	No placebo; comparing guargum and wheat bran
Parisi 2005	No placebo group; comparing different doses of guar gum
Passaretti 1985	Not an RCT
Passaretti 1989b	Not outcome of interest; sigmoid-rectal motility
Pearson 2000	Not an RCT
Piai 1987a	Inappropriate patients; mixture of IBS and functional constipation
Piai 1987b	Inappropriate patients; IBS in remission
Pittler 1998	Not an RCT; a meta-analysis
Prior 1986a	Only abstract; full text not available
Prior 1986b	Duplicate publication; abstract publication of Prior 1987
Prout 1983	No placebo; comparing two doses of mebeverine
Quilici 1998	Not an RCT
Quilici 2003	Not an RCT
Rasmussen 1982	Inappropriate intervention; diet
Rees 1979	Cross-over study; no first phase data available
Rhodes 1978	Inaprporiate intervention; sedative-anticholinergic drug combinations
Rhodes 1980	No extractable results

(*Continued*)

Ritchie 1980	No placebo; comparing psychotropic drug, smooth-muscle relaxant, and bulking agent
Sagduyu 2002	Not an RCT; a letter
Sato 2006	Not an RCT; a review
Schaffstein 1990	No placebo; comparing trimebutine and mebeverine
Schutz 1992	Not an RCT
Secco 1983	Not an RCT
Sharma 1987	Not an RCT
Shaughnessy 2000	Not an RCT
Shrivastava 1984	Not outcome of interest
Singh 2007	Not an RCT
Slawson 2002	Not an RCT
Snook 1994	Cross-over study; no first phase data available
Soifer 1987	Not an RCT
Soifer 1992	Not outcome of interest; colon motility
Soriano 1992	Not an RCT
Stiefelhagen 2008	Not an RCT
Swiatczak 1998	Not an RCT; comparing before and after treatment with bran
Talley 2003	Not an RCT
Talley 2004	Not an RCT
Talley 2008b	Not an RCT; a review
Tan 2007	Not an RCT; a review
Tanum 1996	Inappropriate patients; mixture of IBS and NUD patients
Tanum 2000	Not outcome of interest; assessment of personality traits
Tarpila 2004	No placebo; comparing flaxseed and psyllium

(*Continued*)

Tarquini 1984	No placebo; comparing octilonium bromide and octilonium bromide with a benzodiazepine
Tasman-Jones 1973	Cross-over study; no first phase data available
Tinozzi 1984	No placebo; comparing tiropramide hydrochloride and octylonium bromide
Tomas-Ridocci 1992	Not the appropriate patients; patients with chronic constipation with or without IBS
Toussaint 1981	No placebo; comparing trimebutine and mebeverine
Tripathi 1983	Duplicate publication with Shrivastava 1984
Tsuneoka 1987	No placebo; comparing trimebutine maleate and mepenzolate bromide
Tudor 1986	No placebo; comparing alverine citrate and mebeverine hydrochloride
van Kerkhoven 2007	Not an RCT; a letter
Van Outryve 1995	No placebo; comparing mebeverine and mebeverine sustained release
Van Steensel 1990	Not an RCT
Villagrasa 1991	No placebo; comparing fibre-rich diet and otilonium bromide
Wald 1990	Not an RCT
Wald 2002	Not an RCT; a review
Wang 2003	No placebo; comparing fluoxetine, paroxetine and doxepin
Wittmann 1999	No RCT; healthy patients compared with IBS patients
Woolner 2000	Not an RCT; preliminary before-after study of low-fibre diet
Yuan 2003	Not an RCT
Yuan 2005	No placebo; comparing trimebutine maleat and pinaveriumbromide
Zhang 2002	No placebo; comparing otilonium bromide, collodal bismuth tartrate and compound diphenoxylate
Zhou 2002	No placebo; comparing paroxetine and pinaverium bromide versus paroxetine versus pinaverium bromide
Zuckerman 2006	Not an RCT; therapeutic recommendations

Characteristics of studies awaiting assessment *[ordered by study ID]*

Abdul-Baki 2009

Methods	RCT
Participants	107 IBS patients
Interventions	Antidepressant imipramine 25 mg versus matched placebo for 12 weeks
Outcomes	Global symptom relief
Notes	

Bijkerk 2009

Methods	RCT
Participants	275 patients with IBS General practice
Interventions	Bulking agent 12 weeks of treatment with: psyllium 10 g or bran 10 g or placebo 10 g (rice flour)
Outcomes	Adequate symptom relief IBS symptom severity score Severity of abdominal pain IBS quality of life scale
Notes	

Everitt 2010

Methods	RCT
Participants	135 IBS patients (Rome III)
Interventions	Antispasmodic and bulking agent mebeverine methylcellulose placebo
Outcomes	IBS severity scale IBS-QOL
Notes	

Khalif 2009

Methods	RCT
Participants	118 IBS patients (Rome II)
Interventions	Antispasmodic oral buscopan (20 mg TID) buscopan suppository (30 mg OD) oral drotaverine (80 mg TID) calcium gluconate tablets (1 TID) calendula suppository (OD)
Outcomes	Pain score
Notes	

Ladabaum 2010

Methods	RCT
Participants	54 non-depressed IBS patients
Interventions	Antidepressant citalopram (20 mg/.day for 4 weeks, then 40 mg/day for 4 weeks) placebo
Outcomes	Adequate relief of IBS symptoms IBS-QOL
Notes	

Merat 2010

Methods	RCT
Participants	90 IBS outpatients
Interventions	Antispasmodic Peppermint oil, colpermin (1 capsule TID for 8 weeks) Placebo (1 capsule TID for 8 weeks)
Outcomes	Abdominal pain QOL
Notes	

Pace 2010

Methods	RCT
Participants	186 IBS patients (Rome II)
Interventions	Antispasmodic octatropine (40 mg BID) and diazepam (2.5 mg BID) or placebo
Outcomes	Satisfactory relief of abdominal pain abdominal swelling abdominal pain and discomfort symptom severity number of bowel movements
Notes	

Reme 2010

Methods	RCT
Participants	149 IBS patients
Interventions	Antispasmodic mebeverine or mebeverine and cognitive behavior therapy
Outcomes	Psychological distress (anxiety and depression)
Notes	

Saps 2009

Methods	RCT
Participants	90 children with functional gastrointestinal disorders
Interventions	Antidepressant amitriptyline (dose based on weight) or placebo
Outcomes	Therapeutic response
Notes	

Wittmann 2010

Methods	RCT
Participants	412 IBS patients (Rome III)
Interventions	Antispasmodic alverine citrate (60 mg) with simeticone (300 mg) BID or matching placebo
Outcomes	Abdominal pain
Notes	

DATA AND ANALYSES

Comparison 1. Bulking agents: Abdominal pain

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Comparing nr(%) of successfully treated IBS patients	1	80	Risk Ratio (M-H, Fixed, 95% CI)	0.91 [0.61, 1.36]
1.1 Insoluble fibres	0	0	Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
1.2 Soluble fibres	1	80	Risk Ratio (M-H, Fixed, 95% CI)	0.91 [0.61, 1.36]
2 Comparing scores on abdominal pain in IBS patients	4	186	Std. Mean Difference (IV, Fixed, 95% CI)	0.03 [-0.34, 0.40]
2.1 Insoluble fibres	3	126	Std. Mean Difference (IV, Fixed, 95% CI)	0.0 [-0.52, 0.52]
2.2 Soluble fibres	1	60	Std. Mean Difference (IV, Fixed, 95% CI)	0.06 [-0.45, 0.57]

Comparison 2. Bulking agents: Global assessment

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Comparing nr(%) of successfully treated patients with IBS	11	565	Risk Ratio (M-H, Random, 95% CI)	1.10 [0.91, 1.33]
1.1 Insoluble fibres	5	244	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.76, 1.19]
1.2 Soluble fibre	6	321	Risk Ratio (M-H, Random, 95% CI)	1.28 [0.91, 1.78]
2 Comparing scores on global assessment in IBS patients	1	56	Std. Mean Difference (IV, Fixed, 95% CI)	-0.22 [-0.74, 0.31]
2.1 Insoluble fibres	1	56	Std. Mean Difference (IV, Fixed, 95% CI)	-0.22 [-0.74, 0.31]
2.2 Soluble fibres	0	0	Std. Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]

Comparison 3. Bulking agents: Outcome on symptom score

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Comparing symptom scores in IBS patients	3	126	Std. Mean Difference (IV, Fixed, 95% CI)	-0.00 [-0.43, 0.43]
1.1 Insoluble fibres	3	126	Std. Mean Difference (IV, Fixed, 95% CI)	-0.00 [-0.43, 0.43]
1.2 Soluble fibres	0	0	Std. Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]

Comparison 4. Spasmolytics: Abdominal pain

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Comparing nr(%) of successfully treated IBS patients on Abdominal pain	13	1392	Risk Ratio (M-H, Random, 95% CI)	1.32 [1.12, 1.55]
1.1 Alverine	1	107	Risk Ratio (M-H, Random, 95% CI)	1.19 [0.87, 1.62]
1.2 Cimetropium/dicylomine	1	97	Risk Ratio (M-H, Random, 95% CI)	1.56 [1.06, 2.28]
1.3 Mebeverine	1	80	Risk Ratio (M-H, Random, 95% CI)	0.82 [0.38, 1.76]
1.4 Otilonium	1	325	Risk Ratio (M-H, Random, 95% CI)	1.27 [0.96, 1.68]
1.5 Peppermint oil	1	101	Risk Ratio (M-H, Random, 95% CI)	2.15 [1.54, 3.00]
1.6 Pinaverium	3	158	Risk Ratio (M-H, Random, 95% CI)	1.57 [1.08, 2.26]
1.7 Pirenzepine	1	24	Risk Ratio (M-H, Random, 95% CI)	0.67 [0.25, 1.78]
1.8 Propinox	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
1.9 Scopolamine derivatives	1	360	Risk Ratio (M-H, Random, 95% CI)	1.00 [0.84, 1.19]
1.10 Trimebutine	3	140	Risk Ratio (M-H, Random, 95% CI)	1.32 [1.07, 1.64]
2 Comparing scores on abdominal pain in IBS patients	8	455	Std. Mean Difference (IV, Random, 95% CI)	1.14 [0.47, 1.81]
2.1 Alvarine	0	0	Std. Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
2.2 Cimetropium/dicyclomine	3	146	Std. Mean Difference (IV, Random, 95% CI)	1.08 [0.73, 1.43]
2.3 Mebeverine	0	0	Std. Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
2.4 Otilonium	1	70	Std. Mean Difference (IV, Random, 95% CI)	0.43 [-0.04, 0.91]
2.5 Peppermint oil	1	57	Std. Mean Difference (IV, Random, 95% CI)	3.88 [2.98, 4.79]
2.6 Pinaverium	2	114	Std. Mean Difference (IV, Random, 95% CI)	0.44 [-0.20, 1.08]
2.7 Pirenzepine	0	0	Std. Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
2.8 Propinox	1	68	Std. Mean Difference (IV, Random, 95% CI)	0.45 [-0.04, 0.93]
2.9 Scopolamine derivatives	0	0	Std. Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
2.10 Trimebutine	0	0	Std. Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]

Comparison 5. Spasmolytics: Global assessment

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Comparing nr (%) of successfully treated patients	22	1983	Risk Ratio (M-H, Random, 95% CI)	1.49 [1.25, 1.77]
1.1 Alverine	1	107	Risk Ratio (M-H, Random, 95% CI)	1.20 [0.80, 1.80]
1.2 Cimtetropium/dicyclomine	4	255	Risk Ratio (M-H, Random, 95% CI)	1.78 [1.15, 2.75]
1.3 Mebeverine	1	80	Risk Ratio (M-H, Random, 95% CI)	0.42 [0.16, 1.07]
1.4 Otilonium	3	363	Risk Ratio (M-H, Random, 95% CI)	1.79 [1.31, 2.44]
1.5 Peppermint oil	2	225	Risk Ratio (M-H, Random, 95% CI)	2.25 [1.70, 2.98]
1.6 Pinaverium	4	308	Risk Ratio (M-H, Random, 95% CI)	1.66 [1.25, 2.19]
1.7 Pirenzepine	1	24	Risk Ratio (M-H, Random, 95% CI)	0.83 [0.35, 2.00]
1.8 Propinox	1	75	Risk Ratio (M-H, Random, 95% CI)	0.77 [0.26, 2.30]
1.9 Scopolamine derivatives	3	426	Risk Ratio (M-H, Random, 95% CI)	4.43 [0.47, 41.67]

1.10 Trimebutine	2	120	Risk Ratio (M-H, Random, 95% CI)	0.97 [0.68, 1.38]
2 Comparing scores on global assessment in IBS patients	2	331	Std. Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
2.1 Alvarine	0	0	Std. Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
2.2 Cimetropium/ dicyclomine	0	0	Std. Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
2.3 Mebeverine	0	0	Std. Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
2.4 Otilonium	1	271	Std. Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
2.5 Peppermint oil	0	0	Std. Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
2.6 Pinaverium	1	60	Std. Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
2.7 Pirenzepine	0	0	Std. Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
2.8 Propinox	0	0	Std. Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
2.9 Scopolamine derivatives	0	0	Std. Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
2.10 Trimebutine	0	0	Std. Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]

Comparison 6. Spasmolytics: Outcome on symptom score

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Comparing nr (%) of patients successfully treated	4	586	Risk Ratio (M-H, Random, 95% CI)	1.86 [1.26, 2.76]
1.1 Alvarine	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
1.2 Cimetropium/ dicyclomine	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
1.3 Mebeverine	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
1.4 Otilonium	1	317	Risk Ratio (M-H, Random, 95% CI)	1.64 [1.15, 2.34]
1.5 Peppermint oil	3	269	Risk Ratio (M-H, Random, 95% CI)	1.94 [1.09, 3.46]
1.6 Pinaverium	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
1.7 Pirenzepine	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
1.8 Propinox	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
1.9 Scopolamine derivatives	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
1.10 Trimebutine	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
2 Comparing symptom scores in IBS patients	4	243	Std. Mean Difference (IV, Random, 95% CI)	2.39 [0.50, 4.29]
2.1 Alvarine	0	0	Std. Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
2.2 Cimetropium/ dicyclomine	0	0	Std. Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
2.3 Mebeverine	0	0	Std. Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
2.4 Otilonium	1	28	Std. Mean Difference (IV, Random, 95% CI)	0.20 [-0.55, 0.94]
2.5 Peppermint oil	1	57	Std. Mean Difference (IV, Random, 95% CI)	9.86 [7.92, 11.81]
2.6 Pinaverium	2	158	Std. Mean Difference (IV, Random, 95% CI)	0.51 [0.19, 0.84]
2.7 Pirenzepine	0	0	Std. Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
2.8 Propinox	0	0	Std. Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
2.9 Scopolamine derivatives	0	0	Std. Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
2.10 Trimebutine	0	0	Std. Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]

Comparison 7. Antidepressants: Abdominal pain

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Comparing nr(%) of successfully treated patients with IBS	8	517	Risk Ratio (M-H, Random, 95% CI)	1.49 [1.05, 2.12]
1.1 SSRI's	4	197	Risk Ratio (M-H, Random, 95% CI)	2.29 [0.79, 6.68]
1.2 TCA's	4	320	Risk Ratio (M-H, Random, 95% CI)	1.26 [1.03, 1.55]
2 Comparing scores on abdominal pain in patients with IBS	3	124	Std. Mean Difference (IV, Random, 95% CI)	1.80 [-0.57, 4.16]
2.1 SSRI's	1	23	Std. Mean Difference (IV, Random, 95% CI)	4.60 [2.93, 6.28]
2.2 TCA's	2	101	Std. Mean Difference (IV, Random, 95% CI)	0.53 [-1.23, 2.29]

Comparison 8. Antidepressants: Global assessment

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Comparing nr (%) of successfully treated patients with IBS	11	750	Risk Ratio (M-H, Random, 95% CI)	1.57 [1.23, 2.00]
1.1 SSRI's	4	227	Risk Ratio (M-H, Random, 95% CI)	1.79 [1.01, 3.20]
1.2 TCA's	8	523	Risk Ratio (M-H, Random, 95% CI)	1.45 [1.13, 1.86]
2 Comparing scores on global assessment in patients with IBS	1	22	Std. Mean Difference (IV, Random, 95% CI)	3.32 [1.95, 4.68]
2.1 SSRI's	1	22	Std. Mean Difference (IV, Random, 95% CI)	3.32 [1.95, 4.68]
2.2 TCA's	0	0	Std. Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]

Comparison 9. Antidepressants: Outcome on symptom score

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Comparing nr (%) of successfully treated IBS patients	3	159	Risk Ratio (M-H, Fixed, 95% CI)	1.99 [1.32, 2.99]
1.1 SSRI's	1	72	Risk Ratio (M-H, Fixed, 95% CI)	1.36 [0.81, 2.27]
1.2 TCA's	2	87	Risk Ratio (M-H, Fixed, 95% CI)	3.16 [1.59, 6.29]
2 Comparing symptom scores of IBS patients	2	122	Std. Mean Difference (IV, Random, 95% CI)	0.38 [-0.30, 1.06]
2.1 SSRI's	1	72	Std. Mean Difference (IV, Random, 95% CI)	0.05 [-0.41, 0.52]
2.2 TCA's	1	50	Std. Mean Difference (IV, Random, 95% CI)	0.75 [0.17, 1.32]

Comparison 10. Adequate concealment bulking agents: abdominal pain

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Comparing scores on abdominal pain	2	119	Std. Mean Difference (IV, Fixed, 95% CI)	0.04 [-0.32, 0.40]

Comparison 11. Adequate concealment bulking agents: global assessment

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 comparing nr of successfully treated IBS patient	5	193	Risk Ratio (M-H, Fixed, 95% CI)	0.91 [0.68, 1.23]

Comparison 12. Adequate concealment spasmolytic agents: abdominal pain

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Comparing scores on abdominal pain in IBS patients	2	115	Std. Mean Difference (IV, Fixed, 95% CI)	0.43 [0.06, 0.80]

Comparison 13. Adequate concealment spasmolytic agents: global assessment

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 comparing nrs of successfully treated IBS patients with spasmolytic agents	3	219	Risk Ratio (M-H, Fixed, 95% CI)	1.35 [0.85, 2.12]

Comparison 14. Adequate concealment antidepressants: abdominal pain

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Comparing nr (%) of successfully treated patients	5	364	Risk Ratio (M-H, Random, 95% CI)	1.35 [0.98, 1.86]
1.1 SSRI	3	156	Risk Ratio (M-H, Random, 95% CI)	1.20 [0.87, 1.67]
1.2 TCA	2	208	Risk Ratio (M-H, Random, 95% CI)	2.19 [0.59, 8.11]

Comparison 15. Adequate concealment antidepressants: global assessment

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Comparing nr (%) of successfully treated IBS patients	4	329	Risk Ratio (M-H, Fixed, 95% CI)	1.42 [1.12, 1.80]

Comparison 16. Adequate concealment antidepressants: Outcome on symptom score

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Comparing symptom scores in IBS patients	1	50	Std. Mean Difference (IV, Fixed, 95% CI)	0.75 [0.17, 1.32]

Analysis 1.1. Comparison 1 Bulking agents: Abdominal pain, Outcome 1 Comparing nr(%) of successfully treated IBS patients.

Review: Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome

Comparison: 1 Bulking agents: Abdominal pain

Outcome: 1 Comparing nr(%) of successfully treated IBS patients

Study or subgroup	Bulking agent n/N	Placebo n/N	Risk Ratio M-H,Fixed,95% CI	Weight	Risk Ratio M-H,Fixed,95% CI
1 Insoluble fibres					
Subtotal (95% CI)	**0**	**0**		**0.0 %**	**0.0 [0.0, 0.0]**
Total events: 0 (Bulking agent), 0 (Placebo)					
Heterogeneity: not applicable					
Test for overall effect: not applicable					
2 Soluble fibres					
Prior 1987	21/40	23/40		100.0 %	0.91 [0.61, 1.36]
Subtotal (95% CI)	**40**	**40**		**100.0 %**	**0.91 [0.61, 1.36]**
Total events: 21 (Bulking agent), 23 (Placebo)					
Heterogeneity: not applicable					
Test for overall effect: Z = 0.45 (P = 0.65)					
Total (95% CI)	**40**	**40**		**100.0 %**	**0.91 [0.61, 1.36]**
Total events: 21 (Bulking agent), 23 (Placebo)					
Heterogeneity: not applicable					
Test for overall effect: Z = 0.45 (P = 0.65)					
Test for subgroup differences: Not applicable					



Analysis 1.2. Comparison 1 Bulking agents: Abdominal pain, Outcome 2 Comparing scores on abdominal pain in IBS patients.

Review: Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome

Comparison: 1 Bulking agents: Abdominal pain

Outcome: 2 Comparing scores on abdominal pain in IBS patients

Study or subgroup	Bulking agent N	Mean(SD)	Placebo N	Mean(SD)	Std. Mean Difference IV,Fixed,95% CI	Std. Mean Difference IV,Fixed,95% CI
1 Insoluble fibres						
Aller 2004	28	-1.6 (1.5)	28	-1.6 (1.9)		0.0 [-0.52, 0.52]
Fowlie 1992	23	-5 (0)	19	-5 (0)		0.0 [0.0, 0.0]
Rees 2005	14	-0.8 (0)	14	-0.9 (0)		0.0 [0.0, 0.0]
Subtotal (95% CI)	**65**		**61**			**0.0 [-0.52, 0.52]**
Heterogeneity: Chi^2 = 0.0, df = 0 (P = 1.00); I^2 =0.0%						
Test for overall effect: Z = 0.0 (P = 1.0)						
2 Soluble fibres						
Longstreth 1981	26	-0.59 (0.51)	34	-0.62 (0.52)		0.06 [-0.45, 0.57]
Subtotal (95% CI)	**26**		**34**			**0.06 [-0.45, 0.57]**
Heterogeneity: not applicable						
Test for overall effect: Z = 0.22 (P = 0.83)						
Total (95% CI)	**91**		**95**			**0.03 [-0.34, 0.40]**
Heterogeneity: Chi^2 = 0.02, df = 1 (P = 0.88); I^2 =0.0%						
Test for overall effect: Z = 0.16 (P = 0.87)						
Test for subgroup differences: Chi^2 = 0.02, df = 1 (P = 0.88), I^2 =0.0%						



Analysis 2.1. Comparison 2 Bulking agents: Global assessment, Outcome 1 Comparing nr(%) of successfully treated patients with IBS.

Review: Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome

Comparison: 2 Bulking agents: Global assessment

Outcome: 1 Comparing nr(%) of successfully treated patients with IBS



Analysis 2.2. Comparison 2 Bulking agents: Global assessment, Outcome 2 Comparing scores on global assessment in IBS patients.

Review: Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome

Comparison: 2 Bulking agents: Global assessment

Outcome: 2 Comparing scores on global assessment in IBS patients

Study or subgroup	Bulking agent N	Mean(SD)	Placebo N	Mean(SD)	Std. Mean Difference IV,Fixed,95% CI	Weight	Std. Mean Difference IV,Fixed,95% CI
1 Insoluble fibres							
Aller 2004	28	-1.5 (0.9)	28	-1.3 (0.9)		100.0 %	-0.22 [-0.74, 0.31]
Subtotal (95% CI)	**28**		**28**			**100.0 %**	**-0.22 [-0.74, 0.31]**
Heterogeneity: not applicable							
Test for overall effect: Z = 0.82 (P = 0.41)							
2 Soluble fibres							
Subtotal (95% CI)	**0**		**0**			**0.0 %**	**0.0 [0.0, 0.0]**
Heterogeneity: not applicable							
Test for overall effect: not applicable							
Total (95% CI)	**28**		**28**			**100.0 %**	**-0.22 [-0.74, 0.31]**
Heterogeneity: not applicable							
Test for overall effect: Z = 0.82 (P = 0.41)							
Test for subgroup differences: Not applicable							



Analysis 3.1. Comparison 3 Bulking agents: Outcome on symptom score, Outcome 1 Comparing symptom scores in IBS patients.

Review: Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome

Comparison: 3 Bulking agents: Outcome on symptom score

Outcome: 1 Comparing symptom scores in IBS patients

Study or subgroup	Bulking agent N	Mean(SD)	Placebo N	Mean(SD)	Std. Mean Difference IV,Fixed,95% CI	Std. Mean Difference IV,Fixed,95% CI
1 Insoluble fibres						
Aller 2004	28	-1.5 (0.9)	28	-1.3 (0.9)		-0.22 [-0.74, 0.31]
Fowlie 1992	23	-5 (0)	19	-3 (0)		0.0 [0.0, 0.0]
Lucey 1987	14	-1 (4.6)	14	-3.5 (6.2)		0.44 [-0.31, 1.20]
Subtotal (95% CI)	**65**		**61**			**0.00 [-0.43, 0.43]**
Heterogeneity: Chi^2 = 2.01, df = 1 (P = 0.16); I^2 =50%						
Test for overall effect: Z = 0.00 (P = 1.0)						
2 Soluble fibres						
Subtotal (95% CI)	**0**		**0**			**0.0 [0.0, 0.0]**
Heterogeneity: not applicable						
Test for overall effect: not applicable						
Total (95% CI)	**65**		**61**			**0.00 [-0.43, 0.43]**
Heterogeneity: Chi^2 = 2.01, df = 1 (P = 0.16); I^2 =50%						
Test for overall effect: Z = 0.00 (P = 1.0)						
Test for subgroup differences: Not applicable						

Analysis 4.1. Comparison 4 Spasmolytics: Abdominal pain, Outcome 1 Comparing nr(%) of successfully treated IBS patients on Abdominal pain.

Review: Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome

Comparison: 4 Spasmolytics: Abdominal pain

Outcome: 1 Comparing nr(%) of successfully treated IBS patients on Abdominal pain



(*Continued . . .*)

(. . . *Continued*)

Study or subgroup	Spasmolytic n/N	Placebo n/N	Risk Ratio M-H,Random,95% CI	Weight	Risk Ratio M-H,Random,95% CI
Dubarry 1977	9/10	5/10		4.4 %	1.80 [0.94, 3.46]
Virat 1987	29/39	23/39		10.1 %	1.26 [0.92, 1.74]
Subtotal (95% CI)	**79**	**79**		**18.8 %**	**1.57 [1.08, 2.26]**
Total events: 56 (Spasmolytic), 36 (Placebo)					
Heterogeneity: Tau^2 = 0.04; Chi^2 = 3.04, df = 2 (P = 0.22); I^2 =34%					
Test for overall effect: Z = 2.39 (P = 0.017)					
7 Pirenzepine					
Gilvarry 1989	4/12	6/12		2.3 %	0.67 [0.25, 1.78]
Subtotal (95% CI)	**12**	**12**		**2.3 %**	**0.67 [0.25, 1.78]**
Total events: 4 (Spasmolytic), 6 (Placebo)					
Heterogeneity: not applicable					
Test for overall effect: Z = 0.81 (P = 0.42)					
8 Propinox					
Subtotal (95% CI)	**0**	**0**		**0.0 %**	**0.0 [0.0, 0.0]**
Total events: 0 (Spasmolytic), 0 (Placebo)					
Heterogeneity: not applicable					
Test for overall effect: not applicable					
9 Scopolamine derivatives					
Schafer 1990	106/182	104/178		14.2 %	1.00 [0.84, 1.19]
Subtotal (95% CI)	**182**	**178**		**14.2 %**	**1.00 [0.84, 1.19]**
Total events: 106 (Spasmolytic), 104 (Placebo)					
Heterogeneity: not applicable					
Test for overall effect: Z = 0.04 (P = 0.97)					
10 Trimebutine					
Fielding 1980	12/30	11/30		4.5 %	1.09 [0.57, 2.07]
Ghidini 1986	29/30	21/30		12.2 %	1.38 [1.08, 1.76]
Moshal 1979	7/10	6/10		4.4 %	1.17 [0.61, 2.23]
Subtotal (95% CI)	**70**	**70**		**21.2 %**	**1.32 [1.07, 1.64]**
Total events: 48 (Spasmolytic), 38 (Placebo)					
Heterogeneity: Tau^2 = 0.0; Chi^2 = 0.77, df = 2 (P = 0.68); I^2 =0.0%					
Test for overall effect: Z = 2.54 (P = 0.011)					
Total (95% CI)	**696**	**696**		**100.0 %**	**1.32 [1.12, 1.55]**
Total events: 407 (Spasmolytic), 323 (Placebo)					
Heterogeneity: Tau^2 = 0.04; Chi^2 = 25.95, df = 12 (P = 0.01); I^2 =54%					
Test for overall effect: Z = 3.40 (P = 0.00067)					
Test for subgroup differences: Chi^2 = 22.57, df = 8 (P = 0.00), I^2 =65%					

Analysis 4.2. Comparison 4 Spasmolytics: Abdominal pain, Outcome 2 Comparing scores on abdominal pain in IBS patients.

Review: Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome

Comparison: 4 Spasmolytics: Abdominal pain

Outcome: 2 Comparing scores on abdominal pain in IBS patients

Study or subgroup	Spasmolitic N	Mean(SD)	Placebo N	Mean(SD)	Std. Mean Difference IV,Random,95% CI	Std. Mean Difference IV,Random,95% CI
1 Alvarine						
Subtotal (95% CI)	**0**		**0**			**0.0 [0.0, 0.0]**
Heterogeneity: not applicable						
Test for overall effect: not applicable						
2 Cimetropium/dicyclomine						
Centonze 1988	23	-0.25 (0.48)	21	-1.48 (1.3)		1.26 [0.60, 1.91]
Dobrilla 1990	35	-0.18 (0.53)	34	-0.91 (0.71)		1.15 [0.64, 1.67]
Passaretti 1989a	16	-0.44 (0.51)	17	-0.82 (0.49)		0.74 [0.03, 1.45]
Subtotal (95% CI)	**74**		**72**			**1.08 [0.73, 1.43]**
Heterogeneity: $Tau^2 = 0.0$; $Chi^2 = 1.23$, df = 2 (P = 0.54); $I^2 = 0.0\%$						
Test for overall effect: Z = 6.06 (P < 0.00001)						
3 Mebeverine						
Subtotal (95% CI)	**0**		**0**			**0.0 [0.0, 0.0]**
Heterogeneity: not applicable						
Test for overall effect: not applicable						
4 Otilonium						
Baldi 1991	33	-2.57 (1.72)	37	-3.43 (2.15)		0.43 [-0.04, 0.91]
Subtotal (95% CI)	**33**		**37**			**0.43 [-0.04, 0.91]**
Heterogeneity: not applicable						
Test for overall effect: Z = 1.79 (P = 0.073)						
5 Peppermint oil						
Cappello 2007	28	-1.5 (0.3)	29	-2.5 (0.2)		3.88 [2.98, 4.79]
Subtotal (95% CI)	**28**		**29**			**3.88 [2.98, 4.79]**
Heterogeneity: not applicable						
Test for overall effect: Z = 8.43 (P < 0.00001)						
6 Pinaverium						
Awad 1995	19	-2.3 (1.78)	19	-3.1 (1.78)		0.44 [-0.20, 1.08]
Virat 1987	38	-0.8 (0)	38	-1.1 (0)		0.0 [0.0, 0.0]
Subtotal (95% CI)	**57**		**57**			**0.44 [-0.20, 1.08]**
Heterogeneity: $Tau^2 = 0.0$; $Chi^2 = 0.0$, df = 0 (P = 1.00); $I^2 = 0.0\%$						
Test for overall effect: Z = 1.34 (P = 0.18)						



(*Continued . . .*)

(. . . *Continued*)

Study or subgroup	Spasmolitic N	Mean(SD)	Placebo N	Mean(SD)	Std. Mean Difference IV,Random,95% CI	Std. Mean Difference IV,Random,95% CI
7 Pirenzepine						
Subtotal (95% CI)	**0**		**0**			**0.0 [0.0, 0.0]**
Heterogeneity: not applicable						
Test for overall effect: not applicable						
8 Propinox						
Pulpeiro 2000	35	-1.63 (0.99)	33	-2.09 (1.05)		0.45 [-0.04, 0.93]
Subtotal (95% CI)	**35**		**33**			**0.45 [-0.04, 0.93]**
Heterogeneity: not applicable						
Test for overall effect: Z = 1.81 (P = 0.070)						
9 Scopolamine derivatives						
Subtotal (95% CI)	**0**		**0**			**0.0 [0.0, 0.0]**
Heterogeneity: not applicable						
Test for overall effect: not applicable						
10 Trimebutine						
Subtotal (95% CI)	**0**		**0**			**0.0 [0.0, 0.0]**
Heterogeneity: not applicable						
Test for overall effect: not applicable						
Total (95% CI)	**227**		**228**			**1.14 [0.47, 1.81]**
Heterogeneity: $Tau^2 = 0.72$; $Chi^2 = 53.25$, df = 6 (P<0.00001); I^2 =89%						
Test for overall effect: Z = 3.32 (P = 0.00089)						
Test for subgroup differences: $Chi^2 = 52.02$, df = 4 (P = 0.00), I^2 =92%						



Analysis 5.1. Comparison 5 Spasmolytics: Global assessment, Outcome 1 Comparing nr (%) of successfully treated patients.

Review: Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome

Comparison: 5 Spasmolytics: Global assessment

Outcome: 1 Comparing nr (%) of successfully treated patients



(*Continued . . .*)

(. . . *Continued*)

Study or subgroup	Spasmolitic n/N	Placebo n/N	Risk Ratio M-H,Random,95% CI	Weight	Risk Ratio M-H,Random,95% CI
Capanni 2005	73/91	31/87		7.4 %	2.25 [1.67, 3.04]
Lech 1988	13/23	6/24		3.3 %	2.26 [1.04, 4.93]
Subtotal (95% CI)	**114**	**111**		**10.7 %**	**2.25 [1.70, 2.98]**
Total events: 86 (Spasmolitic), 37 (Placebo)					
Heterogeneity: $Tau^2 = 0.0$; $Chi^2 = 0.00$, df = 1 (P = 0.99); $I^2 = 0.0\%$					
Test for overall effect: Z = 5.68 (P < 0.00001)					
6 Pinaverium					
Chen 2004	30/74	14/46		5.2 %	1.33 [0.79, 2.23]
Delmont 1981	24/30	17/30		6.7 %	1.41 [0.98, 2.02]
Levy 1977	19/25	7/25		4.0 %	2.71 [1.39, 5.28]
Virat 1987	25/39	13/39		5.3 %	1.92 [1.16, 3.18]
Subtotal (95% CI)	**168**	**140**		**21.2 %**	**1.66 [1.25, 2.19]**
Total events: 98 (Spasmolitic), 51 (Placebo)					
Heterogeneity: $Tau^2 = 0.02$; $Chi^2 = 3.93$, df = 3 (P = 0.27); $I^2 = 24\%$					
Test for overall effect: Z = 3.53 (P = 0.00042)					
7 Pirenzepine					
Gilvarry 1989	5/12	6/12		2.8 %	0.83 [0.35, 2.00]
Subtotal (95% CI)	**12**	**12**		**2.8 %**	**0.83 [0.35, 2.00]**
Total events: 5 (Spasmolitic), 6 (Placebo)					
Heterogeneity: not applicable					
Test for overall effect: Z = 0.41 (P = 0.68)					
8 Propinox					
Pulpeiro 2000	5/39	6/36		2.0 %	0.77 [0.26, 2.30]
Subtotal (95% CI)	**39**	**36**		**2.0 %**	**0.77 [0.26, 2.30]**
Total events: 5 (Spasmolitic), 6 (Placebo)					
Heterogeneity: not applicable					
Test for overall effect: Z = 0.47 (P = 0.64)					
9 Scopolamine derivatives					
Nigam 1984	10/21	0/21		0.4 %	21.00 [1.31, 336.75]
Ritchie 1979	4/12	0/12		0.4 %	9.00 [0.54, 150.81]
Schafer 1990	138/182	114/178		8.9 %	1.18 [1.03, 1.36]
Subtotal (95% CI)	**215**	**211**		**9.7 %**	**4.43 [0.47, 41.67]**
Total events: 152 (Spasmolitic), 114 (Placebo)					
Heterogeneity: $Tau^2 = 2.82$; $Chi^2 = 7.53$, df = 2 (P = 0.02); $I^2 = 73\%$					
Test for overall effect: Z = 1.30 (P = 0.19)					
10 Trimebutine					
Fielding 1980	13/30	17/30		5.2 %	0.76 [0.46, 1.28]
Ghidini 1986	22/30	20/30		7.0 %	1.10 [0.79, 1.53]

(*Continued* . . .)

(. . . *Continued*)

Study or subgroup	Spasmolitic n/N	Placebo n/N	Risk Ratio M-H,Random,95% CI	Weight	Risk Ratio M-H,Random,95% CI
Subtotal (95% CI)	**60**	**60**		**12.2 %**	**0.97 [0.68, 1.38]**
Total events: 35 (Spasmolitic), 37 (Placebo)					
Heterogeneity: $Tau^2 = 0.02$; $Chi^2 = 1.45$, df = 1 (P = 0.23); $I^2 = 31\%$					
Test for overall effect: Z = 0.19 (P = 0.85)					
Total (95% CI)	**1008**	**975**		**100.0 %**	**1.49 [1.25, 1.77]**
Total events: 579 (Spasmolitic), 382 (Placebo)					
Heterogeneity: $Tau^2 = 0.08$; $Chi^2 = 58.37$, df = 21 (P = 0.00002); $I^2 = 64\%$					
Test for overall effect: Z = 4.46 (P < 0.00001)					
Test for subgroup differences: $Chi^2 = 28.38$, df = 9 (P = 0.00), $I^2 = 68\%$					

Analysis 5.2. Comparison 5 Spasmolytics: Global assessment, Outcome 2 Comparing scores on global assessment in IBS patients.

Review: Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome

Comparison: 5 Spasmolytics: Global assessment

Outcome: 2 Comparing scores on global assessment in IBS patients

Study or subgroup	Treatment N	Mean(SD)	Control N	Mean(SD)	Std. Mean Difference IV,Fixed,95% CI	Std. Mean Difference IV,Fixed,95% CI
1 Alvarine						
Subtotal (95% CI)	**0**		**0**			**0.0 [0.0, 0.0]**
Heterogeneity: not applicable						
Test for overall effect: not applicable						
2 Cimetropium/dicyclomine						
Subtotal (95% CI)	**0**		**0**			**0.0 [0.0, 0.0]**
Heterogeneity: not applicable						
Test for overall effect: not applicable						
3 Mebeverine						
Subtotal (95% CI)	**0**		**0**			**0.0 [0.0, 0.0]**
Heterogeneity: not applicable						



(*Continued* . . .)

(. . . *Continued*)

Study or subgroup	Treatment N	Mean(SD)	Control N	Mean(SD)	Std. Mean Difference IV,Fixed,95% CI	Std. Mean Difference IV,Fixed,95% CI
Test for overall effect: not applicable						
4 Otilonium						
Battaglia 1998	138	-3.19 (0)	133	-3.46 (0)		0.0 [0.0, 0.0]
Subtotal (95% CI)	**138**		**133**			**0.0 [0.0, 0.0]**
Heterogeneity: not applicable						
Test for overall effect: Z = 0.0 (P < 0.00001)						
5 Peppermint oil						
Subtotal (95% CI)	**0**		**0**			**0.0 [0.0, 0.0]**
Heterogeneity: not applicable						
Test for overall effect: not applicable						
6 Pinaverium						
Delmont 1981	30	-4 (0)	30	-3.87 (0)		0.0 [0.0, 0.0]
Subtotal (95% CI)	**30**		**30**			**0.0 [0.0, 0.0]**
Heterogeneity: not applicable						
Test for overall effect: Z = 0.0 (P < 0.00001)						
7 Pirenzepine						
Subtotal (95% CI)	**0**		**0**			**0.0 [0.0, 0.0]**
Heterogeneity: not applicable						
Test for overall effect: not applicable						
8 Propinox						
Subtotal (95% CI)	**0**		**0**			**0.0 [0.0, 0.0]**
Heterogeneity: not applicable						
Test for overall effect: not applicable						
9 Scopolamine derivatives						
Subtotal (95% CI)	**0**		**0**			**0.0 [0.0, 0.0]**
Heterogeneity: not applicable						
Test for overall effect: not applicable						
10 Trimebutine						
Subtotal (95% CI)	**0**		**0**			**0.0 [0.0, 0.0]**
Heterogeneity: not applicable						
Test for overall effect: not applicable						
Total (95% CI)	**168**		**163**			**0.0 [0.0, 0.0]**
Heterogeneity: Chi^2 = 0.0, df = 0 (P<0.00001); I^2 =0.0%						
Test for overall effect: Z = 0.0 (P < 0.00001)						
Test for subgroup differences: Chi^2 = 0.0, df = -1 (P = 0.0), I^2 =0.0%						

-10 -5 0 5 10

Placebo Spasmolytic agent

Analysis 6.1. Comparison 6 Spasmolytics: Outcome on symptom score, Outcome 1 Comparing nr (%) of patients successfully treated.

Review: Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome

Comparison: 6 Spasmolytics: Outcome on symptom score

Outcome: 1 Comparing nr (%) of patients successfully treated

Study or subgroup	Spasmolytic n/N	Placebo n/N	Risk Ratio M-H,Random,95% CI	Weight	Risk Ratio M-H,Random,95% CI
1 Alvarine					
Subtotal (95% CI)	**0**	**0**		**0.0 %**	**0.0 [0.0, 0.0]**
Total events: 0 (Spasmolytic), 0 (Placebo)					
Heterogeneity: not applicable					
Test for overall effect: not applicable					
2 Cimetropium/dicyclomine					
Subtotal (95% CI)	**0**	**0**		**0.0 %**	**0.0 [0.0, 0.0]**
Total events: 0 (Spasmolytic), 0 (Placebo)					
Heterogeneity: not applicable					
Test for overall effect: not applicable					
3 Mebeverine					
Subtotal (95% CI)	**0**	**0**		**0.0 %**	**0.0 [0.0, 0.0]**
Total events: 0 (Spasmolytic), 0 (Placebo)					
Heterogeneity: not applicable					
Test for overall effect: not applicable					
4 Otilonium					
Battaglia 1998	58/157	36/160		26.1 %	1.64 [1.15, 2.34]
Subtotal (95% CI)	**157**	**160**		**26.1 %**	**1.64 [1.15, 2.34]**
Total events: 58 (Spasmolytic), 36 (Placebo)					
Heterogeneity: not applicable					
Test for overall effect: Z = 2.75 (P = 0.0059)					
5 Peppermint oil					
Capanni 2005	88/91	29/87		27.7 %	2.90 [2.15, 3.91]
Cappello 2007	18/28	10/29		19.4 %	1.86 [1.05, 3.31]
Czalbert 1990	16/17	12/17		26.8 %	1.33 [0.96, 1.85]
Subtotal (95% CI)	**136**	**133**		**73.9 %**	**1.94 [1.09, 3.46]**
Total events: 122 (Spasmolytic), 51 (Placebo)					
Heterogeneity: Tau^2 = 0.22; Chi^2 = 13.78, df = 2 (P = 0.001); I^2 =85%					
Test for overall effect: Z = 2.25 (P = 0.024)					
6 Pinaverium					
Subtotal (95% CI)	**0**	**0**		**0.0 %**	**0.0 [0.0, 0.0]**
Total events: 0 (Spasmolytic), 0 (Placebo)					
Heterogeneity: not applicable					



(*Continued* . . .)

(. . . *Continued*)

Study or subgroup	Spasmolytic n/N	Placebo n/N	Risk Ratio M-H,Random,95% CI	Weight	Risk Ratio M-H,Random,95% CI
Test for overall effect: not applicable					
7 Pirenzepine					
Subtotal (95% CI)	**0**	**0**		**0.0 %**	**0.0 [0.0, 0.0]**
Total events: 0 (Spasmolytic), 0 (Placebo)					
Heterogeneity: not applicable					
Test for overall effect: not applicable					
8 Propinox					
Subtotal (95% CI)	**0**	**0**		**0.0 %**	**0.0 [0.0, 0.0]**
Total events: 0 (Spasmolytic), 0 (Placebo)					
Heterogeneity: not applicable					
Test for overall effect: not applicable					
9 Scopolamine derivatives					
Subtotal (95% CI)	**0**	**0**		**0.0 %**	**0.0 [0.0, 0.0]**
Total events: 0 (Spasmolytic), 0 (Placebo)					
Heterogeneity: not applicable					
Test for overall effect: not applicable					
10 Trimebutine					
Subtotal (95% CI)	**0**	**0**		**0.0 %**	**0.0 [0.0, 0.0]**
Total events: 0 (Spasmolytic), 0 (Placebo)					
Heterogeneity: not applicable					
Test for overall effect: not applicable					
Total (95% CI)	**293**	**293**	◆	**100.0 %**	**1.86 [1.26, 2.76]**
Total events: 180 (Spasmolytic), 87 (Placebo)					
Heterogeneity: $Tau^2 = 0.12$; $Chi^2 = 13.38$, df = 3 (P = 0.004); $I^2 = 78\%$					
Test for overall effect: Z = 3.12 (P = 0.0018)					
Test for subgroup differences: $Chi^2 = 0.24$, df = 1 (P = 0.63), $I^2 = 0.0\%$					

Analysis 6.2. Comparison 6 Spasmolytics: Outcome on symptom score, Outcome 2 Comparing symptom scores in IBS patients.

Review: Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome

Comparison: 6 Spasmolytics: Outcome on symptom score

Outcome: 2 Comparing symptom scores in IBS patients



(*Continued . . .*)

(. . . *Continued*)

Study or subgroup	Spasmolytic N	Mean(SD)	Placebo N	Mean(SD)	Std. Mean Difference IV,Random,95% CI	Weight	Std. Mean Difference IV,Random,95% CI
8 Propinox							
Subtotal (95% CI)	**0**		**0**			**0.0 %**	**0.0 [0.0, 0.0]**
Heterogeneity: not applicable							
Test for overall effect: not applicable							
9 Scopolamine derivatives							
Subtotal (95% CI)	**0**		**0**			**0.0 %**	**0.0 [0.0, 0.0]**
Heterogeneity: not applicable							
Test for overall effect: not applicable							
10 Trimebutine							
Subtotal (95% CI)	**0**		**0**			**0.0 %**	**0.0 [0.0, 0.0]**
Heterogeneity: not applicable							
Test for overall effect: not applicable							
Total (95% CI)	**135**		**108**			**100.0 %**	**2.39 [0.50, 4.29]**
Heterogeneity: $Tau^2 = 3.44$; $Chi^2 = 88.09$, df = 3 ($P<0.00001$); $I^2 = 97\%$							
Test for overall effect: $Z = 2.48$ ($P = 0.013$)							
Test for subgroup differences: $Chi^2 = 88.09$, df = 2 ($P = 0.00$), $I^2 = 98\%$							

Analysis 7.1. Comparison 7 Antidepressants: Abdominal pain, Outcome 1 Comparing nr(%) of successfully treated patients with IBS.

Review: Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome

Comparison: 7 Antidepressants: Abdominal pain

Outcome: 1 Comparing nr(%) of successfully treated patients with IBS



Analysis 7.2. Comparison 7 Antidepressants: Abdominal pain, Outcome 2 Comparing scores on abdominal pain in patients with IBS.

Review: Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome

Comparison: 7 Antidepressants: Abdominal pain

Outcome: 2 Comparing scores on abdominal pain in patients with IBS



Analysis 8.1. Comparison 8 Antidepressants: Global assessment, Outcome 1 Comparing nr (%) of successfully treated patients with IBS.

Review: Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome

Comparison: 8 Antidepressants: Global assessment

Outcome: 1 Comparing nr (%) of successfully treated patients with IBS



Analysis 8.2. Comparison 8 Antidepressants: Global assessment, Outcome 2 Comparing scores on global assessment in patients with IBS.

Review: Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome

Comparison: 8 Antidepressants: Global assessment

Outcome: 2 Comparing scores on global assessment in patients with IBS

Study or subgroup	Antidepressants N	Mean(SD)	Placebo N	Mean(SD)	Std. Mean Difference IV,Random,95% CI	Weight	Std. Mean Difference IV,Random,95% CI
1 SSRI's							
Tack 2006a	11	-5 (0.8)	11	-7.3 (0.5)		100.0 %	3.32 [1.95, 4.68]
Subtotal (95% CI)	**11**		**11**			**100.0 %**	**3.32 [1.95, 4.68]**
Heterogeneity: not applicable							
Test for overall effect: Z = 4.76 (P < 0.00001)							
2 TCA's							
Subtotal (95% CI)	**0**		**0**			**0.0 %**	**0.0 [0.0, 0.0]**
Heterogeneity: not applicable							
Test for overall effect: not applicable							
Total (95% CI)	**11**		**11**			**100.0 %**	**3.32 [1.95, 4.68]**
Heterogeneity: not applicable							
Test for overall effect: Z = 4.76 (P < 0.00001)							
Test for subgroup differences: Not applicable							



Analysis 9.1. Comparison 9 Antidepressants: Outcome on symptom score, Outcome 1 Comparing nr (%) of successfully treated IBS patients.

Review: Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome

Comparison: 9 Antidepressants: Outcome on symptom score

Outcome: 1 Comparing nr (%) of successfully treated IBS patients

Study or subgroup	Antidepressants n/N	Placebo n/N	Risk Ratio M-H,Fixed,95% CI	Weight	Risk Ratio M-H,Fixed,95% CI
1 SSRI's					
Masand 2009	19/36	14/36		65.2 %	1.36 [0.81, 2.27]
Subtotal (95% CI)	**36**	**36**		**65.2 %**	**1.36 [0.81, 2.27]**
Total events: 19 (Antidepressants), 14 (Placebo)					
Heterogeneity: not applicable					
Test for overall effect: Z = 1.17 (P = 0.24)					
2 TCA's					
Bahar 2008	6/16	0/17		2.3 %	13.76 [0.84, 226.13]
Vahedi 2008	17/27	7/27		32.6 %	2.43 [1.21, 4.89]
Subtotal (95% CI)	**43**	**44**		**34.8 %**	**3.16 [1.59, 6.29]**
Total events: 23 (Antidepressants), 7 (Placebo)					
Heterogeneity: Chi^2 = 1.61, df = 1 (P = 0.20); I^2 =38%					
Test for overall effect: Z = 3.28 (P = 0.0010)					
Total (95% CI)	**79**	**80**		**100.0 %**	**1.99 [1.32, 2.99]**
Total events: 42 (Antidepressants), 21 (Placebo)					
Heterogeneity: Chi^2 = 4.27, df = 2 (P = 0.12); I^2 =53%					
Test for overall effect: Z = 3.29 (P = 0.0010)					
Test for subgroup differences: Chi^2 = 3.74, df = 1 (P = 0.05), I^2 =73%					

Analysis 9.2. Comparison 9 Antidepressants: Outcome on symptom score, Outcome 2 Comparing symptom scores of IBS patients.

Review: Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome

Comparison: 9 Antidepressants: Outcome on symptom score

Outcome: 2 Comparing symptom scores of IBS patients

Study or subgroup	Antidepressants N	Mean(SD)	Placebo N	Mean(SD)	Std. Mean Difference IV,Random,95% CI	Weight	Std. Mean Difference IV,Random,95% CI
1 SSRI's							
Masand 2009	36	-2.7 (7.44)	36	-3.1 (7.44)		53.2 %	0.05 [-0.41, 0.52]
Subtotal (95% CI)	**36**		**36**			**53.2 %**	**0.05 [-0.41, 0.52]**
Heterogeneity: not applicable							
Test for overall effect: Z = 0.23 (P = 0.82)							
2 TCA's							
Vahedi 2008	25	-0.5 (1.45)	25	-1.6 (1.45)		46.8 %	0.75 [0.17, 1.32]
Subtotal (95% CI)	**25**		**25**			**46.8 %**	**0.75 [0.17, 1.32]**
Heterogeneity: not applicable							
Test for overall effect: Z = 2.55 (P = 0.011)							
Total (95% CI)	**61**		**61**			**100.0 %**	**0.38 [-0.30, 1.06]**
Heterogeneity: Tau^2 = 0.17; Chi^2 = 3.40, df = 1 (P = 0.07); I^2 =71%							
Test for overall effect: Z = 1.09 (P = 0.27)							
Test for subgroup differences: Chi^2 = 3.40, df = 1 (P = 0.07), I^2 =71%							

Analysis 10.1. Comparison 10 Adequate concealment bulking agents: abdominal pain, Outcome 1 Comparing scores on abdominal pain.

Review: Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome

Comparison: 10 Adequate concealment bulking agents: abdominal pain

Outcome: 1 Comparing scores on abdominal pain

Study or subgroup	Bulking agent N	Mean(SD)	Placebo N	Mean(SD)	Std. Mean Difference IV,Fixed,95% CI	Weight	Std. Mean Difference IV,Fixed,95% CI
Fowlie 1992	23	-5 (16.5)	19	-5 (16.5)		35.1 %	0.0 [-0.61, 0.61]
Longstreth 1981	37	-0.59 (0.51)	40	-0.62 (0.52)		64.9 %	0.06 [-0.39, 0.50]
Total (95% CI)	**60**		**59**			**100.0 %**	**0.04 [-0.32, 0.40]**

Heterogeneity: Chi^2 = 0.02, df = 1 (P = 0.88); I^2 =0.0%

Test for overall effect: Z = 0.20 (P = 0.84)

Test for subgroup differences: Not applicable



Analysis 11.1. Comparison 11 Adequate concealment bulking agents: global assessment, Outcome 1 comparing nr of successfully treated IBS patient.

Review: Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome

Comparison: 11 Adequate concealment bulking agents: global assessment

Outcome: 1 comparing nr of successfully treated IBS patient

Study or subgroup	Bulking agent n/N	Placebo n/N	Risk Ratio M-H,Fixed,95% CI	Weight	Risk Ratio M-H,Fixed,95% CI
Fowlie 1992	14/23	13/19		31.2 %	0.89 [0.57, 1.39]
Jalihal 1990	9/11	6/9		14.5 %	1.23 [0.72, 2.10]
Longstreth 1981	7/26	14/34		26.6 %	0.65 [0.31, 1.38]
Ritchie 1979	5/7	0/12		0.8 %	17.88 [1.13, 281.81]
Soltoft 1976	7/29	11/23		26.9 %	0.50 [0.23, 1.09]
Total (95% CI)	**96**	**97**		**100.0 %**	**0.91 [0.68, 1.23]**

Total events: 42 (Bulking agent), 44 (Placebo)

Heterogeneity: Chi^2 = 8.66, df = 4 (P = 0.07); I^2 =54%

Test for overall effect: Z = 0.59 (P = 0.56)

Test for subgroup differences: Not applicable



Analysis 12.1. Comparison 12 Adequate concealment spasmolytic agents: abdominal pain, Outcome 1 Comparing scores on abdominal pain in IBS patients.

Review: Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome

Comparison: 12 Adequate concealment spasmolytic agents: abdominal pain

Outcome: 1 Comparing scores on abdominal pain in IBS patients

Study or subgroup	Spasmolytic N	Mean(SD)	Control N	Mean(SD)	Std. Mean Difference IV,Fixed,95% CI	Weight	Std. Mean Difference IV,Fixed,95% CI
Awad 1995	20	-2.3 (1.78)	20	-3 (1.78)		34.9 %	0.39 [-0.24, 1.01]
Pulpeiro 2000	39	-1.63 (0.99)	36	-2.09 (1.05)		65.1 %	0.45 [-0.01, 0.91]
Total (95% CI)	**59**		**56**			**100.0 %**	**0.43 [0.06, 0.80]**

Heterogeneity: Chi^2 = 0.02, df = 1 (P = 0.88); I^2 =0.0%

Test for overall effect: Z = 2.25 (P = 0.024)

Test for subgroup differences: Not applicable



Analysis 13.1. Comparison 13 Adequate concealment spasmolytic agents: global assessment, Outcome 1 comparing nrs of successfully treated IBS patients with spasmolytic agents.

Review: Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome

Comparison: 13 Adequate concealment spasmolytic agents: global assessment

Outcome: 1 comparing nrs of successfully treated IBS patients with spasmolytic agents

Study or subgroup	Spasmolytic n/N	Placebo n/N	Risk Ratio M-H,Fixed,95% CI	Weight	Risk Ratio M-H,Fixed,95% CI
Chen 2004	30/74	14/46		71.9 %	1.33 [0.79, 2.23]
Pulpeiro 2000	5/39	6/36		26.0 %	0.77 [0.26, 2.30]
Ritchie 1979	4/12	0/12		2.1 %	9.00 [0.54, 150.81]
Total (95% CI)	**125**	**94**		**100.0 %**	**1.35 [0.85, 2.12]**

Total events: 39 (Spasmolytic), 20 (Placebo)

Heterogeneity: $Chi^2 = 2.75$, df = 2 (P = 0.25); $I^2 = 27\%$

Test for overall effect: Z = 1.28 (P = 0.20)

Test for subgroup differences: Not applicable

Analysis 14.1. Comparison 14 Adequate concealment antidepressants: abdominal pain, Outcome 1 Comparing nr (%) of successfully treated patients.

Review: Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome

Comparison: 14 Adequate concealment antidepressants: abdominal pain

Outcome: 1 Comparing nr (%) of successfully treated patients

Study or subgroup	Antidepressants n/N	Placebo n/N	Risk Ratio M-H,Random,95% CI	Weight	Risk Ratio M-H,Random,95% CI
1 SSRI					
Kuiken 2003	9/19	5/21		9.8 %	1.99 [0.81, 4.89]
Tabas 2004	14/30	19/36		21.1 %	0.88 [0.54, 1.45]
Vahedi 2005	23/25	18/25		32.2 %	1.28 [0.98, 1.67]
Subtotal (95% CI)	**74**	**82**		**63.1 %**	**1.20 [0.87, 1.67]**
Total events: 46 (Antidepressants), 42 (Placebo)					
Heterogeneity: Tau^2 = 0.03; Chi^2 = 2.91, df = 2 (P = 0.23); I^2 =31%					
Test for overall effect: Z = 1.11 (P = 0.27)					
2 TCA					
Drossman 2003	64/107	27/57		29.8 %	1.26 [0.92, 1.73]
Vahedi 2008	14/22	3/22		7.1 %	4.67 [1.56, 13.99]
Subtotal (95% CI)	**129**	**79**		**36.9 %**	**2.19 [0.59, 8.11]**
Total events: 78 (Antidepressants), 30 (Placebo)					
Heterogeneity: Tau^2 = 0.75; Chi^2 = 5.39, df = 1 (P = 0.02); I^2 =81%					
Test for overall effect: Z = 1.17 (P = 0.24)					
Total (95% CI)	**203**	**161**		**100.0 %**	**1.35 [0.98, 1.86]**
Total events: 124 (Antidepressants), 72 (Placebo)					
Heterogeneity: Tau^2 = 0.06; Chi^2 = 8.86, df = 4 (P = 0.06); I^2 =55%					
Test for overall effect: Z = 1.83 (P = 0.068)					
Test for subgroup differences: Chi^2 = 0.76, df = 1 (P = 0.38), I^2 =0.0%					

Analysis 15.1. Comparison 15 Adequate concealment antidepressants: global assessment, Outcome 1 Comparing nr (%) of successfully treated IBS patients.

Review: Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome

Comparison: 15 Adequate concealment antidepressants: global assessment

Outcome: 1 Comparing nr (%) of successfully treated IBS patients

Study or subgroup	Antidepressants n/N	Placebo n/N	Risk Ratio M-H,Fixed,95% CI	Weight	Risk Ratio M-H,Fixed,95% CI
Drossman 2003	55/115	21/57		45.8 %	1.30 [0.88, 1.92]
Kuiken 2003	10/19	9/21		13.9 %	1.23 [0.64, 2.36]
Tabas 2004	19/30	10/36		14.8 %	2.28 [1.26, 4.13]
Talley 2008a	12/17	6/8		13.3 %	0.94 [0.57, 1.56]
Talley 2008a	18/18	5/8		12.2 %	1.59 [0.94, 2.70]
Total (95% CI)	**199**	**130**		**100.0 %**	**1.42 [1.12, 1.80]**

Total events: 114 (Antidepressants), 51 (Placebo)

Heterogeneity: $Chi^2 = 5.59$, df = 4 (P = 0.23); $I^2 = 28\%$

Test for overall effect: Z = 2.91 (P = 0.0036)

Test for subgroup differences: Not applicable

Analysis 16.1. Comparison 16 Adequate concealment antidepressants: Outcome on symptom score, Outcome 1 Comparing symptom scores in IBS patients.

Review: Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome

Comparison: 16 Adequate concealment antidepressants: Outcome on symptom score

Outcome: 1 Comparing symptom scores in IBS patients



ADDITIONAL TABLES

Table 1. Bulking agents: main results

	Dichotomous outcomes RR (95% CI)	**Continuous outcomes** SMD (95% CI)
Abdominal pain	0.91 (0.61 to 1.36)	0.03 (-0.34 to 0.40)
Global assessment	1.11 (0.91 to 1.35)	
Symptom score		0.00 (-0.43 to 0.43)

Table 2. Antispasmodics: main results

	Dichotomous outcomes RR (95% CI)	**Continuous outcomes** SMD (95% CI)
Abdominal pain	1.32 (1.12 to 1.55)	1.14 (0.47 to 1.81)
Global assessment	1.49 (1.25 to 1.77)	
Symptom score	1.86 (1.26 to 2.76)	2.39 (0.50 to 4.29)

Table 3. Antidepressants: main results

	Dichotomous outcomes RR (95% CI)	**Continuous outcomes** SMD (95% CI)
Abdominal pain	1.49 (1.05 to 2.12)	1.80 (-0.57 to 4.16)
Global assessment	1.57 (1.23 to 2.00)	3.32 (1.95 to 4.68)
Symptom score	1.99 (1.32 to 2.99)	0.38 (-0.30 to 1.06)

WHAT'S NEW

Last assessed as up-to-date: 20 March 2009.

Date	**Event**	**Description**
21 February 2013	Amended	Correction of minor errors in additional tables

HISTORY

Protocol first published: Issue 1, 2002

Review first published: Issue 2, 2005

Date	**Event**	**Description**
29 September 2011	Amended	Change in address for contact author
26 April 2011	New citation required and conclusions have changed	Change in authors, conclusions changed due to new data
26 April 2011	New search has been performed	New search, new studies included

CONTRIBUTIONS OF AUTHORS

Preparation of protocol

Coordination of reviewers

Data collection

Data review

Preparation of report

DECLARATIONS OF INTEREST

Greg Rubin owns shares in Glaxo Smith Kline and has received payment for consultancy from pharma companies. The other authors report no known declarations of interest.

INDEX TERMS

Medical Subject Headings (MeSH)

Abdominal Pain [therapy]; Antidepressive Agents [*therapeutic use]; Dietary Fiber [*therapeutic use]; Irritable Bowel Syndrome [*therapy]; Parasympatholytics [*therapeutic use]; Phytotherapy [methods]; Plantago; Randomized Controlled Trials as Topic

MeSH check words

Humans